Friday, 8 October 2010

13.00–14.00 **Turquoise Hall 2**
Masterclass lunch

14.00–17.00 **Turquoise Hall 2**
Young Oncologist Masterclass
The importance of conducting well-designed clinical trials
Co-Chairs: Susana N. Banerjee, London, UK and Marina C. Garassino, Milan, Italy
Session Shooters: Raffaele Califano, Manchester, UK, Konstantinos Kompasioras, Haidari, Attica, Athens, Greece, Christophe Massard, Villejuif, France

14.00 Statistical issues and how to use biomarkers as surrogates in the 21st century
Marc Buyse, Ottignies Louvain-la-Neuve, Belgium
14.50 Coffee break
15.10 Biobanking in clinical trials: What, when and how should I collect samples?
Maria Grazia Daidone, Milan, Italy
16.00 Break
16.10 Stopping a cancer trial early: is it really for the benefit of patients? What about the quality of data?
Pinuccia Valagussa, Milan, Italy

18.30–20.00 **Gold Hall**
Opening Ceremony

18.30 ESMO Presidential address
David J. Kerr, Oxford, UK
18.55 Congress Local Committee Welcome
Umberto Veronesi, Milan, Italy and Roberto Labianca, Bergamo, Italy
19.05 Welcome to Lombardy
Roberto Formigoni, President of Lombardy Region (TBC)
19.15 Welcome to Milan
Letizia Moratti, Mayor of Milan
19.25 Scientific address
Rolf A. Stahel, Zurich, Switzerland, Scientific Chair
19.35 ESMO Award to Alberto Costa
19.40 Performance: “The best of Italian Opera”
20.00 Welcome Reception in the Gold Foyer

Saturday, 9 October 2010

08.00–08.45 **Turquoise Hall 2**
Young Oncologist Breakfast
How to write an outstanding manuscript
David J. Kerr, Oxford, UK

08.00–09.00 **Yellow Hall 1**
Challenge Your Expert session
Cancer of unknown primary site (CUP): 20 questions to be answered
Nicholas Pavlidis, Ioannina, Greece

08.00–09.00 **Yellow Hall 2**
Challenge Your Expert session
Mesothelioma
Walter Weder, Zurich, Switzerland

08.00–09.00 **Yellow Hall 3**
Challenge Your Expert session
Genetic counselling for hereditary predisposition to ovarian and breast cancer
James Mackay, London, UK

08.00–09.00 **Green Hall 3**
Challenge Your Expert session
Osteosarcoma
Stefan Bielack, Stuttgart, Germany

08.00–09.00 **Green Halls 1+2**
Patient Cases session
Team work in palliative care
Co-Chairs: Philip J. Larkin, Dublin, Ireland and Lukas Radbruch, Bonn, Germany

08.00 What nurses contribute
Philip J. Larkin, Dublin, Ireland
08.10 What doctors contribute
Lukas Radbruch, Bonn, Germany
08.20 Discussion

08.00–09.00 **Orange Halls 2+3**
Patient Cases session
Hepatocellular carcinoma: A multi-step therapeutic approach
Co-Chairs: Jordi Bruix, Barcelona, Spain and Jean-Luc Raoul, Rennes, France

08.00 An early-stage HCC
Jordi Bruix, Barcelona, Spain
08.10 An intermediate case of HCC
Jean-Luc Raoul, Rennes, France
08.20 Discussion
08.00–09.00 **Orange Hall 1**
Multidisciplinary Interactive session (MIS)
Optimal integration of chemotherapy and radiotherapy in small cell lung cancer
Co-Chairs: Fiona Blackhall, Manchester, UK and Corinne Faivre-Finn, Manchester, UK

08.00 Radiotherapy
Corinne Faivre-Finn, Manchester, UK

08.15 Medical Oncology
Fiona Blackhall, Manchester, UK

08.30 Discussion

09.00–10.30 **Gold Hall**
Educational session
Diagnostic and management issues in metastatic breast cancer
Chairs: Fabrice André, Villejuif, France and José Baselga, Boston, MA, USA

09.00 What can the pathologist offer for optimal treatment choice?
Giuseppe Viale, Milan, Italy
09.30 Treatment of triple negative breast cancer
Fabrice André, Villejuif, France
10.00 Treatment of Her2-overexpressing breast cancer
José Baselga, Boston, MA, USA

09.00–10.30 **Pink Hall**
Educational session
How much do we know about cancer cells?
Chair: Carlos Cordon-Cardo, New York, NY, USA
Co-Chair: Marco A. Pierotti, Milan, Italy

09.00 The epithelial-mesenchymal transition (EMT) phenomenon
Pierre Savagner, Montpellier, France
09.30 Cancer stem cells
Carlos Cordon-Cardo, New York, NY, USA
10.00 Circulating cancer cells
Dimitrios Mavroudis, Heraklion, Greece

09.00–10.30 **Blue Hall**
Educational session
Advances in neuroendocrine tumors
Chair: William Travis, New York, NY, USA
Co-Chair: George Pentheroudakis, Kardamitsa, Greece

09.00 Lung neuroendocrine
William Travis, New York, NY, USA
09.30 Gastrointestinal neuroendocrine tumors
Kjell Oeberg, Uppsala, Sweden
10.00 Merkel tumors
Jürgen Becker, Würzburg, Germany

09.00–10.30 **Silver Hall**
Proffered Paper session
Supportive and palliative care
Chair: Jørn Herrstedt, Odense, Denmark
Co-Chair: Fausto Roila, Terni, Italy

09.00 1234O – Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS)
Clelia Madeddu, Cagliari, Italy
09.15 1235O – A randomized controlled trial of antimicrobial prophylaxis infusion after gastric cancer surgery (OGSG0501)
Yukinori Kurokawa, Osaka, Japan
09.45 Invited Discussant, Abstracts 1234O and 1235O
Simon Van Belle, Ghent, Belgium

09.00 1181O – First randomized trial comparing balloon kyphoplasty (BKP) to non-surgical management among cancer patients with vertebral compression fractures
Leonard Bastian, Leverkusen, Germany
10.00 1236O – Control of nausea with palonosetron versus granisetron both combined with dexamethasone in patients undergoing cisplatin (CDDP) – or anthracycline plus cyclophosphamide (AC/EC)-based regimens
Kaoru Kubota, Tokyo, Japan

10.15 Invited Discussant, Abstracts 1181O and 1236O
Fausto Roila, Terni, Italy

09.00–10.30 Red Hall
Special Symposium
ESMO/CSCO Joint Symposium. Personalised medicine:
Do ethnic differences matter?
Co-Chairs: David J. Kerr, Oxford, UK and Shu-Kui Qin, Nanjing, China

09.00 Pharmagenomic and SNP in diverse ethnicity
Howard McLeod, Chapel Hill, NC, USA

09.20 Hepatocellular carcinoma (HCC)
Shu-Kui Qin, Nanjing, China

09.40 Personalized management of lung cancer:
EGFR mutation and beyond
Tony S. K. Mok, Hong Kong, China

10.00 Colorectal cancer
David J. Kerr, Oxford, UK

10.20 Conclusions

09.30–10.30 Orange Hall 1
Multidisciplinary Interactive session (MIS)
Locally advanced pancreatic cancer
Co-Chairs: Christophe Louvet, Paris, France and Hanno Riess, Berlin, Germany

09.30 Medical Oncology
Hanno Riess, Berlin, Germany

09.45 Medical Oncology
Christophe Louvet, Paris, France

10.00 Radiotherapy
Florence Huguet, Paris, France

10.15 Discussion

11.00–12.30 Gold Hall
Educational session
Treatment of PT1NO breast cancer
Chair: Angelo Di Leo, Prato, Italy
Co-Chair: Fatima Cardoso, Lisbon, Portugal

11.00 Multigene predictors to assess risk of relapse
Christos Sotiriou, Brussels, Belgium

11.30 Benefits and adverse effects of endocrine therapy
Marco Colleoni, Milan, Italy

12.00 Chemotherapy with or without trastuzumab
Angelo Di Leo, Prato, Italy

11.00–12.30 Violet Hall
Educational session
Advances in the treatment of advanced colorectal cancer
Chair: Claus-Henning Koehne, Oldenburg, Germany
Co-Chair: Thierry André, Paris, France

11.00 What can the molecular pathologist offer for optimal decision-making?
Philip Quirke, Leeds, UK

11.30 Chemotherapy: Which drugs and when?
Alberto Sobrero, Genoa, Italy

12.00 How to integrate molecular targeted agents in the continuum of care
Claus-Henning Koehne, Oldenburg, Germany

11.00–12.30 Pink Hall
Educational session
Prevention and treatment of side effects of systemic treatment
Chair: Mario Dicato, Luxembourg
Co-Chair: Jørn Herrstedt, Odense, Denmark

11.00 Anemia
Mario Dicato, Luxembourg

11.30 Cardiotoxicity
Josep Tabernero, Barcelona, Spain

12.00 Bone loss
Jean-Jacques Body, Brussels, Belgium

11.00–12.30 Blue Hall
Educational session
Updates in B-cell malignancies
Chair: Michele Ghielmini, Bellinzona, Switzerland
Co-Chair: Håkan Mellstedt, Stockholm, Sweden

11.00 Multiple myeloma
Meletios Dimopoulos, Athens, Greece

11.30 Follicular lymphoma
Michele Ghielmini, Bellinzona, Switzerland

12.00 Chronic lymphocytic leukemia
Michael Hallek, Cologne, Germany
11.00–12.30 Silver Hall
Proffered Paper session
Chest tumors I
Chair: Luis Paz-Ares, Seville, Spain
Co-Chair: Rolf A. Stahel, Zurich, Switzerland

11.00 LBA13 – Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced non-small-cell lung cancer (NSCLC) patients (pts) with EGFR activating mutations
Caicun Zhou, Shanghai, China

11.15 LBA14 – First biomarker analyses from a phase III, randomised, open-label, first-line study of erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese patients (pts) with advanced non-small-cell lung cancer (NSCLC) with EGFR activating mutations (OPTIMAL, CTONG 0802)
Yi-long Wu, Guangzhou, China

11.30 Invited Discussant, LBA13 and LBA14
Federico Cappuzzo, Livorno, Italy

11.45 3630 – Final results from ARQ 197-209: a global randomized placebo-controlled phase 2 clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR-inhibitor naïve patients with advanced non-small cell lung cancer (NSCLC)
Lecia Sequist, Boston, MA, USA

12.00 LBA15 – Randomized multicenter double-blind placebo-controlled phase II study evaluating MetMAb, an antibody to met receptor, in combination with erlotinib, in patients with advanced non-small-cell lung cancer
David Spiegel, Nashville, TN, USA

12.15 Invited Discussant, Abstract 3630 and LBA15
Luis Paz-Ares, Seville, Spain

11.00–12.30 Red Hall
Special Symposium
ESMO/ESTRO/ESSO Joint Symposium. Surgery, radiotherapy and ablation of metastatic disease and chemotherapy for localized disease: Changing roles in multidisciplinary management of colorectal cancer
Co-Chairs: Jean Bourhis, Villejuif, France and David J. Kerr, Oxford, UK

11.00 Image guided therapy of metastases from colorectal cancer
Thierry de Baere, Villejuif, France

11.20 It’s resectable, but is it curable?
Graeme Poston, Liverpool, UK

11.40 Radiotherapy: From palliation to cure and prophylaxis?
Guy Storme, Brussels, Belgium

12.00 Locoregional delivery of chemotherapy for metastatic CRC – what’s the evidence?
Rachel Midgley, Oxford, UK

12.20 Conclusions
Peter Naredi, Umeå, Sweden

12.45–13.35 Violet Hall
Keynote Lecture
Polymorphisms in drug metabolising enzymes and drug transporters: Influence on drug pharmacokinetics and patient response to treatment
Chair: Marco A. Pierotti, Milan, Italy
Speaker: Jos Beijnen, Amsterdam, Netherlands

13.00–14.00 Green Halls 1+2
Poster Symposium (Discussion session)
Breast cancer, early
Co-Chairs: Bryan Hennessy, Dublin, Ireland and Xavier Pivot, Besançon, France

216PD – ABCSG-24: Efficacy of anthracycline- and taxane-based neoadjuvant therapy ± capecitabine (C) in triple-negative early breast cancer (TNBC)
Guenther Steger, Vienna, Austria

217PD – Adjuvant endocrine therapy, alone or in combination with zoledronic acid (ZOL), in premenopausal patients (pts) with endocrine-responsive early breast cancer (EBC): Subgroup analyses of ABCSG-12
Guenther Steger, Vienna, Austria

218PD – The development of a formulation of trastuzumab for subcutaneous administration
Vernon Harvey, Auckland, New Zealand

219PD – Neo-adjuvant chemotherapy treatment and response in different breast cancer subtypes: pooled multi-layer analysis of the German trials
Michael Untch, Berlin, Germany

220PD – A presurgical trial of lapatinib versus placebo in Her-2 positive breast cancer
Andrea De Censi, Genoa, Italy

13.00 Invited Discussant, Abstracts 216PD-220PD
Xavier Pivot, Besançon, France

221PD – Validation of PRO_10, a multigene prognostic signature, in patients (pts) with early, estrogen receptor positive (ER+) postmenopausal breast cancer (BC)
Andreas Moor, Berne, Switzerland

222PD – Prospective transGEICAM study of Oncotype DX® in clinical decision making in estrogen receptor-positive node-negative breast cancer women
Joan Albanell, Barcelona, Spain
223PD – Economic impact of Oncotype DX assay in axillary node negative breast cancer, (AxN-BC) with positive hormone receptor (rec+) and normal HER-2 (HER2-)
Elaine Wilson, Dublin, Ireland
13.15 Invited Discussant, Abstracts 221PD-223PD
Bryan Hennessy, Dublin, Ireland
13.30 General Discussion

13.00–14.00 Orange Halls 2+3
Poster Symposium (Discussion session)
Colorectal cancer
Co-Chairs: Fortunato Ciardiello, Naples, Italy, Gunnar Folprecht, Dresden, Germany and Graeme Poston, Liverpool, UK

581PD – Trial participation in a multicentre phase III trial (CAIRO) in advanced colorectal cancer (ACC) patients (pts) in the Netherlands, and a comparison of outcome between trial and non-trial pts
Cornelis Punt, Nijmegen, Netherlands
582PD – Cetuximab plus XELIRI versus cetuximab plus XELOX as first-line treatment for patients with metastatic colorectal cancer (mCRC). Analysis of the randomized trial of the German AIO CRC study group: KRK-0204
Sebastian Stintzing, Munich, Germany
583PD – Efficacy and safety of second-line treatment with panitumumab plus irinotecan, both given every three weeks (Q3W), in patients (pts) with wild-type (WT) K-RAS metastatic colorectal cancer (mCRC): A study from the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD)
Auxiladora Gomez, Cordoba, Spain
13.00 Invited Discussant, Abstracts 581PD-583PD
Gunnar Folprecht, Dresden, Germany
584PD – Impact of KRAS status on survival in patients (pts.) with metastatic colorectal cancer (mCRC) undergoing bevacizumab (bev) containing chemotherapy regimen – Analysis of the AIO Colorectal Cancer Study Group
Anke Claudia Reinacher-Schick, Bochum, Germany
585PD – The multi-targeted kinase inhibitor AEE788 exerts anti-proliferative effects in BRAF mutated colorectal cancer cells
Araceli Valverde, Cordoba, Spain
586PD – High throughput somatic profiling of the Ras-Raf-MAP and PI3K-PTEN-Akt pathways in advanced colorectal cancer and correlations with response to cetuximab
Christopher Smith, Cardiff, UK
13.12 Invited Discussant. Abstracts 584PD-586PD
Fortunato Ciardiello, Naples, Italy
587PD – Oncologic and functional outcomes after preoperative chemoradiotherapy followed by intersphincteric resection for very low rectal cancer
Masaaki Ito, Kashiwa, Japan
588PD – Trans-arterial chemoembolization of metastatic colorectal carcinoma (MCRC) to the liver adopting polyvinyl alcohol microspheres (PAM) loaded with irinotecan compared with FOLFIRI (CT): Evaluation at two years of a phase III clinical trial
Giammaria Fiorentini, Empoli, Italy
13.24 Invited Discussant, Abstracts 587PD-588PD
Graeme Poston, Liverpool, UK
13.36 General Discussion

13.00–14.00 Yellow Hall 1
Poster Symposium (Discussion session)
Gynecological cancer
Co-Chairs: James Brenton, Cambridge, UK and Ate van der Zee, Groningen, Netherlands

973PD – The ENDORAD trial: RAD001 (everolimus) monotherapy as second-line or third line treatment of advanced endometrial carcinoma: a phase II trial of GINECO group
Isabelle Ray-coquard, Paris, France
974PD – Single-agent activity and safety of the investigational Aurora A kinase inhibitor MLN8237 in patients with platinum-treated epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
Ursula Matulonis, Boston, MA, USA
975PD – A randomized, double-blind, placebo-controlled phase II study of AMG 386 plus weekly paclitaxel in patients (pts) with advanced ovarian cancer
Ignace Vergote, Leuven, Belgium
976PD – Tolerability of trabectedin (Tr) plus pegylated liposomal doxorubicin (PLD) in platinum sensitive (P-S) vs. platinum resistant (P-R) patients (pts) with relapsed ovarian cancer
Karin Boman, Umeå, Sweden
13.00 Invited Discussant, Abstracts 973PD-976PD
James Brenton, Cambridge, UK
977PD – Prognostic value of early complete metabolic response by FDG-PET during neo-adjuvant chemotherapy in advanced ovarian cancer patients
Marta Rosati, Bologna, Italy
978PD – Safety and subgroup efficacy analyses in GOG218, a phase III trial of bevacizumab (BEV) in the
primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) or Fallopian tube cancer (FTC): A Gynecologic Oncology Group study
Robert Burger, Philadelphia, PA, USA
979PD — Expression of DNA repair genes as biomarkers of outcome in epithelial ovarian cancer: A GEICO study
Andres M Poveda, Valencia, Spain
13.15 Invited Discussant, Abstracts 977PD-979PD
Ate van der Zee, Groningen, Netherlands
13.30 General Discussion

13.00–14.00 Yellow Hall 2
Poster Symposium (Discussion session)
Biomarkers I
Co-Chairs: Giampaolo Tortora, Naples, Italy and Johan Vansteenkiste, Leuven, Belgium

160PD — Smoking-induced p16 methylation in young women
Yuk Ting Ma, Birmingham, UK
161PD — Diagnostic markers in bronchial fluid of lung cancer patients; immunoassay development and validation
Sergio Carrera, Barakaldo, Spain
162PD — ProGRP levels in patients with lung cancer
Rita Passerini, Milan, Italy
163PD — Long term follow-up for EBUS-TBNA negative mediastinal lesions
Matthew N. Wong, Hong Kong, China
164PD — Detection of tumor angiogenesis in solid tumours via the expression of v 3 integrin using an RGD peptide, [18F]fluciclatide, and positron emission tomography (PET) imaging
Rohini Sharma, London, UK
13.00 Invited Discussants, Abstract 160PD-164PD
Johan Vansteenkiste, Leuven, Belgium
165PD — An EZH2 polymorphism predicts progression-free survival (PFS) in metastatic colorectal cancer (CRC) patients treated with first-line FOLFIRI plus bevacizumab (BV)
Francesco Crea, Pisa, Italy
166PD — The single nucleotide polymorphism C>G rs420549 in TGFBR1 and microRNA 511 (miR-511) as a new biomarkers in advanced colorectal cancer
José Carlos Villa Guzmán, Ciudad Real, Spain
167PD — Predictive value of the simultaneous detection of somatic quantitative molecular alterations using the quantitative multiplex PCR of short fluorescent fragments method (QMPSF) in stage II-III colon cancer: A prospective study
Laura Debeir, Rouen, France
168PD — Baseline levels of circulating angiogenic factors in metastatic colorectal cancer pts (mCRC) treated with bevacizumab (BEV)
Antonia Martinetti, Milan, Italy
169PD — Clinical significance of incidental focal colorectal uptake detected in 18F-FDG PET-CT studies
Jordi Fuertes, Barcelona, Spain
13.15 Invited Discussants, Abstracts 165PD-169PD
Giampaolo Tortora, Naples, Italy
13.30 General Discussion

13.00–14.00 Yellow Hall 3
Poster Symposium (Discussion session)
Supportive and palliative care
Co-Chairs: Dorothy M. K. Keefe, Adelaide, Australia and Lukas Radbruch, Bonn, Germany

1199PD — Cognitive symptoms in cancer patients attending medical oncology clinics
Victoria Bray, Sydney, Australia
1200PD — What Greek women with breast cancer want to know about their illness and how much do they want to participate in treatment decision making?
Aygoustina Almyroudi, Ioannina, Greece
1182PD — Attitude and knowledge about end-of-life support: A Bavarian survey
Wolfgang Sandtnner, Landshut, Germany
1237PD — Effect of low-molecular-weight heparin (LMWH) nadroparin on hemostatic variables in ambulatory cancer patients enrolled in the PROTECHT trial
Anna Falanga, Bergamo, Italy
13.00 Invited Discussants, Abstracts 1199PD-1200PD-1182PD-1237PD
Johan Vansteenkiste, Leuven, Belgium
1238PD — Granulocyte colony stimulating factor (G-CSF) prophylaxis and febrile neutropenia (FN) incidence in patients with solid tumours receiving myelotoxic chemotherapy who are assessed as high risk for FN: IMPACT SOLID study
Anna Falanga, Bergamo, Italy
1183PD — Randomized phase II trial (NCT00637975) evaluating activity and toxicity of fixed dose of oxycodone and increasing dose of pregabalin versus increasing dose of oxycodone and fixed dose of pregabalin for the treatment of oncological neuropathic pain (NEUROPAIN-01)
Marina Garassino, Milan, Italy
13.15 Invited Discussant, Abstracts 977PD-979PD
Ate van der Zee, Groningen, Netherlands
13.30 General Discussion
13.15 Invited Discussant, Abstracts 1238PD-1239PD-1183PD
Dorothy M. K. Keefe, Adelaide, Australia
13.30 General Discussion

14.00–15.30 Blue Hall
Special Symposium
ESMO/JSMS Joint Symposium. Biomarkers and
selected therapeutics in lung and gastrointestinal cancer
Co-Chairs: David J. Kerr, Oxford, UK and Kazuo Tamura, Fukuoka, Japan
14.00 Recent progress in JSMO and society activities
Kazuo Tamura, Fukuoka, Japan
14.05 EGFR-TKI for EGFR mutated NSCLC: New evidence
Isamu Okamoto, Osaka, Japan
14.25 Anti-HER2 and angiogenesis inhibitors for gastric cancer:
Updated results
Atsushi Ohtsu, Kashiwa, Japan
14.45 Predictive biomarkers in the treatment of advanced colorectal cancer
Josep Tabernero, Barcelona, Spain
15.05 The immediate future of customized treatment in lung cancer
Rafael Rosell, Badalona, Barcelona, Spain
15.25 Conclusions
David J. Kerr, Oxford, UK

14.15–15.45 Gold Hall
Educational session
Early-stage NSCLC: Challenges in staging and adjuvant treatment
Chair: Thierry Le Chevalier, Villejuif, France
Co-Chair: Paul Baas, Amsterdam, Netherlands
14.15 Evidence-based staging
Johan Vansteenkiste, Leuven, Belgium
14.45 Adjuvant chemotherapy: Where is it going?
Thierry Le Chevalier, Villejuif, France
15.15 Do we have markers to select patients for adjuvant therapies?
Krzysztof Konopa, Gdansk, Poland

14.15–15.45 Silver Hall
Educational session
Challenging issues in ovarian cancer
Chair: Jonathan Ledermann, London, UK
Co-Chair: Cristiana Sessa, Bellinzona, Switzerland
14.15 How can proteomic profiling guide us in selecting therapy?
Elise Kohn, Bethesda, MD, USA
14.45 The addition of new drugs to standard therapy in the
first-line treatment of ovarian cancer
Michael Bookman, Tucson, AZ, USA
15.15 Optimal treatment for relapsing ovarian cancer
Jonathan Ledermann, London, UK

14.15–15.45 Violet Hall
Educational session (Repetition)
Diagnostic and management issues in metastatic breast cancer
Chairs: Fabrice André, Villejuif, France and
José Baselga, Boston, MA, USA
14.15 What can the pathologist offer for optimal treatment choice?
Giuseppe Viale, Milan, Italy
14.45 Treatment of triple negative breast cancer
Fabrice André, Villejuif, France
15.15 Treatment of Her2-overexpressing breast cancer
José Baselga, Boston, MA, USA

14.15–15.45 Pink Hall
Educational session (Repetition)
Advances in neuroendocrine tumors
Chair: William Travis, New York, NY, USA
Co-Chair: George Pentheroudakis, Kardamitsia, Greece
14.15 Lung neuroendocrine
William Travis, New York, NY, USA
14.45 Gastrointestinal neuroendocrine tumors
Kjell Oeberg, Uppsala, Sweden
15.15 Merkel tumors
Jürgen Becker, Würzburg, Germany

16.00–17.30 Gold Hall
Educational session (Repetition)
Advances in the treatment of advanced colorectal cancer
Chair: Claus-Henning Koehne, Oldenburg, Germany
Co-Chair: Thierry André, Paris, France
16.00 What can the molecular pathologist offer for optimal decision-making?
Philip Quirke, Leeds, UK
16.30 Chemotherapy: Which drugs and when?
Alberto Sobrero, Genoa, Italy
17.00 How to integrate molecular targeted agents in the
continuum of care
Claus-Henning Koehne, Oldenburg, Germany
16.00–17.30 Silver Hall
Educational session (Repetition)
New therapeutic opportunities in urological cancer
Chair: Joaquim Bellmunt, Barcelona, Spain
Co-Chair: Vesa Kataja, Kuopio, Finland

16.00 New hormonal agents in the treatment of advanced prostate cancer
Johann de Bono, Sutton, UK
16.30 New agents for bladder cancer
Joaquim Bellmunt, Barcelona, Spain
17.00 How to select targeted therapy in renal cancer
Bernard Escudier, Villejuif, France

16.00–17.30 Violet Hall
Educational session (Repetition)
Treatment of PT1NO breast cancer
Chair: Angelo Di Leo, Prato, Italy
Co-Chair: Fatima Cardoso, Lisbon, Portugal

16.00 Multigene predictors to assess risk of relapse
Christos Sotiriou, Brussels, Belgium
16.30 Benefits and adverse effects of endocrine therapy
Marco Colleoni, Milan, Italy
17.00 Chemotherapy with or without trastuzumab
Angelo Di Leo, Prato, Italy

16.00–17.30 Pink Hall
Educational session (Repetition)
How much do we know about cancer cells?
Chair: Carlos Cordon-Cardo, New York, NY, USA
Co-Chair: Marco A. Pierotti, Milan, Italy

16.00 The epithelial-mesenchymal transition (EMT) phenomenon
Pierre Savagner, Montpellier, France
16.30 Cancer stem cells
Carlos Cordon-Cardo, New York, NY, USA
17.00 Circulating cancer cells
Dimitrios Mavroudis, Heraklion, Greece

16.00–17.30 Green Halls 1+2
Special Session
Chronic Disease Alliance: A time to work across specialties
Chair: Hans-Jörg Senn, St. Gallen, Switzerland

16.00 Introduction
Hans-Jörg Senn, St. Gallen, Switzerland
16.05 Reducing mortality — prevention and treatment
Richard Peto, Oxford, UK

16.25 Cardioncology — An alliance for prevention and treatment
Roberto Ferrari, Ferrara, Italy
16.45 Diabetes and cancers
Ulf Smith, Gothenburg, Sweden
17.05 The burden of chronic respiratory diseases in Europe
Nikolaos Siafakas, Heraklion-Crete, Greece
17.25 Conclusions
David J. Kerr, Oxford, UK

17.30–19.30 Blue Hall
ESMO Examination 2010
8th ESMO Patient Seminar

15.00–15.10 Red Hall
Introduction

15.00 Lorenz Jost, Bruderholz, Switzerland
15.05 Francesco De Lorenzo, Rome, Italy

15.10–16.40 Red Hall
Cancer: We all care and share
Co-Chairs: Francesco De Lorenzo, Rome, Italy and TBC

15.10 The status of cancer in Europe now
Andrea Micheli, Milan, Italy
15.25 What the European Union can do for patients
Alojz Peterle, Brussels, Belgium
15.40 What cancer advocacy groups can do for patients
Jan Geissler, Riemerling, Germany
15.55 General Discussion

16.40–17.10
Coffee break

17.10–18.40 Red Hall
Understanding new methods and new treatments of cancer
Co-Chairs: Roberto Labianca, Bergamo, Italy and Elisabetta Iannelli, Rome, Italy

17.10 Targeted therapy: A general overview
Manfred Kaufmann, Witten, Germany
17.30 My life with targeted therapy
Elisabetta Iannelli, Rome, Italy
17.40 Targeted therapy: Hope or hype
Jean-Charles Soria, Villejuif, France
18.00 Participation in phase I studies
Silvia Marsoni, Milan, Italy
18.20 General Discussion

Since the beginning
Weleda has been supporting patient care
It all started with an empathetic bedside manner caring for the whole person and was followed by the development of natural organic cosmetics. Nowadays it includes the support of clinical research. Therefore our support of ESMO is a logical consequence of all our efforts to improve the patient’s quality of life.

In harmony with nature and the human being
Since 1921

www.weleda.it
Breast cancer, advanced
Chair: Fatima Cardoso, Lisbon, Portugal

287P – The impact of educational material (EM) on compliance and persistence rates with adjuvant aromatase inhibitor (AI) treatment: First year data, presented on behalf of the CARIATIDE study investigators
Christos Markopoulou, Athens, Greece

288P – Phase I study of S-1 plus trastuzumab combination therapy in human epidermal-growth receptor 2-positive metastatic breast cancer
Tsutomu Takashima, Osaka, Japan

289P – Trastuzumab-based therapy after disease progression following lapatinib and capecitabine in HER2-positive (HER2+) metastatic breast cancer (MBC)
Giulio Metro, Rome, Italy

290P – Level of HER2/neu gene (HER2) amplification in primary and metastatic sites in HER2-positive metastatic breast cancer and response to trastuzumab(T)-based therapy
Giuseppe Gullo, Dublin, Ireland

291P – Lapatinib (L) plus capecitabine (C) in HER2-positive metastatic breast cancer (MBC): An exploratory analysis of overall survival (OS) based on poststudy therapy
Eleni Stergiou, Thessaloniki, Greece

292P – Evaluation of neratinib (HKI-272) and paclitaxel pharmacokinetics (PK) in Asian and caucasian patients with ErbB2+ breast cancer: A Phase I/II study of neratinib in combination with paclitaxel
Richat Abbas, Collegeville, PA, USA

293P – HER-2 status correlation between primary breast cancer and corresponding distant metastatic sites
Isabel Frahm, Buenos Aires, Argentina

294P – Australian breast cancer patients enrolled in the lapatinib expanded access program (LEAP)
Jodi Lynch, Kogarah, Australia

295P – Trastuzumab (T) tolerability and activity in HER2+ metastatic breast cancer (MBC) patients (pts) aged ≥65 years
Alessandra Bernardi, Bologna, Italy

296P – Neoadjuvant chemotherapy (NAC) with docetaxel and liposome-encapsulated doxorubicin in locally advanced HER2-breast cancer (LABC)
Marco Merlano, Cuneo, Italy

297P – Taxane-based treatment options for patients with HER2-positive advanced breast cancer: Results of an observational study
Mahmut Gümüş, Istanbul, Turkey
298P – A phase 1 study of neratinib (HKI-272) in combination with paclitaxel in Japanese patients with solid tumors
Yoshinori Ito, Tokyo, Japan

299P – Ixabepilone (Ixa) and capecitabine (C) in patients (pts) with triple-negative breast cancer (TNBC): A retrospective analysis of phase II and phase III clinical studies
Henri Roché, Toulouse, France

300P – Sorafenib (SOR) plus capecitabine (CAP) in patients (pts) with triple-negative (TN) advanced breast cancer (BC): Subgroup analysis of SOLTI-0701, a double-blind, randomised, placebo (PL)-controlled phase IIb study
Henri Roché, Toulouse, France

301P – Paclitaxel (P) and bevacizumab (Bev), as first-line chemotherapy, in patients with HER2-negative metastatic breast cancer (MBC). The Hellenic Cooperative Oncology Group experience with biomarker evaluation
Helen Kourea, Patras, Greece

302P – Updated results from a large, multicentre study of 1st-line bevacizumab (Bev) combined with paclitaxel (Pac) for HER2-negative metastatic breast cancer (mBC) in routine oncology practice
Frank Förster, Chemnitz, Germany

303P – High prevalence and poor prognosis of triple negative tumors in Hispanic patients with breast cancer
Monika Blake, Mexico City, Mexico

304P – Safety and efficacy of maintenance bevacizumab in HER2-negative metastatic breast cancer
Michelangelo Russillo, Rome, Italy

305P – Sequential vinorelbine (VNR)/capecitabine (CAP) combination followed by metronomic CAP as first-line treatment in HER2-negative metastatic breast cancer (MBC): Prospective evaluation of activity, safety and quality of life
Raffaella Palumbo, Pavia, Italy

306P – Meta-analysis of randomized clinical trials (RCTs) exploring single agent chemotherapy (SACH) versus multi-agent chemotherapy (MACH) in addition to trastuzumab (T) for HER-2-overexpressing advanced breast cancer (ABC): What is the most appropriate comparator?
Isabella Sperduti, Rome, Italy

307P – Neo-adjuvant chemotherapy (NACT) in hormonal receptor positive (HR+) or triple negative (TN) operable breast cancer (BC): A randomized study comparing standard to response–adapted sequence
Hervé Cure, Reims, France

308P – Capecitabine (X) in advanced breast cancer in the real life setting – First 12-month results from the ELIXIR cohort
Phillipe Dalivoust, Marseille, France

309P – Factors affecting survival in patients given multiple lines of chemotherapy (CT) for metastatic breast cancer (MBC): What do we gain beyond the third-line?
Giovanni Bernardo, Pavia, Italy

310P – A qualitative systematic review of the evidence base for non cross-resistance between steroidal and non-steroidal aromatase inhibitors (AIs) in metastatic breast cancer
Jayeta Chakrabarti, Surrey, UK

311P – Male breast cancer: About 127 cases collected at the National Institute of Oncology from 1985 to 2007
Mouna Bourhafour, Rabat, Morocco

312P – Oral chemotherapy to optimize care of metastatic breast cancer (MBC) patients: Considering women’s preference and quality of life (QoL)
Maria Strada, Pavia, Italy

313P – Indirect comparison and UK cost-effectiveness analysis of paclitaxel albumin vs docetaxel for pretreated metastatic breast cancer
Francois Prunieras, Paris, France

314P – Interim analysis of the German non-interventional post marketing surveillance study (NIS) on Quality of Life (QoL) of capecitabine in patients with metastatic breast cancer (MBC)
Matthias Zaiss, Freiburg, Germany

315P – A retrospective survey of systemic anticancer therapy in women with metastatic breast cancer (MBC) in Belgium
Christel Fontaine, Brussels, Belgium

316P – Implication of breast cancer phenotype in patients with leptomeningeal carcinomatosis
Davis Torrejon, Barcelona, Spain

317P – To detect the expression of cytokeratin 19 in peripheral blood of patients with breast cancer and its clinical significance
Xiu Dong, Dalian, China

318P – Serum IL-8 as a prognostic marker for triple negative advanced breast cancer
Gouri Shankar Bhattacharyya, Kolkata, India

319P – A clinicopathological analysis of breast cancer patients with a family history
Yukie Yoda, Chuo-ku, Tokyo, Japan

320P – Ixabepilone (Ixa)-associated peripheral neuropathy (PN): Retrospective review of data from phase II and III clinical trials
Linda Vahdat, New York, NY, USA

321P – Vinflunine after failure of a first-line vinorelbine based chemotherapy in advanced breast cancer: Results of a phase II multicentre study
P. Bougnoux, Tours, France
322P – A phase I-II study of dasatinib (D) in combination with weekly (w) paclitaxel (P) for patients (pts) with metastatic breast carcinoma (MBC)
Monica Fornier, New York, NY, USA
323P – Population pharmacokinetic-pharmacodynamic (PK/ PD) analysis of safety and efficacy of eribulin in metastatic or locally advanced breast cancer patients
Ziad Hussein, Hatfield, UK
324P – Effectiveness of taxane monotherapy (TM) and taxane combination (TC) treatment in patients with advanced breast cancer
Mutlu Demiray, Osmangazi-Bursa, Turkey
325P – Increasing role of metastasectomy in metastatic breast cancer patients: Who benefits more?
Fatih Selcukbircik, Istanbul, Turkey
327P – Neoadjuvant chemotherapy with GM- or G-CSF: Differential effects on dendritic cell subsets in patients with locally advanced breast cancer
Hester van Cuijisen, Amsterdam, Netherlands
328P – Intrathecal chemotherapy (ITCT) improves prognosis in leptomeningeal carcinomatosis (LC) from breast cancer (BC): A single institution experience
Mafalda Oliveira, Lisboa, Portugal
329P – Does obesity hamper response to trastuzumab (T) in post-menopausal patients (pts) with metastatic breast cancer (MBC)?
I. Nuñez, Barcelona, Spain

Gastrointestinal tumors

Chair: TBC

713P – Randomized, double-blind, placebo-controlled, multicentre phase III study of capecitabine / cisplatin + bevacizumab (bev) or placebo (pl) as 1st-line therapy in patients (pts) with advanced gastric cancer (AGC) (AVAGAST update)
Eric Van Cutsem, Leuven, Belgium
714P – Novel chemotherapy combinations in advanced gastric cancer: An updated meta-analysis
Anna Dorothea Wagner, Lausanne, Switzerland
715P – Epirubicin (E) in combination with cisplatin (CDDP) and capecitabine (C) versus docetaxel (D) combined with 5-fluorouracil (5-FU) by continuous infusion (C.I.) as front-line therapy in patients with advanced gastric cancer (AGC): Preliminary results of a randomised phase II trial of the Gruppo Oncologico dell’Italia Meridionale
Nicola Silvestris, Bari, Italy
716P – mFOLFOX-4 followed by mFOLFIRI or the reverse sequence in metastatic gastric cancer
Suee Lee, Busan, South Korea
717P – An Interim analysis of a phase II, open-label, multi-center, prospective study of paclitaxel plus capecitabine with subsequent capecitabine maintenance as first-line treatment in advanced gastric cancer
Xiaotian Zhang, Beijing, China
718P – Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TFOX) for advanced gastric and oesophageal adenocarcinoma (AGEC). Tolerance and response in 38 patients: Preliminary report
Simon Pernot, Malakoff, France
719P – Phase II study of weekly paclitaxel, cisplatin, and 5-fluorouracil (PCF) for advanced gastric cancer
Kazuhiro Nishikawa, Osaka, Japan
720P – Retrospective study regarding the efficacy of 2nd or higher line chemotherapy of patients in advanced or recurrent gastric cancer (ARGC) after the failure of S-1 or S-1 combination chemotherapy (S+ )
Kazuma Kobayashi, Kochi City, Japan
721P – Triplet combination of capecitabine plus oxaliplatin and irinotecan in the treatment of patients with previously untreated advanced gastric cancer (AGC)
Elena Franceschelli, Milan, Italy
722P – Survival benefit associated with fluoropyrimidines, platinum agents, taxanes, and irinotecan during all lines of treatment in patients with advanced gastric cancer
Kohei Shitara, Nagoya, Japan
723P – Phase 2 study of telatinib in combination with capecitabine and cisplatin as first-line treatment in patients with advanced cancer of the stomach or gastro-esophageal junction (GEJ)
Maria Alsina, Barcelona, Spain
724P – Prognostic significance of free peritoneal tumor cells (FPTCs) in the perioperative setting in patients with gastric carcinoma undergoing a potentially curative resection
Sylvie Lorenzen, Heidelberg, Germany
725P – Phase II study of everolimus in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum
Dok Hyun Yoon, Seoul, South Korea
726P – Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer patients treated with adjuvant chemotherapy after curative resection
Seok Yun Kang, Suwon, South Korea
727P – Expression of BAX predicts outcome in advanced gastric cancer patients treated with 5-fluorouracil and platinum palliative chemotherapy
Seong Hyun Jeong, Suwon, South Korea
728P - miRNA-196b and miRNA-363 were identified as gastric cancer specific miRNAs in human gastric cancer tissue using microarray experiment
Jae Yong Cho, Seoul, South Korea
729P - mRNA expression of BRCA1, RAP80 and SUMO ligases (PIAS1 and PIAS4) and survival in gastric cancer patients (p) receiving second-line docetaxel (doc)
Jia Wei, Nanjing, China
730P - SUVmax of F-18 FDG-PET/CT in advanced gastric cancer with tubular adenocarcinoma: Correlation with pathologic findings including immunohistochemical staining
Hong-Suk Song, Daegu, South Korea
731P - Predictive factors for adjuvant therapy in patients with localized gastric & gastro-esophageal junction (G/GEJ) cancer: A population based study
Shahid Ahmed, Saskatoon, SK, Canada
732P - Prognostic impact of immunohistochemical expression of Ki-67 in patient with advanced gastric cancer who underwent curative resection
Uhm Doyung, Incheon, South Korea
733P - Predictive significance of preoperative peripheral blood values for stage T4 gastric cancer
Masaki Aizawa, Kashiwa, Japan
734P - Survival benefit of gastrectomy ± metastasectomy in metastatic gastric cancer patients receiving chemotherapy
Ki Hwan Kim, Seoul, South Korea
735P - 10-year follow-up of gastric submucosal tumors
Akira Sawaki, Nagoya, Japan
736P - Development of a comprehensive registry of gastrointestinal stromal tumor (GIST) patients (pts) in Eastern Ontario
Esmeralda Marginean, Ottawa, ON, Canada
737P - Cost-effectiveness of adjuvant imatinib in patients with surgically resected localized gastrointestinal stromal tumors (GIST): Canadian societal perspective
Vivek Pawar, Medford, OR, USA
738P - Patient preferences for reducing toxicities of treatments for gastrointestinal stromal tumor (GIST): A conjoint analysis study
Juan Marcos Gonzalez, Research Triangle Park, NC, USA
739P - Randomized cross-over AIO phase III trial comparing gemcitabine plus erlotinib followed by capecitabine vs. capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer
Stefan Boeck, Munich, Germany
740P - 5-fluorouracil/leucovorin (5FU/LV) combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma
Elias Assaf, Créteil, France
741P - Conatumumab (CON) or AMG 479 or placebo (pbo) + gemcitabine (GEM) in patients (pts) with metastatic pancreatic cancer (mPC): A placebo-controlled, randomized, phase II study
Hedy Kindler, Chicago, IL, USA
742P - A prospective, randomized, double-blind, placebo controlled, group sequential trial of Polyclonal Antibody Stimulator (PAS) for the treatment of advanced pancreatic cancer
J. Oortgiesen, Research Triangle Park, NC, USA
743P - Results of a phase I/II study of nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer with SPARC and CA19-9 correlatives
Ramesh Ramanathan, Scottsdale, AZ, USA
744P - Efficacy of continuous infused 5-fluorouracil, doxorubicin, and mitomycin (iFAM) in the treatment of gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in salvage setting
Kyu-Hyoung Lim, Seoul, South Korea
745P - Gemcitabine (G) fixed rate dose infusion (FDR) plus erlotinib (E) in patients with advanced pancreatic cancer (APC)
Alberto Muñoz, Baracaldo, Spain
746P - A prognostic model to identify patients with advanced pancreas adenocarcinoma who could benefit from second-line chemotherapy
Seung Taek Kim, Cheonan, South Korea
747P - Evaluation of progression-free survival (PFS) by blinded independent central review (BICR) in patients (pts) with progressive, well-differentiated pancreatic neuroendocrine tumours (NET) treated with sunitinib (SU) or placebo
Eric Van Cutsem, Leuven, Belgium
748P - Therapeutic synergism of lapatinib and NVP-AEW541 against human pancreatic tumour cells
Adela Mazo, Barcelona, Spain
749P - Potentiation of gemcitabine effects with a cetuximab and trastuzumab combination in a novel human pancreatic orthotopic model
Anna Vidal-Pla, Barcelona, Spain
750P - Efficacy and safety of sorafenib (Sor) in patients (pts) with advanced hepatocellular carcinoma (HCC): Subgroup analyses of the SHARP and Asia-Pacific (AP) trials by baseline (BL) transaminase (ALT/AST)/alpha-fetoprotein (AFP) and bilirubin (Bil) levels
Jean-Luuc Raoul, Rennes, France
751P – Quality of life assessment with combined EORTC QLQ-C30 and EORTC-HCC18 as a prognostic factor for patients with hepatocellular carcinoma: A prospective study  
Leung Li, Shatin, Hong Kong, China

752P – Preliminary pharmacokinetics (PK) and safety comparison of Child-Pugh A (CPA) vs. Child-Pugh B (CPB) patients (pts) enrolled in a phase II study in hepatocellular carcinoma (HCC)  
Justin Ricker, Abbott Park, IL, USA

753P – Efficacy and tolerability of bevacizumab (B) and erlotinib (E) as first-line therapy in Asian patients (pts) with advanced hepatocellular carcinoma (HCC): A phase II trial  
Chih-Hung Hsu, Taipei, Taiwan

754P – Management and cancer outcomes of secondary malignancies following liver transplantation  
Hilary Martin, Bedford Park, Australia

755P – Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: A multicenter AGEO study  
Thomas Aparicio, Bobigny, France

756P – Alcohol, tobacco, and risk of gastrointestinal (GI) cancers  
Arthur Klatsky, Oakland, CA, USA

---

**Genitourinary tumors**

Co-Chairs: Maria De Santis, Vienna, Austria and Thomas Powles, London, UK

879P – Reduction in surgical and non-surgical interventions for prostate cancer with Dutasteride Treatment in the REduction by DUtasteride of prostate Cancer Events (REDUCE) study  
Roger Rittmaster, Raleigh-Durham, NC, USA

880P – Integrated safety results from 4 randomized, double-blind, placebo-controlled studies of sipuleucel-T  
Mark Frohlich, Seattle, WA, USA

881P – An open-label phase II study of treatment with sunitinib in patients suffering from metastatic castrated refractory prostate cancer (CRPC) after progression with docetaxel-based regimen  
Stephane Oudard, Paris, France

882P – Cetuximab in combination with docetaxel in patients (pts) with metastatic castration resistant (mCRPC) and docetaxel-refractory prostate cancer: Final analysis of the multicenter phase II trial SAKK 08/07  
Richard Cathomas, Chur, Switzerland

883P – Baseline cardiovascular risk factors predict cardiovascular (CV) events during androgen deprivation therapy (ADT) with degarelix  
Laurence Klotz, Toronto, ON, Canada

884P – Circulating tumor cells (CTC) and prostate-specific antigen (PSA) as response indicator biomarkers in chemotherapy-naive patients with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100  
Mohammad Hirmand, San Francisco, CA, USA

885P – First results of high-intensity focused ultrasound for localized and locally advanced hormone-resistant prostate cancer  
Vyacheslav Solovov, Samara, Russian Federation

886P – Immune vs. clinical response monitoring in patients with metastatic hormone-refractory prostate cancer receiving combined Prostate GVAX and anti-CTLA4 immunotherapy  
Winald Gerritsen, Amsterdam, Netherlands

887P – Radium-223 chloride, a novel, highly targeted alpha-pharmaceutical for treatment of bone metastases from castration-resistant prostate cancer (CRPC): Hematologic and safety profile with repeated dosing  
Christopher Parker, Surrey, UK

888P – A phase II prospective study of ketoconazole in patients with metastatic hormone-refractory prostate cancer receiving combined Prostate GVAX and anti-CTLA4 immunotherapy  
Elena Verzoni, Milan, Italy

889P – Hot flushes (HF) during androgen deprivation therapy: Direct comparison of monthly degarelix and leuprolide in a phase 3 trial  
Peter Iversen, Copenhagen, Denmark

890P – Neutral endopeptidase (NEP) and endothelin 1 (ET-1) are inversely expressed in hormone-naive prostate cancer and are predictors of biochemical failure from radical prostatectomy  
Panagiotis Vlachostergios, Larissa, Greece

891P – Incidence of cancer treatment-induced bone loss (CTIBL) in non-osteoporotic men with prostate cancer (PC) receiving androgen deprivation therapy (ADT) and efficacy of treatment with zoledronic acid (ZOL): Results from the ROBUST bone mineral density (BMD) sub-study  
Tim van den Wyngaert, Edegem, Belgium

892P – The influence of family history of breast and prostate cancer on prostate cancer diagnoses in the REduction by DUtasteride of prostate Cancer Events (REDUCE) study  
Ramiro Castro, Raleigh-Durham, NC, USA

893P – Efficacy and tolerability of bevacizumab (B) and erlotinib (E) as first-line therapy in Asian patients (pts) with advanced hepatocellular carcinoma (HCC): A phase II trial  
Mark Frohlich, Seattle, WA, USA

---

**Pharmacokinetics (PK) and safety comparison of Child-Pugh A (CPA) vs. Child-Pugh B (CPB) patients (pts) enrolled in a phase II study in hepatocellular carcinoma (HCC)  
Justin Ricker, Abbott Park, IL, USA

---

**Management and cancer outcomes of secondary malignancies following liver transplantation  
Hilary Martin, Bedford Park, Australia

---

**Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: A multicenter AGEO study  
Thomas Aparicio, Bobigny, France

---

**Alcohol, tobacco, and risk of gastrointestinal (GI) cancers  
Arthur Klatsky, Oakland, CA, USA

---

**Genitourinary tumors**

Co-Chairs: Maria De Santis, Vienna, Austria and Thomas Powles, London, UK

---

**Reduction in surgical and non-surgical interventions for prostate cancer with Dutasteride Treatment in the ReDuction by DUtasteride of prostate Cancer Events (REDUCE) study  
Roger Rittmaster, Raleigh-Durham, NC, USA

---

**Integrated safety results from 4 randomized, double-blind, placebo-controlled studies of sipuleucel-T  
Mark Frohlich, Seattle, WA, USA

---

**An open-label phase II study of treatment with sunitinib in patients suffering from metastatic castrated refractory prostate cancer (CRPC) after progression with docetaxel-based regimen  
Stephane Oudard, Paris, France

---

**Cetuximab in combination with docetaxel in patients (pts) with metastatic castration resistant (mCRPC) and docetaxel-refractory prostate cancer: Final analysis of the multicenter phase II trial SAKK 08/07  
Richard Cathomas, Chur, Switzerland
894P – Pharmacogenomic profile of castration-resistant prostate cancer: The influence of AR +1733 G>A and SHBG +5790 G>A polymorphisms
Marta Sousa, Porto, Portugal

895P – Adjuvant effect of IV clodronate on delay of bone metastasis in high-risk prostate cancer patients: A prospective study
Paulo Rodrigues, São Paulo, Brazil

896P – A multi-institutional phase II study of single agent ABI-007 in platinum refractory urothelial carcinoma
Yoo-Joung Ko, Toronto, ON, Canada

897P – Carboplatin and gemcitabine in elderly and/or frail patients (pts) with advanced transitional cell carcinoma (TCC): A phase II study
Abdelbari Baitar, Antwerp, Belgium

898P – Accelerated MVAC chemotherapy in patients with advanced bladder cancer pretreated with platinum-gemcitabine regimens
Julien Edeline, Rennes, France

899P – The combination of DNA repair gene polymorphisms significantly affect the risk of bladder cancer in population of Southwest China
Zhiwen Chen, Chongqing, China

900P – Multicenter Phase II study of sunitinib in patients with transitional cell carcinoma of the urothelium (TCCU) who failed or progressed after first-line chemotherapy (CT) for locally advanced or metastatic disease. Preliminary results
Christine Theodore, Saint-Cloud, France

901P – A phase II study of paclitaxel, ifosfamide and nedaplatin as a second-line treatment in patients with cisplatin-refractory metastatic urothelial cancer
Hiroshi Kitamura, Sapporo, Japan

902P – Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A Japanese phase II study in patients with cytokine-refractory metastatic renal cell cancer (mRCC)
Yoshihiko Tomita, Yamagata, Japan

903P – Microbubble ultrasound compared to dynamic contrast MRI and CT for the assessment of vascular response to sunitinib in renal cell carcinoma
Georg Bjarnason, Toronto, Canada

904P – Incidence and management of hepatic toxicity in pazopanib-treated patients
Vicki Goodman, Collegeville, PA, USA

905P – Sorafenib safety over time in >4600 patients with renal cell carcinoma (RCC): Insights from an integrated database of 8 company-sponsored trials
Timothy Eisen, Cambridge, UK

906P – Sorafenib in older patients with advanced renal cell carcinoma: Subanalysis by age of an integrated database of 8 company-sponsored clinical trials
Giuseppe Procopio, Milan, Italy

907P – Axitinib pharmacokinetics and blood pressure changes in front-line metastatic renal cell carcinoma (RCC) patients
Mayer Fishman, Tampa, FL, USA

908P – Are TKIs still active in patients treated with TKI and everolimus? Experience from 36 patients treated in France in the RECORD 1 trial
Aurore Blesius, Villejuif, France

909P – Serum thrombospondin-1 (TSP-1), basic-fibroblast growth factor (B-FGF), vascular endothelial growth factor (VEGF) and VEGF receptor-2 (VEGFR-2) as predictive factors for sorafenib plus interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC): Biologic results from the “RAPSODY” randomized phase II trial
Sergio Bracarda, Arezzo, Italy

910P – Second-line treatment with pazopanib following first-line sunitinib or bevacizumab in advanced renal cell carcinoma: Preliminary results of a phase II trial
John Hainsworth, Nashville, TN, USA

911P – Phase 3 RECORD-1 study of everolimus in metastatic renal cell carcinoma (mRCC): Subgroup analysis of patients (pts) with 1 versus 2 prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI) therapies
Emiliano Calvo, Madrid, Spain

912P – Bevacizumab (B) plus immunotherapy (IT) plus chemotherapy (C) (BIC) in metastatic renal cell cancer (mRCC): Results and evaluation of circulating T-regulatory cells (TREG) and other cytokines. A GOIRC study
Rodolfo Passalacqua, Cremona, Italy

913P – Clinical outcome of Asian vs. non-Asian patients with metastatic renal cell carcinoma (mRCC) with continuous once-daily dosing of sunitinib as first-line therapy
Carlos Barrios, Porto Alegre, Brazil

914P – Comparative outpatient resource utilization study of metastatic renal cell carcinoma patients receiving oral vs. intravenous mTOR inhibitors
Zhimei Liu, East Hanover, NJ, USA

915P – Trough PK concentration, age of patient, and baseline ALT are important factors in predicting ALT elevations in pazopanib treated mRCC patients
Lini Pandite, Research Triangle Park, NC, USA
916P – Sorafenib (Sor) dosage patterns in >4600 patients (pts) with renal cell carcinoma (RCC), including the elderly and pts treated for >12 months (mo): Results from an integrated database of 8 company-sponsored trials
Carsten Bokemeyer, Hamburg, Germany

917P – Zoledronic acid (ZOL) reduces the incidence of skeletal-related event (SREs) and may improve survival in patients with bone metastases (mets) from renal cell carcinoma (RCC): A retrospective integrated analysis
Dirk Jäger, Heidelberg, Germany

918P – Sequential therapy in metastatic renal cell carcinoma — simulation and comparison of progression-free-survival outcomes
Gerald Mickisch, Bremen, Germany

919P – Targeted therapy in first-line therapy of metastatic renal cell cancer (mRCC): Systematic review with meta-analysis (SRMA)
Sergio Bracarda, Arezzo, Italy

920P – mTOR Inhibition and renal cell carcinoma; a comparison between sirolimus and temsirolimus
Ateesha Mohamed, Research Triangle Park, NC, USA

921P – Bone metastasis in clear cell renal cell carcinoma: a predictive factor for outcome on sunitinib in retrospective analysis
Emilio Poffiri, Birmingham, UK

922P – An Italian multicentre retrospective analysis of 189 advanced renal-cell carcinoma patients treated sequentially, either with sorafenib followed by sunitinib, or vice versa
Camillo Porta, Pavia, Italy

923P – Thyroid-stimulating hormone (TSH) levels in patients with metastatic renal cell cancer treated with sunitinib
Andrea Necchi, Milan, Italy

924P – Baseline quality of life as a prognostic tool of median survival in patients receiving sunitinib for metastatic renal cell carcinoma
David Cella, Chicago, IL, USA

925P – An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory mRCC patients using a robust matching technique
Giuseppe Di Lorenzo, Naples, Italy

926P – A phase II study of safety and efficacy of temsirolimus (CCI-779) administered as a single agent in East Asian patients with advanced renal cell carcinoma
Yan Sun, Beijing, China

927P – Cost-effectiveness of treating metastatic renal cell carcinoma (mRCC) patients whose disease failed on VEGF-TKI therapies with everolimus compared to treating with best supportive care (BSC) alone: A Canadian societal perspective
Khalid El Ouagari, Dorval, QC, Canada

928P – PREDICT global non-interventional study: baseline characteristics of RCC patients treated with sorafenib
Dirk Jäger, Heidelberg, Germany

929P – Randomized, placebo-controlled, phase III study of everolimus in patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis of patients intolerant of prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI) therapy
Sergio Bracarda, Arezzo, Italy

930P – Patient preferences for targeted agents in renal cell carcinoma (RCC): A benefit risk conjoint study
Ateesha Mohamed, Research Triangle Park, NC, USA

931P – The outcome of patients who fail sunitinib and do not have access to sunitinib therapy
Emilio Poffiri, Birmingham, UK

932P – Incidence, time and mode of detection of testis cancer (TC) relapses: Retrospective analysis of a single-institution cohort on a uniform follow-up program
Mark Bachner, Vienna, Austria

933P – Teratoma with malignant differentiation in male germ-cell tumors (GCT): Updated results from a single institution series and future perspectives
Andrea Necchi, Milan, Italy

934P – Salvage chemotherapy (CT) of patients (pts) with late-relapse metastatic germ cell tumor (mGCT): Single institute experience
Mikhail Fedyanin, Moscow, Russian Federation

935P – Increased age is associated with thromboembolic events in patients with germ cell tumors treated with chemotherapy
Ignacio Garcia-Escobar, Madrid, Spain

936P – Updated results of adjuvant carboplatin (carbo AUC 7 and 7.7) in stage I seminoma (sem) of the testis from the BOC Oncology Centre
Marios Decatris, Nicosia, Cyprus

937P – Salvage chemotherapy with high dose chemotherapy and peripheral blood stem cell transplant in patients with germ cell tumors
Theofanis Vassileiadis, Thessaloniki, Greece

938P – Updated results of the combination of paclitaxel, cisplatin and gemcitabine (TPG) followed by surgery as third-line therapy for male germ cell tumors
Emilio Poffiri, Birmingham, UK

939P – A combination of cisplatin and 5-fluorouracil plus a taxane for advanced squamous-cell carcinoma (SCC) of the penis. A single institution series
Andrea Necchi, Milan, Italy
Geriatric oncology
Chair: Riccardo Audisio, Liverpool, UK

576P – Treatment of lymphoma in the elderly – toxicities and outcomes
Louise Fullam, Dublin, Ireland
577P – Multiple tumors in elderly patients: Epidemiology and survival in a single center experience
Antonella Brunello, Padova, Italy
578P – 2-year tolerance of adjuvant trastuzumab for early breast cancer occurring in elderly: A companion study of the GERICO-06 phase II trial
Marc Debled, Bordeaux, France
579P – Cancer in an Italian nursing home
Claudia D’Alessandro, Milan, Italy

Health services and public health
Chair: TBC

1094P – Rare cancers in Europe
Gemma Gatta, Milan, Italy
1095P – Cancer registry integration in the Umbria Regional Cancer Network: Breast cancer as a model to build a supportive information system
Fabrizio Stracci, Perugia, Italy
1096P – A review of data collected on non-small cell lung cancer (NSCLC) patients in cancer registries, databases, retrospective and non-randomized prospective studies
Henrik Finnern, Ingelheim, Germany
1097P – Development of a multi-centric assessment tool for measuring and improving standardised organisation and provision of care in cancer structures
Mahasti Saghatchian, Villejuif, France
1098P – Integrated care pathways (ICPs) for non-small cell lung cancer (NSCLC) patients (Pts): A multidisciplinary quality improvement project
Simona Rizzato, Udine, Italy
1099P – Patient (pt) reported symptoms of chemotherapy (chemo) and VEGFR/EGFR antibody therapies for the treatment of metastatic colorectal cancer (mCRC) in a US community-based oncology practice network
Elaine Yu, South San Francisco, CA, USA
1100P – What have we accomplished with targeted chemotherapy for incurable solid cancers?
Henry Conter, Edmonton, AB, Canada
1101P – Health resource utilization (HRU) associated with skeletal-related events (SREs) in patients (pts) with bone metastases (BM) – US interim analysis (IA) results from a multinational observational study
Peter Suenaert, Uxbridge, UK
1102P – The Italian cross-sectional survey on the management of bone health in oncology: The ZETA study
Francesco Bertoldo, Verona, Italy
1103P – Long-term economic burden of cancer patients
Nobuo Koinuma, Sendai, Japan
1104P – Environmental contamination with cytotoxic drugs in the home setting in outpatients on cancer chemotherapy
Michiko Yuki, Fukushima, Japan
1105P – Reducing mortality rates related to capecitabine induced diarrhoea: Importance of clinical audit
Sindu Vivekanandan, Colchester, UK
1106P – Healthcare costs of second-line (2L) metastatic colorectal cancer (mCRC) patients treated with bevacizumab (BV) versus cetuximab (CX)
Yeunmi Yim, South San Francisco, CA, USA
1107P – Testing and treatment patterns in HER2+ breast cancer patients in the adjuvant setting
Deepa Lalla, South San Francisco, CA, USA
1108P – A new organizational model in the city of Milan has improved the best setting of care for terminal patients
Shela Piva, Milan, Italy
1109P – A survey on ethics committees reviewing cancer clinical trials in India
Mohandas K. Mallath, Mumbai, India
1110P – An awareness and screening programme of cervical cancer in rural West Bengal
Jayasri Basak, Kolkata, India
1111P – Darbepoetin alfa versus epoetin alfa for treatment of chemotherapy-induced anemia: A health economic evaluation
Jindrich Finek, Plzen, Czech Republic
1112P – Interactions with anticancer agents in clinical practice: More frequent than we imagine
Ariane Mouzon, Yvoir, Belgium
1113P – Clinical outcome of patients with cancer submitted to hemodialysis (HD) at the Brazilian National Cancer Institute (INCA)
Daniel Herchenhorn, Rio de Janeiro, Brazil
1114P – Cancer research is leading the way – A study of cancer publications in pivotal medical journals over the last two decades
Paul Barnfield, Toronto, ON, Canada
Melanoma
Chair: TBC

1326P – Ipilimumab produces durable objective responses in patients with previously treated, advanced melanoma: Results from a phase III trial
Christian Ottensmeier, Southampton, UK

1327P – Ipilimumab improves overall survival in patients with previously treated, advanced melanoma: Long-term survival results from a phase III trial
John Haanen, Amsterdam, Netherlands

1328P – Health related quality of life (HRQL) outcomes of ipilimumab treatment in patients with previously treated unresectable stage III or IV melanoma (USIII/IV Mel)
Dennis Revicki, Bethesda, MD, USA

1329P – Assessment of pharmacokinetic interaction between ipilimumab and chemotherapy in a randomized study
Jeffrey Weber, Tampa, FL, USA

1330P – Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both in a phase III study of previously-treated patients with advanced melanoma: Update of clinical characteristics of patients
Caroline Robert, Villejuif, France

1331P – Clinical response to ipilimumab: Effect of systemic corticosteroids used to manage immune-related adverse events (irAEs)
Paul Lorigan, Manchester, UK

1332P – Long term survival of high risk melanoma patients immunized with an allogeneic whole cell genetically modified vaccine (AGI-101) after complete resection
Andrzej Mackiewicz, Poznan, Poland

1333P – Toward the characterization of a genetic profile with prognostic value at CDKN2A locus in melanoma patients
Giuseppe Palmieri, Sassari, Italy

1334P – Use of subcutaneous NGcGM3/VSSP vaccine in the treatment of advanced melanoma patients. A phase I/II clinical trial
Elias Gracia, Ciudad de la Habana, Cuba

1335P – CTC biomarker assessment to aid dosing selection of E6201, a potential MEK1 inhibitor, for treatment of BRAF-mutated melanoma
Andrew Eisen, Woodcliff Lake, NJ, USA

1336P – Cyclin dependent kinase 4 as a therapeutic target for metastatic melanoma
Thamir Mahgoub, Dublin, Ireland

1337P – The effects of patient and tumor characteristics and treatment modalities on prognosis of patients with uveal melanoma
Deniz Tural, Istanbul, Turkey

1338P – Histology and outcomes of newly detected lung lesions in malignant melanoma (MM) patients
Elizabeth Smyth, New York, NY, USA

1339P – Socio-economic status and education level influence Breslow thickness, disease free and overall survival in clinical stage I-II AJCC skin melanoma
Mario Mandalà, Bergamo, Italy

Neuroendocrine tumors and CUP
Chair: TBC

846P – Phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of pancreatic neuroendocrine tumors (NET): Impact of somatostatin analogue (SSA) treatment on progression-free survival (PFS)
Juan Valle, Manchester, UK

847P – Sunitinib efficacy and tolerability in patients with neuroendocrine tumors out of a trial: A Spanish multicenter cohort
Jorge Barriuso, Madrid, Spain

848P – mTOR activation in advanced neuroendocrine tumors in treatment with somatostatin analogues – a single center study
Isabel Fernandes, Lisboa, Portugal

849P – mTOR expression analysis in lung and gastroenteropancreatic poorly differentiated endocrine carcinoma (PDEC)
Laura Catena, Milan, Italy

850P – Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: A phase II study of Spanish Neuroendocrine Tumor Group (GETNE-0801)
Daniel Castellano, Madrid, Spain

851P – Utility of progression-free survival (PFS) as a primary endpoint in clinical studies of advanced neuroendocrine tumors (NET)
Simron Singh, Toronto, ON, Canada

852P – Characteristics associated with health-related quality of life of patients with neuroendocrine tumor (NET)
James Yao, Houston, TX, USA

853P – Prognostic and predictive value of chromogranin A and neuron-specific enolase in patients (pts) with advanced pancreatic neuroendocrine tumors (pNET) treated with everolimus
Kjell Öberg, Uppsala, Sweden
**854P** – Carcinoid & neuroendocrine tumor society of Singapore (CNETS) survey on delay in diagnosis of neuroendocrine tumors (NET)
W. Claxton, Singapore

**855P** – Neuroendocrine tumors: 20-years rare hormonal tumors group experience
Fernando Cirillo, Cremona, Italy

**856P** – A cost-consequence model for octreotide LAR as treatment for metastatic midgut NET
Sonia Pulgar, Florham Park, NJ, USA

**857P** – Diagnosis and management of metastatic malignant disease of unknown primary origin (MUP) – Large cancer centre experience
Syed Zubair, Leeds, UK

**858P** – Molecular profiling as a strategy to prospectively identify primary solid tumours in metastatic cancer patients
Evandro De Azambuja, Brussels, Belgium

**Prevention and screening**
Chair: TBC

**1125P** – Early detection program focusing on primary and secondary health care providers achieved major and sustainable reduction of late stage diagnosis of breast cancer
C. R. Beena Devi, Sarawak, Malaysia

**1126P** – An assessment of annual lung cancer screening in Yokohama: The 27 years’ cumulative data
Yuki Misumi, Yokohama, Japan

**1127P** – A large, multicenter, retrospective epidemiological survey: The incidence and treatment of bone metastatic disease in Chinese cancer patients
Li Zhang, Guangzhou, China

**1128P** – Genetic testing of cancer predisposition and progression: Analysis of gene variations in tumor is required
Evgeny Denisov, Tomsk, Russian Federation

**1129P** – School health program to prevent tobacco use
Natia Jokhadze, Tbilisi, Georgia

**Sarcoma**
Chair: Paolo G. Casali, Milan, Italy

**1348P** – First-line treatment of patients with metastatic or unresectable gastrointestinal stromal tumors (GIST) with nilotinib
Peter Reichardt, Bad Saarow, Germany

**1349P** – Early evaluation of efficacy in molecularly targeted therapy of gastrointestinal stromal tumor
Toshiro Nishida, Osaka, Japan

**1350P** – Correlation of microRNA profile with kinase genotype in gastrointestinal stromal tumours (GISTS)
Maria Pantaleo, Bologna, Italy

**1351P** – Value of educational campaign to raise awareness of gastrointestinal stromal tumours (GIST) and its impact on the referral patterns in a tertiary referral cancer centre
Marios Decatris, Nicosia, Cyprus

**1352P** – Phase I dose-escalation study of imatinib mesylate (IM) associated with fixed dose of oral metronomic cyclophosphamide (MC) in selected tumors which may benefit from IM
Antoine Adenis, Lille, France

**1353P** – Neo-adjuvant chemotherapy with regional hyperthermia (RHT) for localized high-risk soft-tissue sarcoma (HR-STS) with abdominal/retroperitoneal location
Lars Lindner, Munich, Germany

**1354P** – No improvement of outcome with reduced vs. conventional high intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients
Uwe Thiel, Munich, Germany

**1355P** – A retrospective analysis of trabectedin activity in pre-treated advanced Ewing sarcoma (ES): Experience in 31 patients
Palma Dileo, Milan, Italy

**1356P** – Clinical activity of gemcitabine-based chemotherapy in frail and/or heavily pre-treated patients with bone sarcomas
Olivier Mir, Paris, France

**1357P** – Does the mutation of Wnt occur in osteosarcomas?
Kanji Sasaki, Niigata-city, Japan

**1358P** – RNA expression of XPG, ERCC1 and BRCA1 in myxoid liposarcoma patients treated with neoadjuvant trabectedin
Alessandro Gronchi, Milan, Italy

**1359P** – Nonpegylated liposomal doxorubicin plus ifosfamide versus conventional doxorubicin plus ifosfamide in locally advanced or metastatic soft tissue sarcoma: Interim analysis of a randomized phase II trial
Maren Knoedler, Berlin, Germany

**1360P** – Gemcitabine in angiosarcoma
Silvia Stacchiotti, Milan, Italy

**1361P** – Activity of sunitinib in advanced soft tissue sarcoma and its correlation with potential predictive biomarkers
Lore Decoster, Brussels, Belgium

**1362P** – Treatment and outcomes in primary cardiac sarcoma: The IGR experience
Meryem Glaoui, Rabat, Morocco
1363P – Increased Dicer expression levels are associated with higher grades of leiomyosarcomas
Dionysios Papachristou, Rion Patras, Greece
1365P – Pulmonary artery sarcomas presenting as pulmonary hypertension: A review and discussion of further treatment
Ioannis Gounaris, Cambridge, UK

Upper gastrointestinal tumors
Chair: TBC

803P – Phase II study of induction treatment (IT) of cetuximab (Cet) with chemotherapy (docetaxel, cisplatin, 5FU –DCF-) followed by Cet with concurrent chemoradiotherapy (cisplatin) in patients (p) with locoregional oesophageal cancer (LROC). The TTD-06-02/GICOR Spanish Cooperative Groups trial
Fernando Rivera, Santander, Spain
804P – Results of neoadjuvant chemoradiotherapy with docetaxel and 5-FU followed by esophagectomy for locally advanced esophageal cancer
Yoichi Hamai, Hiroshima, Japan
805P – Neoadjuvant therapy in esophageal carcinoma followed by a long interval until resection: A high incidence of complete pathological response
Rachel Blom, Heerlen, Netherlands
806P – Docetaxel, cisplatin and capecitabine (DCX) as perioperative chemotherapy in gastro-esophageal adenocarcinoma. A phase II study of the Arbeitsgemeinschaft Internistische Onkologie AIO
Dmitry Bichev, Berlin, Germany
807P – Predictive factors in locally advanced squamous cell carcinoma (SCC) of the oesophagus treated with preoperative radiochemotherapy (RCT) and surgery
Michael Stahl, Essen, Germany
808P – Rationale and design of the GASTRANOX trial on a low-molecular-weight heparin [LMWH], enoxaparin, with chemotherapy vs. chemotherapy alone in inoperable gastric and gastro-oesophageal cancer
Ajay Kakkar, London, UK
809P – Does external ultrasonography of the neck add diagnostic value to integrated PET-CT scanning in the diagnosis of cervical metastases in patients with esophageal carcinoma?
Meindert Sosef, Heerlen, Netherlands
810P – Response and survival in oesophageal cancer patients following neoadjuvant chemotherapy assessed by FDG-PETCT imaging and correlation to pathologic response

Yogesh Manikyam, Belfast, UK
811P – FDG-PET/CT evaluation of early metabolic response after neoadjuvant chemotherapy in patients with esophageal and GEJ cancer – a pilot study
Milada Zemanová, Prague, Czech Republic
812P – What direct costs are associated with evaluation of upper gastrointestinal cancers? Results of a 32 month audit
Aiza Jamil, Ashford, UK
813P – Comparison of a sequential treatment versus a 5-FU/LV regimen as adjuvant therapy for resected gastric cancer. Tolerability and feasibility analysis of ITACA-S (Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach) trial
Emilio Bajetta, Milan, Italy
814P – Patterns of gastric cancer recurrence after adjuvant chemoradiation
Steven Maclellan, Toronto, ON, Canada
815P – Sunitinib (SU) with cisplatin (P) and capecitabine (X) or oxaliplatin (O) and X (XELOX) in advanced gastric cancer (GC) – a phase I, dose-finding study
Jennifer Tursi, Milan, Italy
816P – Phase I study of sunitinib (SU) plus S-1 and cisplatin (P) in patients (pts) with advanced or metastatic gastric cancer (GC)
Kei Muro, Aichi, Japan
817P – Lapatinib + capecitabine in advanced gastric cancer: an open-label phase II study of non-ErbB2-targeted disease
Heinz-Josef Lenz, Los Angeles, CA, USA
818P – A phase I, dose-finding study of sunitinib (SU) in combination with cisplatin (P) and 5-fluorouracil (5-FU) in patients (pts) with advanced gastric cancer (GC)
Carlos Gómez-Martín, Madrid, Spain
819P – Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402)
Kazumasa Fujitani, Osaka, Japan
820P – Although the AJCC new 7th edition’s number-based N-category improves over the 6th, Lymph Node Ratios are still a better prognostic indicator for overall survival
Iain Tan, Singapore
821P – Clinical outcome of advanced gastric cancer (GC) patients (pts) by human epidermal growth factor receptor 2 (HER2) status when treated before the trastuzumab era
Roberto Pazoo Cid, Zaragoza, Spain
822P – Her2 over-expression and gene amplification in gastric cancer
Young Soo Park, Seoul, South Korea
823P – HER2 status in primary and paired distant metastatic sites of gastric carcinoma
Francesca Negri, Parma, Italy
824P – SOCS-1,-3 gene delivery in gastric cancer cells induces a potent anti-proliferative effect via the suppression of JAK/STAT and P38 MAPK signaling pathways
Satoshi Serada, Ibaraki City (Osaka), Japan
825P – Long term survival post curative intent gastrectomy in gastric cancer patients with positive peritoneal cytology (an independent indicator of poor prognosis)
Hwee Yong Lim, Singapore
826P – Oxaliplatin + 5-fluorouracil/leucovorin (FOLFOX4) in advanced HCC: Updated efficacy results of the EACH trial
Shukui Qin, Nanjing, China
827P – First interim results of the Global Investigation of therapeutic DECisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study
Riccardo Lencioni, Pisa, Italy
828P – Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: A retrospective comparison with previously known prognostic models
Kyung Kee Baek, Seoul, South Korea
829P – Novel KRAS mutation detected amongst gallbladder cancer patients from Eastern India
Rakesh Roy, Kolkata, West Bengal, India

Sunday, 10 October 2010

08.00–08.45 Turquoise 2
Young Oncologist Breakfast
How to conduct effective public speaking and slide presentations
Jan Vermorken, Edegem, Belgium

08.00–09.00 Yellow Hall 1
Challenge Your Expert session (Repetition)
Cancer of unknown primary site (CUP): 20 questions to be answered
Nicholas Pavlidis, Ioannina, Greece

08.00–09.00 Yellow Hall 2
Challenge Your Expert session (Repetition)
Mesothelioma
Walter Weder, Zurich, Switzerland

08.00–09.00 Yellow Hall 3
Challenge Your Expert session (Repetition)
Genetic counselling for hereditary predisposition to ovarian and breast cancer
James Mackay, London, UK

08.00–09.00 Green Hall 3
Challenge Your Expert session (Repetition)
Osteosarcoma
Stefan Bielack, Stuttgart, Germany

08.00–09.00 Green Halls 1+2
Patient Cases
Challenging cases in testicular cancer
Co-Chairs: Carsten Bokemeyer, Hamburg, Germany and Christian Kollmannsberger, Vancouver, BC, Canada

08.00 Treatment options in early stage seminoma
Christian Kollmannsberger, Vancouver, BC, Canada
08.10 Relapsed and/or refractory non-seminoma
Carsten Bokemeyer, Hamburg, Germany
08.20 Discussion

08.00–09.00 Orange Halls 2+3
Patient Cases
How to improve curability of locally advanced head and neck cancer
Co-Chairs: Johannes A. Langendijk, Groningen, Netherlands and Dirk Schrijvers, Antwerp, Belgium

08.00 Site-related co-morbidities in decision making
Johannes Langendijk, Groningen, Netherlands
08.10 Supportive care measures to improve patient outcome
Dirk Schrijvers, Antwerp, Belgium
08.20 Discussion

08.00–09.00 Orange Hall 1
Special Session
European Union Translational Research Program
Coordination of cancer research through the FP7 HEALTH programme
Jan-Willem van de Loo, Brussels, Belgium

08.00–09.00 Silver Hall
Educational session (Repetition)
Early-stage NSCLC: Challenges in staging and adjuvant treatment
Chair: Thierry Le Chevalier, Villejuif, France
Co-Chair: Paul Baas, Amsterdam, Netherlands

08.00 Evidence-based staging
Johan Vansteenkiste, Leuven, Belgium
09.30 Adjuvant chemotherapy: Where is it going?
Thierry Le Chevalier, Villejuif, France
10.00 Do we have markers to select patients for adjuvant therapies?
Krzysztof Konopa, Gdansk, Poland

08.00–10.30 Blue Hall
Educational session (Repetition)
Updates in B-cell malignancies
Chair: Michele Ghielmini, Bellinzona, Switzerland
Co-Chair: Håkan Mellstedt, Stockholm, Sweden

08.00 Multiple myeloma
Meletios Dimopoulos, Athens, Greece
09.30 Follicular lymphoma
Michele Ghielmini, Bellinzona, Switzerland
10.00 Chronic lymphocytic leukemia
Michael Hallek, Cologne, Germany

08.00–10.30 Violet Hall
Proffered Paper session
Upper gastrointestinal tumors
Chair: Arnaud Roth, Geneva, Switzerland
Co-Chair: Claus-Henning Koehne, Oldenburg, Germany

08.00 8000 – Impact of neoadjuvant chemoradiation in localised oesophageal cancer: results of a randomised controlled phase III trial FFCD 9901
Christophe Mariette, Lille, France
09.15 8010 – Final results of the intergroup FFCD-GERCOR-FNCLCC 03-07 phase III study comparing two sequences of chemotherapy in advanced gastric cancers
Rosine Guimbaud, Toulouse, France
09.30 Invited Discussant, Abstracts 8000 and 8010
Michael Stahl, Essen, Germany
09.45 8020 – Photostent-02; Porfimer Sodium photodynamic therapy plus stenting versus stenting alone in patients (pts) with advanced or metastatic cholangiocarcinomas and other biliary tract tumours (BTC): A multicentre, randomised phase III trial
Stephen Pereira, London, UK
10.00 73O – Final results of a randomized phase III trial comparing folfirinox (F: 5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). The Prodige 4 / ACCORD 11 trial
Françoise Desseigne, Lyon, France
10.00 Invited Discussant, Abstracts 8020 and 73O
TBC

09.00–10.45 Pink Hall
Proffered Paper session
Sarcoma
Chair: Axel Le Cesne, Villejuif, France
Co-Chair: Paolo G. Casali, Milan, Italy

09.00 1343O – Bone angiosarcoma: A retrospective analysis of 73 patients from two referral centres
Emanuela Palmerini, Bologna, Italy
09.15 1344O – Safety and efficacy results from a phase 1/2 study of the anti-IGF-IR antibody figitumumab in patients with refractory Ewing’s and othersarcomas
Heribert Juergens, Muenster, Germany
09.30 Invited Discussant, Abstracts 1343O and 1344O
Hans Gelderblom, Leiden, Netherlands
09.45 1345O – A pooled analysis of the final results of the two randomized phase II studies comparing gemcitabine (G) vs gemcitabine + docetaxel (G+D) in patients (pts) with metastatic/relapsed leiomyosarcoma (LMS)
Florence Duffaud, Marseille, France
10.00 1346O – A retrospective analysis of 41 primary localized rectal/pararectal gastrointestinal stromal tumors (GISTs) from the French Sarcoma Group (FSG).
Thanh K. Huynh, Marseille, France
10.15 1347O – Antitumor activity of sunitinib malate (SM) in solitary fibrous tumors (SFT)
Silvia Stacchiotti, Milan, Italy
10.25 Invited Discussant, Abstracts 1345O, 1346O and 1347O
Serge Leyvraz, Lausanne, Switzerland
09.15–10.15 Gold Hall
Controversy session
Over-diagnosis of breast cancer by screening is a peril
Moderator: Ian Smith, London, UK

09.15 Introduction and vote
Ian Smith, London, UK
09.25 Benefit
Harry De Koning, Rotterdam, Netherlands
09.45 Peril
Karsten J. Jørgensen, Copenhagen, Denmark
10.05 Vote and conclusions
Ian Smith, London, UK

09.15–10.15 Orange Hall 1
Multidisciplinary Interactive session (MIS)
Locally advanced rectal cancer
Co-Chairs: Andrés Cervantes, Valencia, Spain and Cornelis van de Velde, Leiden, Netherlands

09.15 Surgery
Cornelis van de Velde, Leiden, Netherlands
09.30 Medical Oncology
Andrés Cervantes, Valencia, Spain
09.45 Discussion

09.30–11.00 Yellow Hall 2
Special Session
Communication skills training (CST)
Chair: Alexander Kiss, Basel, Switzerland
Co-Chair: Friedrich Stiefel, Lausanne, Switzerland

09.30 Introduction
Alexander Kiss, Basel, Switzerland
09.35 CST in oncology: Results from a consensus meeting among European experts in 2009
Friedrich Stiefel, Lausanne, Switzerland
09.55 A reaction to the proposition of the European consensus on CST in oncology
Darius Razavi, Brussels, Belgium
10.15 Mandatory training, minimal requirements an implementation of CST in oncology: The European perspective
Wolf Langewitz, Basel, Switzerland
10.35 The future of CST in oncology
Lesley Fallowfield, Brighton, UK
10.55 Conclusions
Alexander Kiss, Basel, Switzerland

10.30–12.00 Orange Hall 1
Special Symposium
The more (we are), the better (we serve)!
ESMO and OECI: towards high-quality cancer care
Co-Chairs: David J. Kerr, Oxford, UK and Mahasti Saghatelian, Villejuif, France

10.30 Introduction: Quality fatality, necessity or opportunity?
Mahasti Saghatelian, Villejuif, France and Richard Sullivan, London, UK
10.40 The OECI accreditation programme
Mahasti Saghatelian, Villejuif, France
10.55 ESMO designated Centres of Integrated Oncology and Palliative Care
Nathan Cherny, Jerusalem, Israel
11.10 Developing a designation system for cancer centres
Wim van Harten, Amsterdam, Netherlands
11.25 Assessment frameworks for cancer centres: novel methodologies
Richard Sullivan, London, UK
11.40 Q&A and Conclusions
David J. Kerr, Oxford, UK and Mahasti Saghatelian, Villejuif, France

10.45–12.45 Gold Hall
ESMO Clinical Practice Guidelines
Chair: Nicholas Pavlidis, Ioannina, Greece
Co-Chair: Andrés Cervantes, Valencia, Spain

10.45 Introduction
Nicholas Pavlidis, Ioannina, Greece
10.50 ESMO CPG Questionnaire
Andrés Cervantes, Valencia, Spain
10.55 Speaker
Helen Gogas, Athens, Greece
11.15 Discussant
Andrew Tutt, London, UK
11.30 Speaker
Laura Kaireviciute, Kaunas, Lithuania
11.50 Discussant
Alessandro Gronchi, Milan, Italy
12.05 Speaker
Stefan Boeck, Munich, Germany
12.25 Discussant
Stefano Cacini, Ancona, Italy
12.40 Conclusions
Andrés Cervantes, Valencia, Spain
10.45–12.15 Silver Hall
**Educational session (Repetition)**
**Challenging issues in ovarian cancer**
Chair: Jonathan Ledermann, London, UK
Co-Chair: Cristiana Sessa, Bellinzona, Switzerland

10.45 How can proteomic profiling guide us in selecting therapy?
Elise Kohn, Bethesda, MD, USA

11.15 The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer
Michael Bookman, Tucson, AZ, USA

11.45 Optimal treatment for relapsing ovarian cancer
Jonathan Ledermann, London, UK

10.45–12.15 Pink Hall
**Proffered Paper session**
**Melanoma**
Chair: Patrick Schöffski, Leuven, Belgium
Co-Chair: Alexander M. M. Eggermont, Rotterdam, Netherlands

11.00 1324O – Ipilimumab improves survival in previously treated, advanced melanoma patients with poor prognostic factors: Subgroup analyses from a phase III trial
Céleste Lebbé, Paris, France

11.15 Invited Discussant, Abstract 1324O plus 1 expected LBA
Cornelis J.A. Punt, Nijmegen, Netherlands

11.30 1325O – Retrospective analysis of 470 metastatic uveal melanoma (MUM) patients managed at Institut Curie between 2000 and 2008
Sophie Piperno-Neumann, Paris, France

11.45 LBA27 – Phase 1/2 study of GSK2118436, a selective inhibitor of V600 Mutant (Mut) BRAF kinase: Evidence of activity in melanoma brain metastases (Mets)
Georgina Long, Westmead, Australia

12.00 Invited Discussant, Abstract 1325O and LBA27
Caroline Robert, Paris, France

10.45–12.15 Green Halls 1+2
**Educational session (Repetition)**
**Prevention and treatment of side effects of systemic treatment**
Chair: Mario Dicato, Luxembourg
Co-Chair: Jørn Herrstedt, Odense, Denmark

10.45 Anemia
Mario Dicato, Luxembourg

11.15 Cardiotoxicity
Josep Tabernero, Barcelona, Spain

11.45 Bone loss
Jean-Jacques Body, Brussels, Belgium

10.45–12.15 Violet Hall
**Special Symposium**
**Targeted therapies in NSCLC: State-of-the-art and new developments**
Chair: Eva Wardelmann, Bonn, Germany
Co-Chair: Michael Montemurro, Lausanne, Switzerland

11.00 Introduction
Michael Montemurro, Lausanne, Switzerland

11.05 Angiogenesis inhibitors: Are they useful for all sarcomas?
Stefan Sleijfer, Rotterdam, Netherlands

11.25 mTOR inhibitors: From lymphangioleiomyomatosis to where?
Paolo Casali, Milan, Italy

11.45 Is the indication of IGFR antibodies in advanced refractory sarcomas expanding?
Jean-Yves Blay, Lyon, France

12.05 At the crossroads of molecular pathways and sarcoma subtypes
Jean-Michel Coindre, Bordeaux, France

12.25 Conclusions
Eva Wardelmann, Bonn, Germany

371PD — A phase II study of Tumor Treating Fields (TTFields) in combination with pemetrexed for advanced non small cell lung cancer (NSCLC)
Miklos Pless, Winterthur, Switzerland

372PD — Oral vinorelbine (NVBo) and cisplatin (P) with concomitant radiotherapy (RT) followed by either consolidation therapy with NVBo and P plus best supportive care (BSC) or BSC alone in stage (st) III non small cell lung cancer (NSCLC): Preliminary results of a phase III study
Michael Flentje, Würzburg, Germany

373PD — Immunohistochemistry (IHC) with EGFR mutation-specific monoclonal antibodies (mAbs) for screening EGFR mutations in non-small-cell lung cancer (NSCLC) patients
Sara Simonetti, Barcelona, Spain

374PD — S-1 plus carboplatin has become one of the standard regimens for advanced non-small-cell lung cancer: Results of a randomized phase III study conducted by the West Japan Oncology Group (WJTOG 3605)
Takashi Seto, Fukuoka, Japan

375PD — Overall survival (OS) and progression free survival (PFS) results for a randomized phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC)
Thomas Lynch, Jr, New Haven, CT, USA

12.30—13.20 Violet Hall
Keynote Lecture
A historical view and perspectives on angionogenesis inhibition and in particular anti-VEGF therapy in cancer
Chair: Marco A. Pierotti, Milan, Italy
Speaker: Peter Carmeliet, Leuven, Belgium

12.30—13.30 Green Halls 1+2
Poster Symposium (Discussion session)
Chest tumors
Co-Chairs: Lucio Crinò, Perugia, Italy, Filippo de Marinis, Rome, Italy and Robert Pirker, Vienna, Austria

364PD — QOL Analysis from NEJ 002 study comparing gefitinib to chemotherapy for non-small cell lung cancer with mutated EGFR
Hirohisa Yoshizawa, Niigata, Japan

365PD — Randomized phase II study of PF299804, an irreversible human epidermal growth factor receptor (EGFR) inhibitor, versus (v) erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) after chemotherapy (CT) failure: Quantitative and qualitative benefits
Suresh Ramalingam, Atlanta, GA, USA

366PD — Clinical activity of crizotinib (PF-02341066), in ALK-positive patients with non-small cell lung cancer (NSCLC)
David Ross Camidge, Aurora, CO, USA

367PD — A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR/HER1 mutations (LUX-Lung 2)
Wu-Chou, Tainan, Taiwan

12.30 Invited Discussant, Abstracts 364PD-367PD
Filippo de Marinis, Rome, Italy

368PD — A double-blind, randomized, placebo-controlled phase III study of gefitinib (G) versus placebo (P) in patients (Pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021- ILCP)
Veerle Surmont, Ghent, Belgium

369PD — Erlotinib maintenance therapy in patients with stable disease after first-line platinum-doublet chemotherapy for advanced NSCLC
Frederico Cappuzzo, Livorno, Italy

370PD — Final results from the IFCT-GFPC 0502 phase III study: Maintenance therapy in advanced NSCLC with either gemcitabine (G) or erlotinib (E) versus observation (O) after cisplatin-gemcitabine induction chemotherapy (CT), with a predefined second-line treatment
Maurice Pérol, Lyon, France

12.42 Invited Discussant, Abstracts 368PD-370PD
Lucio Crinò, Perugia, Italy

12.30—13.30 Green Hall 3
Poster Symposium (Discussion session)
Health services and public health
Co-Chairs: Christos Chouaid, Paris, France and Heinz Ludwig, Vienna, Austria

1085PD — Maintenance chemotherapy in advanced non-small cell lung cancer: Cost utility of pemetrexed and gemcitabine
Tiago Takahashi, Sao Paulo, Brazil

1086PD — Improving the quality of abstracts for cost-effectiveness analyses (CEA) in oncology
Winson Cheung, Vancouver, BC, Canada

12.30 Invited Discussant, Abstracts 1085PD-1086PD
Christos Chouaid, Paris, France

1087PD — Oral prevalence and clearance of high-risk human papilloma virus (HR-HPV) in healthy people in San Patrignano, a rehabilitation community for substance abusers
Davide Pugliese, Coriano, Italy
1088PD – Breast cancer is a more aggressive disease in Palestinian Arab women than in Jewish women in Israel
Jamal Zidan, Safed, Israel
1089PD – Breast cancer survival in Brazil related with the disparities in health services access
Roberta Wolp Diniz, Villejuif, France
1090PD – Patterns of adjuvant endocrine therapy for early breast cancer in Ontario: A population-based study Yolanda Madarnas, Kingston, ON, Canada
1091PD – Computerized physician order entry systems and chemotherapy (CT) prescription errors
Marianna Aita, Udine, Italy
1092PD – How are departments of cancer medicine organized in Europe? Results from a survey conducted in 7 countries
Karim Fizazi, Villejuif, France
1093PD – What do German office-based community oncologists expect from ESMO? Results from a 2010 survey among members of the Professional Association of Haematologists and Oncologists in Germany (BNHO)
Robert Eckert, Wendlingen, Germany
12.45 Invited Discussant, Abstracts 1087PD-1093PD
Heinz Ludwig, Vienna, Austria
13.00 General Discussion

12.30 Invited Discussant, Abstracts 170PD-173PD
Klaus Pantel, Hamburg, Germany
174PD – Tumor and blood plasma biomarker analyses in the AVAGAST phase III randomized study of first-line bevacizumab + capecitabine/cisplatin in patients with advanced gastric cancer
Manish Shah, New York, NY, USA
175PD – Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (mCRC) patients (pts)
Chiara Cremolini, Livorno, Italy
176PD – SPARC microenvironment signature (SMS) as a prognostic biomarker when combined with LDH and plasma SPARC
Neil Desai, Los Angeles, CA, USA
177PD – Circulating SPARC levels negatively impact chemotherapies in cancer models
Neil Desai, Los Angeles, CA, USA
12.45 Invited Discussant, Abstracts 174PD-177PD
Maria Grazia Daidone, Milan, Italy
13.00 General Discussion

12.30–13.30 Yellow Hall 1
Poster Symposium (Discussion session)
Biomarkers II – Circulating tumor cells and molecular markers
Co-Chairs: Maria Grazia Daidone, Milan, Italy and Klaus Pantel, Hamburg, Germany

170PD – Circulating tumor cells in breast cancer: are currently available detection methods enough?
Cristina Raimondi, Rome, Italy
171PD – Relationship between lymphopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer
Ugo De Giorgi, Lecce, Italy
172PD – Baseline circulating tumour cell (CTC) counts enhance the performance of the Royal Marsden Hospital (RMH) prognostic score to optimise patient selection for phase I clinical trials
Christophe Massard, Sutton, UK
173PD – Enumeration circulating tumor cells (CTCs) is a prognostic and predictive factor for progression-free survival (PFS) and overall survival (OS) in colon cancer patients receiving first-line chemotherapy plus bevacizumab. A TTD Spanish Group Cooperative Study
Javier Sastre, Madrid, Spain
12.30 Invited Discussant, Abstracts 498PD-500PD
Anthony Tolcher, San Antonio, TX, USA
498PD – Dynamic tumor growth evaluation could predict overall survival for patients included in phase I clinical trials
Bertrand Billemont, Paris, France
499PD – Current phase I trials: Dose-levels and first signs of efficacy
Jacques Bonneterre, Lille, France
500PD – Phase I study of the tumor-targeting human L19TNF monoclonal antibody-cytokine fusion protein in patients with advanced solid tumors
Gianluca Spitaleri, Milan, Italy
12.30 Invited Discussant, Abstracts 498PD-500PD
Maria Grazia Daidone, Milan, Italy
13.00 General Discussion

12.30–13.30 Orange Halls 2+3
Poster Symposium (Discussion session)
Developmental therapeutics
Co-Chairs: Johann de Bono, Sutton, UK and Anthony Tolcher, San Antonio, TX, USA

498PD – Dynamic tumor growth evaluation could predict overall survival for patients included in phase I clinical trials
Bertrand Billemont, Paris, France
499PD – Current phase I trials: Dose-levels and first signs of efficacy
Jacques Bonneterre, Lille, France
500PD – Phase I study of the tumor-targeting human L19TNF monoclonal antibody-cytokine fusion protein in patients with advanced solid tumors
Gianluca Spitaleri, Milan, Italy
12.30 Invited Discussant, Abstracts 498PD-500PD
Anthony Tolcher, San Antonio, TX, USA
501PD – A phase I study of IPI-926, an inhibitor of the hedgehog pathway, in patients (pts) with advanced or metastatic solid tumors
Antonio Jimeno, Aurora, CO, USA
502PD – LDE225, a smoothened (Smo) antagonist: Phase I safety and pharmacologic results in patients with advanced tumors
Jordi Rodon Ahnert, Barcelona, Spain
503PD – Treatment of castration refractory prostate cancer patients with 2 different immunotherapeutic approaches against EGFR
Tania Crombet, Havana, Cuba
12.45 Invited Discussant, Abstracts 501PD-503PD
Johann de Bono, Sutton, UK
13.00 General Discussion

12.30–13.30 Yellow Hall 2
Poster Symposium (Discussion session)
Basic science and translational research
Co-Chairs: Cristiana Sessa, Bellinzona, Switzerland and TBC

77PD – P3H collagen prolyl hydroxylases are tissue selective tumour suppressors
Cristiana Lo Nigro, Cuneo, Italy
78PD – Expression of matrix metalloproteinase 1 (MMP1), Dickkopf-1 (Dkk1) and colony-stimulating factor receptor 1 (CSF1R) in bone metastatic tissue (BMT) and in serum of patients with bone metastases (BM) from different solid tumors
Luis Costa, Lisbon, Portugal
79PD – mRNA expression of VEGF family members has prognostic significance in high-risk early breast cancer patients participating in a prospective randomized study of the Hellenic Cooperative Oncology Group (HeCOG)
Helena Linardou, Athens, Greece
12.30 Invited Discussant, Abstracts 77PD-79PD
TBC

80PD – Antitumor activity of nab-paclitaxel and bevacizumab against a new triple negative breast cancer model
Vuong Trieu, Los Angeles, CA, USA
81PD – The mTOR signaling pathway as potential therapeutic target in meningiomas
Christian Mawrin, Magdeburg, Germany
82PD – Novel insights for therapeutic strategies in pancreatic neuroendocrine tumors (pNET)
Aldo Scarpa, Verona, Italy
83PD – Considerations in the development and validation of genomic tests for cancer recurrence and treatment benefit
David J. Kerr, Oxford, UK
12.45 Invited Discussant, Abstracts 80PD-83PD
Cristiana Sessa, Bellinzona, Switzerland
13.00 General Discussion

12.30–13.30 Yellow Hall 3
Poster Symposium (Discussion session)
Hematological malignancies
Co-Chairs: Lena Specht, Copenhagen, Denmark and TBC

1136PD – Melphalan, prednisone, lenalidomide (MPR) versus melphalan (200 mg/m²) and autologous transplantation (MEL200) in newly diagnosed myeloma patients: A phase III trial
Federica Cavallo, Turin, Italy
1137PD – Long term follow up of new cases of acute promyelocytic leukemia treated by arsenic trioxide as sole treatment without ATRA and/or chemotherapy
Ardeshir Ghavamzadeh, Tehran, Iran
1138PD – Results of a randomized, phase II study of bevacizumab and bortezomib vs. bortezomib in patients with relapsed/refractory multiple myeloma: AMBER study
Darrell White, Halifax, NS, Canada
12.30 Invited Discussant, Abstracts 1136PD-1138PD
TBC

1139PD – The role of del(13q14.3) in diffuse large B-cell lymphomas
Ekaterina Chigrinova, Bellinzona, Switzerland
1140PD – Bone marrow involvement and 7q gain in diffuse large B-cell lymphoma: A combination of clinical and molecular data
Ekaterina Chigrinova, Bellinzona, Switzerland
1141PD – Activity and safety of dose-adjusted infusional CHOP chemotherapy with rituximab (DA-POCH-R) in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin’s lymphoma
Daniela Boggiani, Parma, Italy
12.45 Invited Discussant, Abstracts 1139PD-1141PD
Cristiana Sessa, Bellinzona, Switzerland
13.00 General Discussion

12.45 Invited Discussant, Abstracts 501PD-503PD
Johann de Bono, Sutton, UK
13.00 General Discussion
13.30 LBA19 – Cediranib + FOLFOX/XELOX versus placebo + FOLFOX/XELOX in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): A randomized, double-blind, phase III STUDY (HORIZON II)
Paulo Hoff, São Paulo, Brasil

13.45 LBA20 – A phase 2, randomized, double-blind, placebo-controlled study of hedgehog pathway inhibitor (HPI) GDC-0449 in patients with previously untreated metastatic colorectal cancer (mCRC)
Jordan Berlin, Nashville, TN, USA

13.45–15.15 Violet Hall
Special Symposium
ESMO/AIOm Joint Symposium: Young medical oncologists facing daily difficulties in clinical practice
Co-Chairs: Massimo Di Maio, Naples, Italy and Michael V. Karamouzis, Papagou, Greece

13.45 Introduction
Massimo Di Maio, Naples, Italy and Michael V. Karamouzis, Papagou, Greece

13.50 Presenting bad news to the patient
Francesco Atzori, Cagliari, Italy

14.05 The risk of burn out: Are young oncologists at higher risk?
Laurence Albiges, Villejuif, France

14.20 Presenting a completed research project as an oral presentation
Valentina Guarneri, Modena, Italy

14.35 Presenting the data of a project in a manuscript
Evandro De Azambuja, Brussels, Belgium

14.50 Invited Discussant
Valter Torri, Milan, Italy

15.00 Q&A

13.45–15.15 Pink Hall
Special Symposium
Bullseye: PARP
Chair: Johann de Bono, Sutton, UK
Co-Chair: Hilary Calvert, London, UK

13.45 From platinum to PARP
Hilary Calvert, London, UK

13.50targeting the Achilles heel: Synthetic lethality
Alan Ashworth, London, UK

14.10 Encouraging first experiences with PARP inhibitors
Ruth Plummer, London, UK

14.30 Early tales: PARP and BRCA
Jan H M Schellens, Amsterdam, Netherlands

14.50 Later tales: Phase II and beyond
Andrew Tutt, London, UK

15.10 Conclusions
Johann de Bono, Sutton, UK

13.45–15.15 Silver Hall
Educational session
Diagnostic and management issues in gastroesophageal cancer
Chair: Florian Lordick, Hannover, Germany
Co-Chair: João Oliveira, Lisbon, Portugal

13.45 Is there any role for surgery in the multidisciplinary treatment of esophageal cancer?
Michael Stahl, Essen, Germany

14.15 Multimodality treatment for localized gastroesophageal cancer
David Cunningham, Sutton, UK

14.45 New trends for staging and therapy for localized gastroesophageal cancer: The role of PET scan
Florian Lordick, Hannover, Germany

13.45–15.15 Gold Hall
Proffered Paper session
Colorectal cancer
Chair: Jean-Yves Douillard, St. Herblain, France
Co-Chair: Alberto Sobrero, Genoa, Italy

13.30 LBA19 – Cediranib + FOLFOX/XELOX versus placebo + FOLFOX/XELOX in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): A randomized, double-blind, phase III STUDY (HORIZON II)
Paulo Hoff, São Paulo, Brasil

13.45 5800 – mFOLFOX6 + cediranib vs mFOLFOX6 + bevacizumab in previously untreated metastatic colorectal cancer (mCRC): A randomized, double-blind, Phase II/III study (HORIZON III)
Hans-Joachim Schmoll, Halle, Germany

14.00 Invited Discussant, LBA19 and Abstract 5800
Claus-Henning Koehne, Oldenburg, Germany

14.15 LBA20 – Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: The NORDIC VII study (NCT00145314), by the Nordic Colorectal Cancer Biomodulation Group
Kjell Magne Tveit, Oslo, Norway

14.45 Invited Discussant, LBA20 and LBA21
Alberto Sobrero, Genoa, Italy

13.45–15.15 Blue Hall
Special Symposium
Toxicities of targeted therapies: Prevention and management
Chair: Fausto Roila, Terni, Italy
Co-Chair: Dorothy M. K. Keefe, Adelaide, Australia

13.45 Introduction
Dorothy M. K. Keefe, Adelaide, Australia

13.50 Presenting the data of a project in a manuscript
Valentina Guarneri, Modena, Italy

14.15 Multimodality treatment for localized gastroesophageal cancer
David Cunningham, Sutton, UK

14.45 New trends for staging and therapy for localized gastroesophageal cancer: The role of PET scan
Florian Lordick, Hannover, Germany
13.50 Skin toxicity
Mario Lacouture, Chicago, IL, USA
14.15 Gastrointestinal toxicity
Dorothy M. K. Keefe, Adelaide, Australia
14.40 Renovascular and cardiac toxicity
Thomas Suter, Bern, Switzerland
15.05 Conclusions
Fausto Roila, Terni, Italy

15.15–16.15 Gold Hall
Controversy session
Active surveillance in early prognosis prostate cancer should be standard of care
Moderator: Sten Nilsson, Stockholm, Sweden

15.15 Introduction and vote
Sten Nilsson, Stockholm, Sweden
15.25 Pro speaker
Fritz Schröder, Rotterdam, Netherlands
15.45 Contra speaker
Kurt Miller, Berlin, Germany
16.05 Vote and conclusions
Sten Nilsson, Stockholm, Sweden

15.30–17.00 Silver Hall
Educational session
Towards an individualized approach of advanced non-small cell lung cancer
Chair: Enriqueta Felip, Barcelona, Spain
Co-Chair: Rafal Dziadziuszko, Gdansk, Poland

15.30 Should we continue to use the term non-small cell lung cancer?
Adi F Gazdar, Dallas, TX, USA
16.00 How to integrate current knowledge in selecting first-line therapy
Enriqueta Felip, Barcelona, Spain
16.30 Consequences of targeted treatments for second-line therapy
Federico Cappuzzo, Livorno, Italy

15.30–17.30 Violet Hall
Proffered Paper session
Breast cancer, advanced
Chair: Fatima Cardoso, Lisbon, Portugal
Co-Chair: PierFranco Conte, Modena, Italy

15.30 LBA11 – Final Efficacy and Safety Results of a Randomized Phase II Study of the PARP Inhibitor Iniparib (BSI201) in Combination with Gemcitabine/Carboplatin (G/C) in Metastatic Triple Negative Breast Cancer (TNBC)
Joyce O'Shaughnessy, Dallas, TX, USA
15.45 LBA12 – Results of the first randomized phase II study of cationic liposomal paclitaxel (EndoTAGTM-1) targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)
Ahmad Awada, Brussels, BE
16.00 Invited Discussant, LBA11 and LBA12
Richard Bell, Milan, Italy

15.30–17.00 Pink Hall
Educational session
Advances in head and neck cancer
Chair: Jan Vermorken, Edegem, Belgium
Co-Chair: Marshall Posner, New York, NY, USA

15.30 The role of papilloma virus infection
Stina Syrjänen, Turku, Finland
16.00 Integrating systemic agents into multimodality treatment of locally advanced diseases
Marshall Posner, New York, NY, USA
16.30 Optimal treatment for relapsing or metastatic disease
Jan Vermorken, Edegem, Belgium

15.30–17.00 Blue Hall
Educational session
Soft tissue sarcoma: From molecular diagnosis to selection of treatment
Chair: Ian Judson, Sutton, UK
Co-Chair: Serge Leyvraz, Lausanne, Switzerland

15.30 Pathologic diagnosis of soft tissue sarcoma amid molecular biology and targeted therapies
Eva Wardelmann, Bonn, Germany
8th ESMO Patient Seminar

09.30–10.30 Red Hall
Living with cancer: Early rehabilitation
Co-Chairs: Paola Varese, Ovada, Italy and Stella Kyriakides, Nicosia, Cyprus

09.30 Early rehabilitation: where does it lead?
Anita Margulies, Zurich, Switzerland

09.45 The importance of psycho-oncology
Luigi Grassi, Ferrara, Italy

10.00 Common paths in the European Union
Sanja Rozman, Ljubljana, Slovenia

10.15 General Discussion

10.30–10.45 Break

10.45–12.15 Red Hall
Living with cancer: Long-term rehabilitation
Co-Chairs: Elisabetta Iannelli, Rome, Italy and Dorothy M. K. Keefe, Adelaide, Australia

10.45 The long term and late effects of cancer.
Implications for research and public policy
Kevin Stein, Atlanta, GA, USA

11.15 Psychological and social consequences
Patrizia Pugliese, Formello, Rome, Italy

11.30 Poster discussion
AIMaC (Associazione Italiana Malati di Cancro), Italy
APOZ and Friends, Bulgaria
ATTIVECOMEPRIMA, Italy
WALCE (Women Against Lung Cancer in Europe), Italy

12.15–13.15 Lunch
13.15–14.15 Red Hall
Do we always need specific cancer treatment?
Co-Chairs: Kevin Stein, Atlanta, GA, USA and Stella Kyriakides, Nicosia, Cyprus

13.15 General principles in treatment of frail and elderly patients
Matti S. Aapro, Genolier, Switzerland
13.30 What is co-morbidity and how is it evaluated?
Dirk Schrijvers, Antwerp, Belgium
13.45 When not to operate
Alberto Costa, Milan, Italy
14.00 General Discussion

15.15–14.30
Move to breakout sessions

14.30–15.30 Red Hall
Latest developments in breast cancer
Co-Chairs: Rosalba Torrisi, Milan, Italy and Anna Mancuso, Milan, Italy

14.30 Short overview
Rosalba Torrisi, Milan, Italy
14.45 Revision and management of patients with skin problems for radiotherapy
Marie Paule Gardes, Milan, Italy
15.00 General discussion

14.30–15.30 Yellow Hall 1
Latest developments in gastrointestinal tumors
Co-Chairs: Jim Cassidy, Glasgow, UK and TBC

14.30 Short overview
Jim Cassidy, Glasgow, UK
14.45 Management of alopecia problems for best QoL
Alessandra Milani, Milan, Italy
15.00 General discussion

14.30–15.30 Yellow Hall 2
Latest developments in haematological malignancies
Co-Chairs Michael Hallek, Cologne, Germany and Davide Petruzzelli, Brugherio, Italy

14.30 Short overview
Michael Hallek, Cologne, Germany
14.45 Therapeutic relation with the patient
Miriam Magri, Milan, Italy
15.00 General discussion

14.30–15.30 Yellow Hall 3
Latest developments in prostate cancer
Co-Chairs Francesco Montorsi, Milan, Italy IT and Riccardo Valdagni, Milan, Italy

14.30 Short overview
Francesco Montorsi, Milan, Italy
14.45 The rehabilitative nursing function for urinary incontinence. A challenge for best QoL
Mara Marchetti, Milan, Italy
15.00 General discussion

15.30–15.40
Move back to plenary

15.40–16.40 Red Hall
Review and general discussion
Co-Chairs: Lorenz Jost, Bruderholz, Switzerland and TBC

15.40 Best Cancer Reporter Award Ceremony, presented by Kathy Redmond, Milan, Italy
15.45 Short review of major points emerging from the breakout sessions
TBC
16.00 General Discussion

16.40–17.15
Farewell drink
Breast cancer, early
Chair: Luca Gianni, Milan, Italy

224P – Letrozole or anastrozole for the treatment of hormone positive breast cancer: A clinical comparison using indirect statistical techniques
Satyin Kaura, Florham Park, NJ, USA

225P – Effects of exemestane or tamoxifen on bone health within the tamoxifen exemestane adjuvant multinational (TEAM) trial: A meta-analysis
Peyman Hadji, Marburg, Germany

226P – Elevated serum levels of the HER2 extracellular domain (ECD) in primary breast cancer (PBC) with HER2 overexpression predict early failure of adjuvant trastuzumab
Sebastien Thureau, Rouen, France

227P – Her2 status and trastuzumab use among patients with early breast cancer receiving care within the US oncology network
Justin Doan, South San Francisco, CA, USA

228P – Triple-negative (TN) treatment approach in Italy: An update of NEMESI, a multicenter observational study on early breast cancer (EBC) management
Vincenzo Adamo, Milan, Italy

229P – Anthracycline and concurrent radiotherapy significantly reduced breast cancer relapse rate
Nabil Ismaili, Rabat, Morocco

230P – Timing of subsequent surgery (S2) for positive margins (PM) and initiation of adjuvant systemic treatment (Tx) in early breast cancer (EBC)
Leticia de Mattos-Arruda, Barcelona, Spain

231P – A multicenter study of image-guided radiofrequency ablation of small breast carcinomas
Takayuki Kinoshita, Tokyo, Japan

232P – Long term persistent alopecia and suboptimal hair regrowth after adjuvant chemotherapy for breast cancer, alert for an emerging side effect: French ALOPERS observatory
Hugues Bourgeois, Le Mans, France

233P – Adjuvant chemotherapy for early breast cancer in Italy: What has changed today versus the early 2000’s. A comparison between two observational national studies – NORA and NEMESI
Giorgio Mustacchi, Milan, Italy

234P – High-dose chemotherapy and autologous hematopoietic stem cell transplantation as adjuvant treatment in early stage and operable breast cancer: Retrospective long-term analysis of the European experience
Carmelo Bengala, Modena, Italy
235P – Access of high-risk breast cancer patients to adjuvant clinical research programs in French comprehensive cancer centres: A survey by the REMAGUS group
Nawal Ahbeddou, Saint Cloud, France
236P – Early breast cancer: Prognosis related to Ki-67 expression
Raquel Gerson, Mexico City, Mexico
237P – The biological characteristics of early breast cancer (EBC) from NEMESI, an Italian retrospective observational study
Marco Venturini, Negrar, Italy
238P – Adjuvant breast cancer chemotherapy based on sequential anthracyclin and taxane: Retrospective analysis of hematological toxicity
Nuno Couto, Porto, Portugal
239P – NEMESI: A retrospective observational longitudinal study to investigate patient characteristics and treatment in the early breast cancer (EBC) in Italy
Matteo Clavarezza, Milan, Italy
240P – Abdominal obesity and weight gain as a consequence of taxane-based adjuvant chemotherapy for breast cancer
Dimitris Mavroudis, Heraklion, Greece
241P – Impact of Mammaprint on the routine treatment decision making process in an unselected early breast cancer patient population in Belgium
Pino Cusumano, Liège, Belgium
242P – The outcomes of the specialized genetic program provided for the carriers of the genetic alterations predisposing to the breast cancer
Martina Zimovjanova, Prague, Czech Republic
243P – Adjuvant chemotherapy prescription according to multidisciplinary team decision or the MINDACT protocol (Microarray in Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy) (EORTC10041 BIG 3-04)
Carine Mitine, Haine Saint Paul, Belgium
244P – Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy
Yu Hsuan Kuo, Taipei, Taiwan
245P – Impact of different prognostic factors on the development of brain metastasis in adjuvant breast cancer patients
Sara Amin, Giza, Egypt
246P – Are breast cancer (BC) prognostic factors different in young patients?
Zora Baretta, Padova, Italy

247P – Low expression level of nucleostemin (GNL3), stimulator of cancer stem cell feather, is a promising biomarker to predict pathologic complete response (pCR) in neoadjuvant treatment with breast cancer
Kenji Tamura, Tokyo, Chuo-ku, Japan
248P – Predictive factors for complete pathological response after neoadjuvant chemotherapy in breast cancer. Results from a single institution
Vanessa Pons, Valencia, Spain
249P – The 70-gene expression profile for breast cancer patients in Italian hospitals
Daniele Generali, Amsterdam, Netherlands
250P – Evaluation of completeness and quality of the information process during genetic counselling for cancer predisposition. Preliminary results of the genetic counselling service (GCS) of Southern Switzerland
Elena Scaffidi, Viganello, Switzerland
251P – Breastfeeding in breast cancer survivors: Pattern, behaviour and effect on breast cancer outcome
Hatem Azim Jr, Cairo, Egypt

Colorectal cancer
Chair: Eduardo Diaz-Rubio, Madrid, Spain

589P – Integrative evaluation of EGFR downstream signalling functionality to predict response to anti-EGFR monoclonal antibodies in KRAS wild-type mCRC
Anne-Sophie Chretien, Vandoeuvre les Nancy, France
590P – Inter-observer reproducibility of evaluation of EGFR status in colorectal carcinoma
Catherine Julié, Boulogne-Billancourt, France
591P – European reglementation for cetuximab still required the EGFR positive status: Results of a French translational study OMIT of 330 patients to define if this criteria is relevant
Jean-Philippe Metges, Brest, France
592P – “Determina KRAS” Project: What’s new after twenty months?
Jesus Garcia-Foncillas, Pamplona, Spain
593P – Evaluation of KRAS mutation status in primary colorectal tumours and corresponding liver metastases
Nikki Knijn, Nijmegen, Netherlands
594P – Evaluation of KRAS, BRAF and PI3KCA in synchronous and metachronous metastatic colorectal cancer (MCRC)
Fabiola Rojas Llimpe, Bologna, Italy
595P – KRAS mutational status in Japanese patients with colorectal cancer: Results from a multicenter, cross-sectional, large observational study conducted by the Japan Study Group of KRAS mutation in colorectal cancer
Kentaro Yamazaki, Shizuoka, Japan
596P – Early tumor shrinkage for the prediction of efficacy of cetuximab in metastatic colorectal cancer (MCRC): Analysis from the CRYSTAL study
Hubert Piessevaux, Brussels, Belgium
597P – Cetuximab and 1st-line chemotherapy in elderly and younger patients with metastatic colorectal cancer (MCRC): A pooled analysis of the CRyStAL and OPus studies
Gunnar Folprecht, Dresden, Germany
598P – The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan-cetuximab
Mario ScartoZZi, Ancona, Italy
599P – Incidence and prognostic value of BRAF mutation in metastatic colorectal cancer (CRC) with mismatch repair deficiency (dMMR)
Miriam Koopman, Nijmegen, Netherlands
600P – Multicenter phase II study of second-line FOLFIRI+cetuximab with KRAS wild type gene in metastatic CRC (FLIER)
Takeshi Kato, Minoh, Japan
601P – Efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory elderly patients (>65 years) with metastatic colorectal cancer (mCRC)
Christian Jehn, Berlin, Germany
602P – Safety, pharmacokinetics (PK), and efficacy of imprime PGG plus cetuximab (cetux) with and without irinotecan (irino) in advanced metastatic colorectal cancer (mCRC) patients
Ma Tamayo, Manila, Philippines
603P – Early magnesium modifications as a surrogate markers of efficacy of cetuximab based anticancer treatment in advanced colorectal cancer patients
Sara Galluzzo, Rome, Italy
604P – Hypomagnesemia related to anti-EGFR monoclonal antibody therapies: A pooled analysis of randomised trials
Faustro Petrelli, Treviglio, Italy
605P – Genetic polymorphisms of the Fc RIIa-Fc RIIa are not predictive of clinical outcomes after cetuximab based chemotherapy in patients with metastatic colorectal cancer
Seong Joon Park, Seoul, South Korea
606P – Chemotherapy with or without bevacizumab in advanced colorectal cancer: A phase III trial
Georgios Stathopoulos, Athens, Greece
607P – Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab in patients with metastatic colorectal cancer
Yoshito Komatsu, Sapporo, Japan
608P – Bevacizumab (BV) in combination with FOLFOXIRI compared with BV plus FOLFIRI as first-line treatment of metastatic colorectal cancer (MCRC): Preliminary safety results of the TRIBE study by the Gruppo Oncologico Nord-Ovest (GONO)
Gianluca Masi, Pisa, Italy
609P – Efficacy and safety of second-line bevacizumab (BV) plus FOLFIRI / FOLFOX in patients with metastatic colorectal cancer (mCRC) who failed prior-combination chemotherapy without BV: Multicenter retrospective 2nd-BV study in Tsukuba Cancer Clinical Trial Group (TCTG)
Toshikazu Moriwaki, Tsukuba-Shi, Japan
610P – Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine (C) alone or in combination with bevacizumab (B) +/- mitomycin C (M) in advanced colorectal cancer (CRC)
Timothy Price, Adelaide, Australia
611P – Current chemotherapy and monoclonal antibody use patterns in metastatic colorectal cancer in Western Europe
Zhongyun Zhao, Newbury Park, CA, USA
612P – Clinical and economic burden of toxicities associated with monoclonal antibodies for metastatic colorectal cancer (mCRC)
Chakkarin Burudpakdee, Philadelphia, PA, USA
613P – Perfusion computed tomography as prognostic and predictive factor in patients with colorectal cancer liver metastases treated with bevacizumab
Rita De Sanctis, Rome, Italy
614P – A blinded placebo (P) controlled phase I/II dose escalation study (DES) of brivanib (B), an oral selective dual inhibitor of FGF and VEGF signaling, in combination with cetuximab (C) and irinotecan (I) in patients (pts) with KRAS wild type (KWT) advanced or metastatic colorectal cancer (amCRC): Safety, tolerability and pharmacokinetics (PK) findings
Young Suk Park, Seoul, South Korea
615P – A phase II study of cediranib in combination with mFOLFOX6 in Japanese patients (pts) with metastatic colorectal cancer (mCRC)
Kei Muro, Nagoya, Japan
616P – Phase II study of first-line sunitinib (SU) in combination with irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI) in Japanese patients (pts) with unresectable/metastatic colorectal cancer (mCRC)
Akihito Tsuji, Kochi, Japan
617P – Sorafenib (S) with FOLFIRI as first-line therapy for metastatic colorectal cancer (mCRC): A phase I study
Jean Maroun, Ottawa, ON, Canada
618P – A phase II study of two dose levels of vorinostat (V) in combination with fluorouracil (5-FU) and leucovorin (LV) in fluoropyrimidine-refractory colorectal cancer (CRC) patients (pts)
Marwan Fakih, Buffalo, NY, USA
619P – Analysis of plasma biomarkers, DCE-MRI, and KRAS mutations in patients (pts) with advanced colorectal carcinoma (CRC) treated with the multikinase inhibitor regorafenib
Olaf Christensen, Montville, CT, USA
620P – Identification of predictive biomarkers for individual response to mFOLFOX6 in colorectal cancer patients
Masahiko Nishiyama, Hidaka, Saitama, Japan
621P – Intermittent versus continuous erlotinib with concomitant modified ‘XELOX’ (q3W) in first-line treatment of metastatic colorectal cancer (mCRC)
Steven L. Chan, Hong Kong, China
622P – Cost comparison: Capecitabine + oxaliplatin (XELOX) vs 5-FU/LV + oxaliplatin (FOLFOX4) in the adjuvant treatment of patients with colon cancer (aCC)
Klaus Hieke, Binningen, Switzerland
623P – Meta-analysis of the validity of progression-free survival as a surrogate endpoint for overall survival in metastatic colorectal cancer trials
Chirila Costel, Research Triangle Park, NC, USA
624P – Analysis of neurosensory adverse events (NSAEs) induced by FOLFOX4 treatment in advanced/recurrent or adjuvant colorectal cancer in Asian and Western patients (pts)
Kenichi Sugihara, Tokyo, Japan
625P – Significant Impact of Her2/neu,Bcl-2 and P53 overexpression on survival in colorectal cancer (using tissue microarray)
Ola Khorshid, Cairo, Egypt
626P – Thrombocytosis as a predictive and prognostic marker in advanced colorectal cancer (aCRC): Results of the MRC COIN trial explored
Tim Maughan, Cardiff, UK
627P – Natural history of malignant bone disease in colorectal cancer: Final results of a large Italian “bone metastases” survey
Daniele Santini, Rome, Italy
628P – Efficacy of zoledronic acid in patients with colorectal cancer metastatic to bone
Giuseppe Tonini, Rome, Italy
629P – Preliminary results from the South Australian (SA) Clinical Registry for advanced colorectal cancer (CRC) assessing the impact of age and choice of chemotherapy on outcome
Amanda Townsend, Adelaide, Australia
630P – Patients not receiving systemic therapy for metastatic colorectal cancer – what are the drivers and what are the outcomes?
Mark Voskoboynik, Melbourne, Australia
631P – Should the primary tumor be resected in patients with unresectable synchronous metastasis of colorectal cancer? Prognostic retrospective multicentric study of 128 patients
Elise Desot, Reims, France
632P – Survival after surgical resection of hepatic metastases from colorectal cancer: A systematic review and meta-analysis
Aliki Taylor, Uxbridge, UK
633P – Analysis of overall survival among patients with metastatic colorectal cancer, with and without undergoing elective colectomy
Mariana Ferreira, Barretos, Brazil
634P – RIPK1 polymorphism as prognostic marker for survival in patients with colorectal cancer after complete resection
Won Sik Lee, Daegu, South Korea
635P – Resection of colorectal cancer (CRC) metastases after bevacizumab (BV) treatment for 1st-line therapy: Results of the ETNA cohort study
Denis Smith, Bordeaux, France
636P – FUFIRI or mIROX for first-line treatment in metastatic colorectal cancer (mCRC) and secondary resection of liver metastasis: A post-hoc analysis of tumor response and overall survival in the FIRE-trial
Clemens Giessen, Munich, Germany
637P – The role of perioperative bevacizumab in the management of patients with colorectal cancer and liver metastases treated with liver metasasesectomy
Anastasia Constantinidou, London, UK
638P – Liver resection plus local destruction of liver metastases for patients with metastatic colorectal cancer
Igor Sagaidak, Moscow, Russian Federation
639P – Treatment for recurrence after hepatectomy in patients with colorectal cancer and liver metastasis
Shinichi Miyagawa, Matsumoto, Japan
640P – A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: A Hellenic Cooperative Oncology Group study
Christos Papadimitriou, Athens, Greece
641P – Randomised phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (N016968): Impact of age on disease-free survival (DFS) or overall survival (OS)
Daniel Haller, Philadelphia, PA, USA
642P – Efficacy findings from the X-ACT trial of capecitabine vs. 5-FU/LV as adjuvant therapy for patients with stage III colon cancer: No impact of age on disease-free survival or overall survival
Chris Twelves, Leeds, UK
643P – Stroma production within the primary tumor correlates with poor survival for stage I-II colon cancer patients
Wilma Mesker, Leiden, Netherlands
644P – Is mucinous carcinoma an independent histologic type in colon cancer? A significance of mucin in histologic classification
Yuji Maeda, Isehara, Japan
645P – CpG island methylator phenotype and microsatellite instability as a prognostic factor in colon cancer treated with adjuvant FOLFOX chemotherapy
Hyun Jung Lee, Seoul, South Korea
646P – CpG island methylation in MGMT, cadherin E and H promoters, K-ras and B-raf mutations: Determining progression and sequence in colorectal adenoma-carcinoma
Brigitte Metzger, Luxembourg
647P – Importance of perineural invasion in early stage colorectal cancer
Mehmet Ozturk, Istanbul, Turkey
648P – Perineural invasion is a strong independent prognostic factor following pre-operative chemo/radiotherapy for locally advanced rectal cancer
Amandeep Dhadda, Hull, UK
649P – Early detection of colorectal cancer using mass spectrometry based serum protein profiling
Anouck Huijbers, Leiden, Netherlands
650P – Development and measurement of guideline-based indicators for colorectal carcinoma
P. B. Ottevanger, Nijmegen, Netherlands
651P – MGMT -535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy
Byung Woog Kang, Seoul, South Korea
652P – Prognostic impact of insulin-like growth factor gene polymorphisms on survival of patients with colorectal cancer
Jong Gwang Kim, Daegu, South Korea
653P – Is obesity changes the expression profile of genes coding IGF in the colorectal cancer patients?
Ewa Nowakowska Zajdel, Bytom, Poland
654P – Phase II study with panitumumab, oxaliplatin, 5-fluorouracil and concurrent radiotherapy in high-risk locally advanced rectal cancer patients (STARPA/STAR-02 study)
Carmine Pinto, Bologna, Italy
655P – CRAB trial: Updated results from a prospective phase II study evaluating neoadjuvant capecitabine, radiotherapy (RT) and bevacizumab in locally advanced rectal cancer
Vaneja Velenik, Ljubljana, Slovenia
656P – Chemoradiotherapy with 5-FU versus capecitabine on rectal cancer downstaging
Lúcia Águas, Porto, Portugal
657P – Final safety and efficacy results of a phase II trial of Bevacizumab, Capecitabine, Oxaliplatin, Radiation Rectal Cancer Trial (A-CORRECT)
Hagen Kennecke, Vancouver, BC, Canada
658P – Critical role of bevacizumab schedule in combination with chemo-radiotherapy in neo-adjuvant treatment of rectal cancer: Circulating endothelial cells and FDG-PET as markers for early prediction
Antonio Avallone, Naples, Italy
659P – The location of lymphangiogenesis is an independent prognostic factor in rectal cancers with or without preoperative radiotherapy
Annica Holmqvist, Linköping, Sweden
660P – Biomarker profiles are not of predictive value for response and outcome in patients with locally advanced rectal cancer undergoing cetuximab-based preoperative chemoradiotherapy
Kathrin Della, Halle (Saale), Germany
661P – Circulating level of VEGF, E-selectin, TGF-α, EGF and 18F-FDG PET uptake in locally advanced rectal cancer (LARC) patients treated with chemoradiation (CTRT) and panitumumab (StarPan/STAR-02 phase II study)
Sara Pini, Bologna, Italy
662P – Topoisomerase IIα in colorectal carcinoma: Expression and prognostic role
Antonio Juretic, Zagreb, Croatia
663P – A Let-7 microRNA complementary site polymorphism in the KRAS 3'-UTR region as a genetic regulator in advanced colorectal cancer
David Páez, Barcelona, Spain
664P – Circulating tumor cells in colorectal cancer. A prospective study
Virginia Arrazubi, Pamplona, Spain

Gynecological cancer
Chair: TBC

980P – Randomized phase II study of paclitaxel-carboplatin (PC) versus gemcitabine-carboplatin (GC) followed by paclitaxel-carboplatin (PC) in platinum-sensitive recurrent ovarian carcinoma (PSROC): A GEICO
995P – Weekly paclitaxel and paraplatin as first-line treatment in patients with recurrent or metastatic cervical carcinoma
Wael El-Sadda, Mansoura, Dakahlia, Egypt

996P – Chemotherapy using gemcitabine (G) & cisplatin (C) in recurrent and metastatic squamous cell carcinoma of the cervix
Hassen Mahfouf, Algiers, Algeria

997P – EGFR mutation status and the efficacy of gefitinib in combination with paclitaxel and carboplatin as neoadjuvant treatment in locally advanced cancer of cervix: A study from Eastern India
Ritwik Pandey, Kolkata, India

998P – A phase II trial of paclitaxel plus doxorubicin plus carboplatin in patients with intermediate risk, high risk, or recurrent endometrial cancer: A Japan Endometrial Cancer Study Group trial
Seisuke Kumagai, Iwate, Japan

999P – Expression of annexin A4 in endometrial cancer and relation to carboplatin sensitivity
Shinya Matsuzaki, Suita Osaka, Japan

1000P – Incidence of second malignancies (SM) in the treatment field following pelvic radiotherapy (RT): A case-control study from South East Wales (SEW)
Ayman Madi, Newcastle upon Tyne, UK

Head and neck cancer
Chair: Lisa Licitra, Milan, Italy

1012P – The expression of Toll-like receptor pathway molecules in peripheral blood mononuclear cells and its use as a potential biomarker for tumor behavior in laryngeal carcinoma
Katarzyna Starska, Lodz, Poland

1013P – Heat shock proteins 27, 105 expressions in oral tongue squamous cell carcinoma and their correlations with clinicopathological characteristics by immunohistochemistry
Shinya Matsuzaki, Suita Osaka, Japan

1014P – Expression of survivin in adenoid cystic carcinoma of the head and neck and its clinicopathological relationship
Yoon Ho Ko, Seoul, South Korea

1015P – Tumor stage, human papilloma virus (HPV) and smoking status affect the survival of patients with oropharyngeal cancer: An Italian validation study
Roberta Granata, Milan, Italy

1016P – Is concurrent chemoradiotherapy with altered fractionation (C-AFRT) better than standard concurrent chemoradiotherapy (C-RT) in head and neck cancer? An exploratory network meta-analysis using individual patient data
Pierre Blanchard, Villejuif, France
1017P – Larynx preservation (LP) in selected stage III and IV patients (pts) with squamous cell carcinoma (LC) using concurrent chemotherapy (CT) and hyperfractionated radiotherapy (RT)
Raul Giglio, Buenos Aires, Argentina

1018P – Efficacy and safety of induction chemotherapy with cisplatin plus paclitaxel followed by chemoradiotherapy for locally advanced head and neck cancer — An interim analysis of safety and response rate
Alexandre Jácome, Barretos, Brazil

1019P – Is there a role for induction chemotherapy (iCT) in locally advanced head and neck squamous cell carcinoma (LAHNSCC)? A single institution experience
Isabel Sargento, Lisboa, Portugal

1020P – Comparison of two modalities of induction chemotherapy in head and neck cancer with unresectable bulky nodal disease; an intent-to-treat analysis
Svetislav Jelic, Belgrade, Serbia

1021P – Induction docetaxel and S-1 followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma
Hye Ryun Kim, Seoul, South Korea

1022P – Impact of age on prognosis of locally advanced head and neck cancer (LAHNC) treated with chemoradiation (CRT). A single institutional experience
Nerina Denaro, Messina, Italy

1023P – A multicenter phase II trial to evaluate the combination of cetuximab (C) plus TPF (docetaxel, cisplatin and fluorouracil) as induction chemotherapy (IC) followed by cetuximab plus accelerated radiotherapy (RT) with concomitant boost in patients (pts) with unresectable locally advanced squamous cell carcinoma of head and neck (SCCHN)
Ricard Mesia, Barcelona, Spain

1024P – Single-centre experience of quality assurance (QA) measures in a phase II trial of radiotherapy (RT) + panitumumab vs chemo-RT (CRT) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)
Andreas Meister, Aarau, Switzerland

1025P – Phase I study of concurrent pemetrexed, cetuximab and radiation therapy with or without cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)
Lisa Licitra, Milan, Italy

1026P – Impact of salivary composition changes on saliva quality & quality of life after radiotherapy of head and neck cancer: A prospective longitudinal study
Manpreet Tiwana, Dehradun, India

1027P – Oropharyngeal mucositis prophylaxis in combined radioimmunochemotherapy
Wolf Jordan, Lehrte, Germany

1028P – Hypomagnesaemia after induction TPF chemotherapy followed by concomitant cisplatin/cetuximab/radiotherapy (ccRT) in locally advanced head and neck cancer (LAHNC)
Cvetka Grasic Kuhar, Ljubljana, Slovenia

1029P – Clinical outcome and incidence of renal failure (RF) after concurrent chemo-radiation with 3-weekly (3WC) versus weekly (1WC) cisplatin for locally advanced squamouscellar head and neck cancer (SCHNC)
Vittoria Espeli, Geneva, Switzerland

1030P – Body mass index (BMI) in prognosis of locoregionally advanced and metastatic squamous cell carcinoma (SCHNC)
Miroslav Kreacic, Belgrade, Serbia

1031P – Trends in the treatment of locally advanced squamous cell carcinoma of the head and neck (LASCCHN) in Europe between 2006 and 2009
Volker Budach, Berlin, Germany

1032P – Ability of FDG-PET/CT to detect residual disease on posttreatment follow-up of patients with head and neck squamous cell carcinoma treated with chemoradiotherapy compared with CT
Pilar De La Morena, Murcia, Spain

1033P – Recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Changes in 1st-line treatment patterns in Europe 2008–2009
Hansjochen Wilke, Essen, Germany

1034P – Cetuximab in combination with bendamustine as an alternative therapeutic option for recurrent head and neck cancer
Hayssam Zakaria, Lehrte, Germany

1035P – Panitumumab (PMAB) regimen in second-line monotherapy (PRISM) in patients (pts) with recurrent (R) or metastatic (M) squamous cell carcinoma of the head and neck (SCCHN): Interim safety analysis
Danny Rischin, East Melbourne, Australia

1037P – Analysis of antibodies against Epstein-Barr virus and viral DNA quantification as early screening tools of nasopharyngeal carcinoma
Susanna Hutajulu, Yogyakarta, Indonesia
1038P – The continuing role of platinum-based chemotherapy in the era of targeted drugs in advanced nasopharyngeal carcinoma (NPC): A systematic review
Quan-Sing Ng, Singapore

1039P – Phase II trial of first-line capecitabine plus oxaliplatin in patients with metastatic nasopharyngeal carcinoma
Daniel Chua, Happy Valley, Hong Kong, China

1040P – Induction chemotherapy (CT) with docetaxel, cisplatin, and fluorouracil (TPF) followed by concomitant cisplatin plus radiotherapy in locally advanced nasopharyngeal cancer (NPC)
Esma Kerboua, Algiers, Algeria

1041P – A phase II trial of induction chemotherapy with cisplatin, docetaxel and capecitabine followed by concurrent cisplatin- radiotherapy in advanced nasopharyngeal carcinoma
Mohamed Yamouni, Oran, Algeria

1042P – Introduction chemotherapy with docetaxel, cisplatin and S-1(TPS) followed by concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma
Tomoko Yamazaki, Kashiwa, Japan

1043P – A dendritic cell vaccine transduced with Ad5-f35-dLMP1-λ-LMP2 for patients with metastatic nasopharyngeal carcinoma — A phase II clinical trial
John Chia, Singapore

1044P – Prognostic factors influencing outcome of patients with recurrent or metastatic carcinoma (R&M) of the head and neck: Results of an Italian monoinstitutional study
Aurora Mirabile, Milan, Italy

1045P – Radiotherapy after hyperbaric oxygen concurrent with superselective intra-arterial carboplatin chemotherapy enhances survival of patients with oral cancer
Ryoichi Oya, Kitakyushu, Japan

1046P – Oral carcinoma after stem cell transplantation – a single centre experience
Ana Castro, Porto, Portugal

1047P – Local use of carboplatin in complex treatment of retinoblastoma
Rustam Usmanov, Tashkent, Uzbekistan

1048P – Gemcitabine plus oxaliplatin (GEMOX) regimen in radioactive iodine resistant metastatic thyroid cancer: Activity and safety study
Yann Vano, Paris, France

1049P – Olfactory neuroblastoma: Impact of induction chemotherapy and proton beam therapy
Makoto Tahara, Kashiwa, Chiba, Japan

Neuro-oncology
Chair: Roger Stupp, Vevey and Lausanne, Switzerland

1056P – Bevacizumab (B) with irinotecan (I) in recurrent glioblastoma (GBM): A national retrospective cohort of the ANOCEF (Association des Neuro-oncologues d’Expression Française) group
Sophie Taillibert, Paris, France

1057P – Encouraging overall survival (OS) with bevacizumab (Bev) in patients with recurrent high-grade glioma (HGG) treated outside clinical trials
Silvia Hofer, Zurich, Switzerland

1058P – Bevacizumab and irinotecan in recurrent malignant glioma: Results of a French retrospective cohort study OMIT of 264 patients in real practice!
Françoise Grudé, Angers, France

1059P – Efficacy, safety and pattern of relapse of bevacizumab (BEV) versus chemotherapy for recurrent glioblastoma multiforme (GBM): A McGill University study
Solmaz Sahebjam, Montreal, QC, Canada

1060P – Clinical predictive factors of increased overall survival with bevacizumab/irinotecan for primary recurrent glioblastoma (GBM)
Jean Sebastien Frenel, Saint Herblain, Nantes, France

1061P – Experience with the monoclonal antibody bevacizumab (Bev) combined with chemotherapy in children with poorly differentiated glial CNS tumours
Boris Kholodov, Moscow, Russian Federation

1062P – Sorafenib (So) in association with low-dose metronomic temozolomide (TMZ) in recurrent glioblastoma multiforme (GBM): Preliminary results of a phase II study
Lorenza Landi, Livorno, Italy

1063P – TEMOCAR: Carboplatin in addition to radiotherapy and temozolomide in newly diagnosed unresectable glioblastoma
Nicolas Pecuchet, Paris, France

1064P – Contribution of low-molecular weight heparin addition to concomitant chemoradiotherapy in the treatment of glioblastome multiforme
Seyit Zincircioglu, Diyarbakir, Turkey

1065P – Pre-treatment platelet count as a prognostic marker in patients with glioblastoma (GBM) treated with radiotherapy and concurrent and adjuvant temozolomide (RCAT)
Vasiliki Michalarea, London, UK

1066P – Maintenance temozolomide in glioblastoma – 6 versus 12 cycles
Matilde Salgado, Porto, Portugal
1067P – Transition from 2D conventional to 3D conformal radiation therapy in patients with brain gliomas: Clinical outcome (Mansoura University experience)
Ibrahim Awad, Mansoura, Dakhla, Egypt

1068P – MGMT promotor methylation status and Ki-67 in correlation to survival and response to treatment with temozolomide and radiotherapy in newly diagnosed glioblastoma patients
Khaled Abdel Karim, Cairo, Egypt

1069P – Correlation of epidermal growth factor receptor status with treatment outcome in postoperative glioblastoma multiforme patients treated with chemoradiotherapy
Supriya Mallick, New Delhi, India

1070P – Radiotherapy response of brain metastases in patients with non-small cell lung cancer (NSCLC) and methylation status of O6-methyl guanine methyl transferase (MGMT) promoter region
Kenji Hashimoto, Tokyo, Japan

1071P – Pemetrexed (P) plus carboplatin (Cb) as up-front treatment for patients with brain metastases of lung adenocarcinoma
Kader Chouahnia, Bobigny, France

1072P – Influence of cytostatic agents on pH-regulating transporter in glioma cells
Nicole Basler, Greifswald, Germany

1073P – Influence of ABCB1, ABCG2 and MGMT promotor methylation and gene polymorphisms on clinico-pathological characteristics of glioma patients
Sandra Bien, Greifswald, Germany

1074P – Histone deacetylase inhibitor vorinostat reduces expression of platelet-derived growth factor receptor A (PDGFRα) and matrix metalloproteinase-2 (MMP2) genes in glioblastoma cell lines
Pavel Bezceny, London, UK

1075P – The activity of MRP1 membrane transporter confers resistance to anticancer drugs in glioblastoma multiforme cells
Claudia Quezada, Valdivia, Chile

1076P – mRNAs overexpression in glioblastomas versus low-grade gliomas
Juan Carlos Martinez, Madrid, Spain

1077P – Silibinin inhibits invasive properties of human glioblastoma U87MG cells through suppression of cathepsin B and nuclear factor kappa B-mediated induction of matrix metalloproteinase 9
Reza Ghasemi, Tehran, Iran

1078P – The role of multislice CT-angiography to assess giant cranio-facial meningiomas vascular supply mode
David Miminoshvili, Tbilisi, Georgia

**Palliative care**
Chair: TBC

1184P – Evaluation of the possibility of outpatient management of febrile neutropenia patients with an intermediary risk of complications and impact on cost
Isabelle Borget, Villejuif, France

1185P – Bone antiresorptive agents in patients with metastatic bone disease: Pharmacokinetic and pharmacodynamic effects
Peyman Hadji, Marburg, Germany

1186P – Cancer pain management in oncological settings. The role of oxycodone: A new option as starting strategy therapy?
Olga Martelli, Rome, Italy

1187P – Positive airway stenting for symptomatic tracheobronchial strictures in metastatic non-lung cancer patients
Masahiro Endo, Shizuoka, Japan

1188P – Increased patient medication safety in advanced palliative home care through the inclusion of dispensing pharmacists: A development project
Barbro Norrstrom, Alvsjo, Sweden

1189P – Description and prevalence of palliative care inpatients: A prospective study in 14 Belgian hospitals
Marianne Desmedt, Brussels, Belgium

1190P – Analysis of advance directives among terminal cancer patients admitted to a palliative care unit: A single center’s experience
So Yeon Oh, Seoul, South Korea

1191P – Comparison of medical expenditure according to types of hospice care
Bong Seog Kim, Seoul, South Korea

1192P – Literature search on end-of-life aggressiveness of care studies with respect to anticancer treatments
Lea Choung Wong, Singapore

**Supportive care**
Chair: Jørn Herrstedt, Odense, Denmark

1240P – The analgesic therapy of patients with hematologic or solid tumours: Results from Italian ECAD_O survey
Carla Ripamonti, Milan, Italy

1241P – Pain management in critically ill patients: What is important? The results from Italian ECAD_O survey
Carla Ripamonti, Milan, Italy
1242P – Oxycodone/acetaminophen combination tablet in patients with metastatic bone pain: A randomized, double-blinded, placebo-controlled trial
Lei Sima, Beijing, China

1243P – Study on the prevalence of post-treatment chronic pain in breast cancer patients and interference of pain with life functions
Ali Taghizadeh Kermani, Mashhad, Iran

1244P – Multicenter phase II study of an opioid-based pain control program for patients with head and neck cancer treated by chemoradiotherapy
Akihiro Homma, Sapporo, Japan

1245P – Supportive care in relapsed head and neck cancer: Transdermal buprenorphine formulation
Mario Airoldi, Turin, Italy

1246P – First baseline results of a Pan-European phase IV open-label multicentre study of the titration of fentanyl buccal tablets (FBT) in patients with breakthrough cancer pain (BTcP)
Jerzy Jarosz, Warsaw, Poland

1247P – Opioid-induced constipation prevalence and correlation with the therapy: An Italian prospective, multicentric analysis of 1210 oncologic patients
Furio Zucco, Garbagnate Milanese, Italy

1248P – Effects of denosumab vs zoledronic acid (ZA) on pain in patients (pts) with advanced cancer and bone metastases: An integrated analysis of 3 pivotal trials
Charles Cleeland, Houston, TX, USA

1249P – Comparison of denosumab versus zoledronic acid (ZA) for treatment of bone metastases in advanced cancer patients: An integrated analysis of 3 pivotal trials
Allan Lipton, Hershey, PA, USA

1250P – Medical ozone (O3) heals osteonecrosis of the jaw (ONJ) in patients treated with bisphosphonates (BPs). Preliminary results
Carla Ripamonti, Milan, Italy

1251P – Randomized pharmacokinetic evaluation of subcutaneous versus intravenous palonosetron in cancer patients treated with platinum-based chemotherapy
Anabel Del Barrio, Pamplona, Spain

1252P – Aprepitant palonosetron and dexamethasone to prevent nausea and vomiting during multiple cycles of cisplatin-based chemotherapy
Flavia Longo, Rome, Italy

1253P – Evaluation of adrenal suppression after dexamethasone therapy as an antiemetic in cancer patients
Hye-Suk Han, Cheongju, South Korea

1254P – Identification and ranking of side-effects in patients receiving radiotherapy and concomitant weekly cisplatin. A multinational collaborative survey
Christina Ruhlmann, Odense, Denmark

1255P – Dexamethasone (DEX)-sparing regimen for prevention of emesis following moderately emetogenic chemotherapy (MEC): Analysis of prognostic factors affecting anti-emetic outcome. An I.T.M.O. study
Luigi Celio, Milan, Italy

1256P – High-level resistance to antimicrobials in febrile neutropenia: Experience from a tertiary care cancer center in India
Indranil Ghosh, New Delhi, India

1257P – Administration of granulocyte-colony stimulating factors (G-CSF) in solid tumors. An Italian observational study by the OBSERVE Study Group
Sandro Barni, Treviglio, Italy

1258P – Management of febrile neutropenia at an outpatient clinic: Risk self-assessment by a simplified scoring system
Toshiro Mizuno, Tsu City, Japan

1259P – A predictive model to estimate the true risk of severe neutropenia in cancer patients treated with chemotherapy
Eugeniu Banu, Cluj Napoca, Romania

1260P – A randomised trial comparing peripherally inserted central venous catheters (PICC) vs subcutaneously implanted port-chamber catheters (PORT) for delivery of chemotherapy to patients with non-haematological malignancies
Kunal Jain, Ludhiana, India

1261P – Thrombovascular events (TVEs) and predisposing TVE risk factors in cancer patients receiving chemotherapy and epoetin alfa QW or TIW for anemia
Kris Deprince, Beerse, Belgium

1262P – Nadroparin for the prevention of thromboembolic events in ambulatory patients receiving chemotherapy with metastatic or locally advanced cancer: A post-hoc analysis of thromboembolic risk related to type chemotherapy in the PROTECHT study
Giampiero Gasparini, Rome, Italy

1263P – Pulmonary embolism: Unsuspected finding in cancer patients
Ignacio García-Escobar, Madrid, Spain

1264P – Master oncology: A multicenter, case-control, observational study on the epidemiology and risk factors for thromboembolic events in cancer patients
Roberto Labianca, Bergamo, Italy
1265P – Impact of epistaxis on the use of fentanyl pectin nasal spray to treat breakthrough cancer pain
David Brooks, Chesterfield, UK

1266P – A phase III, randomized double-blind placebo-controlled study of epoetin beta in lung and gynecological cancer receiving platinum-based chemotherapy: Japan Erythropoietin Study Group
Akira Yoshizaki, Morioka, Iwate, Japan

1267P – Darbepoetin alfa dosing weekly and every three weeks in cancer patients with chemotherapy-induced anaemia – efficacy data from the CHOICE study
Simon Van Belle, Ghent, Belgium

1268P – Darbepoetin alfa in the treatment of chemotherapy-induced anaemia; effects of target haemoglobin label change: Data from the APRIORI study
Veronika Sárosi, Pécs, Hungary

1269P – A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia
Daniell Mitchell, Glattbrugg, Switzerland

1270P – Anemia and darbepoetin alfa administration in patients treated with CHOP+/-R chemotherapy: Results from an observational study of patients with non-Hodgkin lymphoma
Beatrix Pujol, Zug, Switzerland

1271P – Cardioprotective effect of telmisartan in cancer patients treated with epirubicin
Giovanni Mantovani, Cagliari, Italy

1272P – High incidence of severe sorafenib-induced diarrhea in patients with hyperbilirubinemia and/or hypoalbuminemia
Judith Michels, Paris, France

1273P – Sulphasalazine in the prevention of radiation-induced acute proctitis in patients with prostate cancer
Simin Hemati, Isfahan, Iran

1274P – Duration of paclitaxel (PTX)-induced peripheral neuropathy (PN)
Yuko Tanabe, Tsukiji, Chuo-ku, Tokyo, Japan

1275P – Topical silver sulfadiazine for prevention of acute dermatitis during irradiation for breast cancer
Simin Hemati, Isfahan, Iran

1276P – Pre-emptive skin toxicity treatment for anti-EGFR drugs: Evaluation of efficacy of skin moisturizers and limecicline. A phase II study
Roberta Grande, Frosinone, Italy

1277P – Assessment of supportive care for hand-foot syndrome and stomatitis in relapsed ovarian cancer patients receiving pegylated liposomal doxorubicin
Takeo Otsuki, Sendai, Japan

1279P – Palmar-plantar erythrodysesthesia (PPE) in patients (pts) with ovarian cancer (OC) or metastatic breast cancer (MBC) treated with pegylated liposomal doxorubicin (PLD): An observational study
Maria Luisa Gonzalvez, Murcia, Spain

1280P – Management of oral mucositis (OM) with a mucoc-adhesive oral rinse: European clinical experience
Andreas Duckert, Frankfurt/Oder, Germany

1281P – Functional magnetic resonance imaging with food stimuli in lung cancer patients with and without anorexia
Karla Sanchez Lara, Mexico City, Mexico

1282P – Improvement of physical activity as an alternative objective variable to measure treatment effects of anti cachexia therapy in cancer patients
Giovanni Mantovani, Cagliari, Italy

1283P – Relationship between performance status, nutritional status and chemotherapy dose-intensity in patients with solid tumors
Anatole Cessot, Paris, France

1284P – Evaluation of a hospital-home medical program (HHMP) for the management of chemotherapy-related toxicities in the outpatient setting
Romein Coriat, Paris, France

1285P – Attitudes of health professionals to patients who receive chemotherapy information from the internet and their discussion of internet information with patients
Elaine Davies, Northampton, UK

1286P – Internet usage by patients receiving chemotherapy information – is the Internet beneficial or deleterious to patients?
Elaine Davies, Northampton, UK

1287P – Importance of religion and spirituality in cancer patients cared for in oncological, supportive care, psychological and rehabilitation ambulatory settings
Carla Ripamonti, Milan, Italy

1288P – Sexual dysfunctions and cancer, or cancer and sexual dysfunctions?
Silvia Bonicatto, Gornet, Argentina

1289P – Pharmacological interventions for fertility preservation during chemotherapy – a systematic review and meta-analysis
Irit Ben-Aharon, Petach-Tikva, Israel

1290P – Feasibility of removal of Huber needle by patients or their family members during chemotherapy for colorectal cancer
Kaoru Shibamoto, Shizuoka, Japan
Monday, 11 October 2010

08.00–08.45 Turquoise Hall 2
YO Breakfast
Medical information. Where to find it, what to trust
Medical information: Where to find it, what to trust
Lewis Rowett, Oxford, UK

08.00–09.00 Yellow Hall 1
Challenge Your Expert session
Nasopharyngeal cancer
Anthony Chan, Hong Kong, China

08.00–09.00 Yellow Hall 2
Challenge Your Expert session
Multiple myeloma
Joan Bladé, Barcelona, Spain

08.00–09.00 Yellow Hall 3
Challenge Your Expert session
Advances of systemic treatment in metastatic melanoma
Alexander M. M. Eggermont, Rotterdam, Netherlands

08.00–09.00 Green Hall 3
Challenge Your Expert session
Advances in the treatment of metastatic or unresectable biliary tract cancer
Juan W. Valle, Manchester, UK

08.00–09.00 Green Halls 1+2
Patient Cases
Early endometrial cancer
Co-Chairs: Carien L. Creuzberg, Leiden, Netherlands and Thomas Högberg, Lund, Sweden

08.00 Chemotherapy
Thomas Högberg, Lund, Sweden
08.10 Radiotherapy
Carien L. Creuzberg, Leiden, Netherlands
08.20 Discussion

08.00–09.00 Orange Halls 2+3
Patient Cases
Genotyping GIST for clinical decision-making
Co-Chairs: Alessandro Gronchi, Milan, Italy and Peter Reichardt, Bad Saarow, Germany

08.00 Tailoring the drug
Peter Reichardt, Bad Saarow, Germany
08.10 Tailoring the scalpel  
Alessandro Gronchi, Milan, Italy

08.20 Discussion

09.00–10.30 **Red Hall**  
**Proffered Paper session**

**Biomarkers**
Chair: Carlos Caldas, Cambridge, UK  
Co-Chair: Rafal Dziadziuszko, Gdansk, Poland

09.00 2130 – Distant recurrences at median of 5-years among 9,779 postmenopausal women with hormone receptor-positive early breast cancer treated on the TEAM trial of adjuvant endocrine therapy  
Hans Nortier, Leiden, Netherlands

09.15 2140 – Final results of the Hellenic Cooperative Oncology Group phase III trial (HE10/00) exploring the efficacy of postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in high risk breast cancer patients  
Helen Gogas, Athens, Greece

09.30 Invited Discussant, Abstracts 2130 and 2140  
Heikki Joensuu, Helsinki, Finland

09.45 LBA10 – Optimal treatment of the axilla after positive sentinel lymph node biopsy in primary invasive breast cancer patients (surgery versus radiotherapy): Early results of a randomized clinical trial  
Gábor Péley, Norwich, UK

10.00 2150 – HER2 status as predictor of mammographic screening detection: Comparison of interval- and screen-detected breast cancers  
Antonino Musolino, Parma, Italy

10.15 Invited Discussant, LBA10 and Abstract 2150  
Richard Bell, Milan, Italy

09.00–10.30 **Pink Hall**  
**Proffered Paper session**

**Developmental therapeutics**
Chair: James Spicer, London, UK  
Co-Chair: Christian Dittrich, Vienna, Austria

09.00 4940 – A European multi-institutional study of prognostic factors in cancer patients (pts) treated within phase-I (Ph I) oncology trials  
David Olmos, Sutton, UK

09.15 4950 – The oral MEK 1/2 inhibitor GSK1120212 demonstrates early efficacy signals  
Gerald Falchook, Houston, TX, USA

09.30 Invited Discussant, Abstracts 4940 and 4950  
Francesco Cognetti, Rome, Italy

09.45 4960 – A first-in-human phase I study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin’s lymphoma (NHL)  
Johanna Bendell, Nashville, TN, USA

10.00 4970 – A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors  
Andrew Wagner, Boston, MA, USA

10.15 Invited Discussant, Abstracts 4960 and 4970  
Christian Dittrich, Vienna, Austria
09.45  Bone targeting in prostate cancer
       Karim Fizazi, Villejuif, France
10.05  Results from molecular biology that translate to treatment
       Jack Schalken, Nijmegen, Netherlands
10.25  Conclusions
       Thomas Powles, London, UK

09.00–10.30  Blue Hall
Young Oncologist Forum
Supportive care of cancer patients
Chair: Michael V. Karamouzis, Papagou, Greece
Co-Chair: Serena Di Cosimo, Barcelona, Spain
Session Shooters: Gilberto de Castro Junior, São Paolo, Brazil; Eduardo De Azambuja, Brussels, Belgium; Margaret Hutka, Gliwice, Poland and Pia Osterlund, Helsinki, Finland

09.00  Introduction
       Michael V. Karamouzis, Papagou, Greece
09.05  Management of cancer pain
       Julia Riley, London, UK
09.25  Systemic therapeutic options for bone metastases
       Tiina Saarto, Helsinki, Finland
09.45  Management of fatigue / cachexia
       Stein Kaasa, Trondheim, Norway
10.05  Palliative chemotherapy versus best palliative care – evidence based decision
       Jean-Philippe Durand, Paris, France
10.25  Conclusions
       Serena Di Cosimo, Barcelona, Spain

09.15–10.15  Orange Hall 1
Multidisciplinary Interactive session (MIS)
Localised prostate cancer
Co-Chairs: Alan Horwich, Sutton, UK and Robert A. Huddart, Sutton, UK

09.15  Medical Oncology
       Alan Horwich, Sutton, UK
09.30  Radiotherapy
       Robert Huddart, Sutton, UK
09.45  Discussion

10.30–12.15  Gold Hall
Proffered Paper session
Late-Breaking Abstract Session
Chair: Rolf A. Stahel, Zurich, Switzerland
Co-Chair: Josep Tabernero, Barcelona, Spain

10.30  LBA6 – Sunitinib (SU) in combination with erlotinib (E) for the treatment of advanced/metastatic non-small cell lung cancer (NSCLC): a phase III study
       Giorgio Scagliotti, Orbassano, Italy
10.45  Invited Discussant, LBA6
       Cesare Gridelli, Avellino, Italy
11.00  LBA7 – A Phase III randomized study comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, with lomustine alone in recurrent glioblastoma patients
       Tracy Batchelor, Boston, MA, USA
11.15  LBA9 – A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus + octreotide LAR in patients with advanced neuroendocrine tumors (NET) (RADIANT-2)
       Marianne Pavel, Berlin, Germany
11.45  LBA9 – A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET) (RADIANT-3)
       James Yao, Houston, TX, USA
12.00  Invited Discussant, LBA8 and LBA9
       Michel Ducreux, Villejuif, France
10.45–12.15  Silver Hall
Special Symposium
Breast cancer challenges in the setting of curable disease
Chair: Wolfgang Eiermann, Munich, Germany
Co-Chair: Sabino De Placido, Naples, Italy

10.45  Introduction
Sabino De Placido, Naples, Italy

10.50  Preservation of fertility in young patients
Kutluk Oktay, New York, NY, USA

11.10  Optimizing endocrine treatment of pre-menopausal women
Mitchell Dowsett, London, UK

11.30  Should bone-targeted treatment be used in the adjuvant setting?
Robert Coleman, Sheffield, UK

11.50  Evolving issues in inflammatory breast cancer
Luca Gianni, Milan, Italy

12.10  Conclusions
Wolfgang Eiermann, Munich, Germany

10.45–12.30  Pink Hall
Proffered Paper session
Gynecological cancer
Chair: Antonio Gonzalez Martin, Madrid, Spain
Co-Chair: Michael Bookman, Tucson, AZ, USA

10.45  970O – Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: The MITO-2 (Multicentre Italian Trials in Ovarian cancer) randomized phase III trial
Sandro Pignata, Naples, Italy

10.55  Invited Discussant, Abstract 970O
Antonio Gonzalez Martin, Madrid, Spain

11.10  LBA24 – Results of a randomized, open-label, phase III trial of patupilone (P) versus pegylated liposomal doxorubicin (PLD) in taxane/platinum refractory/resistant patients with recurrent ovarian, fallopian, or peritoneal cancer
Nicoletta Colombo, Milan, Italy

11.25  971O – Phase II study of the oral PARP inhibitor olaparib (AZD2281) versus liposomal doxorubicin in ovarian cancer patients with BRCA1 and/or BRCA2 mutations
Stan Kaye, Sutton, UK

11.50  972O – A randomized phase II clinical trial of the SRC inhibitor saracatinib (AZD0530) and carboplatin + paclitaxel (C+P) versus C+P in patients (pts) with advanced platinum-sensitive epithelial ovarian cancer (EOC)
Christopher Poole, Coventry, UK

12.10  Invited Discussant, 971O, 972O and 2 expected LBAs
Elise Kohn, Bethesda, MA, USA

10.45–12.15  Violet Hall
Special Symposium
ESMO/ASCO Joint Symposium:
The future of antiangiogenesis therapy
Co-Chairs: David J. Kerr, Oxford, UK and George Sledge, Indianapolis, IN, USA

10.45  Introduction
George Sledge, Indianapolis, IN, USA

10.55  The biology of antiangiogenic therapy in the adjuvant setting
Peter Carmeliet, Leuven, Belgium

11.15  Re-appraising the biological basis of antiangiogenic drugs for adjuvant therapy
Robert Kerbel, Toronto, ON, Canada

11.35  An analysis of currently available adjuvant colorectal data
Lee M. Ellis, Houston, TX, USA

11.55  COX-2 inhibition in the adjuvant setting for colorectal cancer
David J. Kerr, Oxford, UK

10.45–12.15  Blue Hall
Special Symposium
Overcoming disparities in cancer control in Europe
Chair: Lars Holmberg, London, UK
Co-Chair: Hans-Jörg Senn, St. Gallen, Switzerland

10.45  Introduction
Hans-Jörg Senn, St. Gallen, Switzerland

10.50  Differences in cancer survival in Europe
Franco Berrino, Milan, Italy

11.10  Social inequalities and cancer
Anton Kunst, Amsterdam, Netherlands

11.30  Cancer control plans in Europe
Andreas Ullrich, Geneva, Switzerland

11.50  Moving forward with cancer control
Nick Fahy, Luxembourg

12.10  Conclusions
Lars Holmberg, London, UK
10.45–11.45 Red Hall
Proffered Paper session
Basic science and translational research
Chair: TBC
Co-Chair: Eric Van Cutsem, Leuven, Belgium

10.45 74O – Clinicopathologic correlation of cancer susceptibility loci from genome-wide association (GWAS) studies of colorectal cancer (CRC)
Derek Power, New York, NY, USA

11.00 75O – Differences in clinicopathological features, DNA copy number profiles and outcome of metastatic colorectal cancer (CRC) patients with hepatic versus extrahepatic disease
Leonie Mekenkamp, Nijmegen, Netherlands

11.15 76O – A novel colorectal cancer susceptibility SNP in the EIF3H promoter influences patient survival and response to treatment
Christopher Smith, Cardiff, UK

11.30 Invited Discussant, Abstracts 74O, 75O and 76O
Eric Van Cutsem, Leuven, Belgium

10.45–12.15 Yellow Hall 2
Special Session
Oncology mentors Forum
Chair: Heine H. Hansen, Copenhagen, Denmark
Co-Chair: Martin Gore, London, UK

10.45 Introduction
Heine H. Hansen, Copenhagen, Denmark

10.50 Global recognition of Medical Oncology
Eduardo Cazap, Buenos Aires, Argentina

11.00 ESMO/ASCO updated Global Core Curriculum for training in medical oncology and log book opportunities
Heine H. Hansen, Copenhagen, Denmark

11.20 How you and your institution can benefit from being a home or host mentor within the ESMO fellowship program
Martin Gore, London, UK

11.35 How to check the status of your trainees knowledge and readiness for the license exam: ESMO examination opportunities
Carsten Bokemeyer, Hamburg, Germany

11.50 Teaching medical oncology to medical students
Nicholas Pavlidis, Ioannina, Greece

12.05 Q&A

12.30–13.20 Violet Hall
Keynote Lecture
Detection, clinical relevance and specific biological properties of disseminated cancer cells
Chair: Carlos Caldas, Cambridge, UK
Speaker: Klaus Pantel, Hamburg, Germany

12.30–13.30 Green Halls 1+2
Poster Symposium (Discussion session)
Breast cancer, advanced
Co-Chairs: John Crown, Dublin, Ireland and Dimitros Tryfonopoulos, Athens, Greece

278PD – Meta-analysis of patients (pts) ≥65 years from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for metastatic breast cancer (MBC)
David Miles, London, UK

279PD – Meta-analysis of patients (pts) previously treated with taxanes from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for metastatic breast cancer (MBC)
David Miles, London, UK

280PD – Outcomes for metastatic breast cancer patients continuing on bevacizumab alone in study E2100
See-Chun Phan, South San Francisco, CA, USA

281PD – Safety subgroup analyses from the CECOG phase III TURANDOT trial: First-line bevacizumab (Bev) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC)
Istvan Lang, Budapest, Hungary

282PD – Evolution of chemotherapy options in HER2-negative metastatic breast cancer (MBC)
Sunil Verma, Toronto, Canada

283PD – Beyond CHAT: Overall survival (OS) update from the CHAT study of first-line trastuzumab (H) plus docetaxel (T) with or without capecitabine (X) in HER2-positive metastatic breast cancer (MBC)
Richard Bell, Geelong, Australia

284PD – Results from two phase I trials of Her2/Neu-directed active cellular immunotherapy in patients with advanced malignancies
Robert Sims, Seattle, WA, USA

285PD – Duration of trastuzumab therapy may improve survival in HER2(+) metastatic breast carcinoma patients in the absence of adjuvant trastuzumab
Ibrahim Türker, Ankara, Turkey
877PD – An international expanded access program (EAP) of everolimus in patients with metastatic renal cell carcinoma (mRCC) who are intolerant of or have progressed after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy
Viktor Grunwald, Hannover, Germany

878PD – The mTOR inhibitor everolimus cooperates with the TLR9 agonist IMO in renal cell carcinoma by interfering with both tumor cells and microenvironment
Giampaolo Tortora, Naples, Italy

12.30–13.30 Orange Halls 2+3
Poster Symposium (Discussion session)
Genitourinary tumors
Co-Chairs: Vesa Kataja, Kuopio, Finland and Thomas Powles, London, UK

870PD – Survival results of the IMPACT trial of sipuleucel-T for advanced prostate cancer
Daniel George, Durham, NC, USA

871PD – Cabazitaxel plus prednisone/prednisolone significantly increases overall survival compared to mitoxantrone plus prednisone/prednisolone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results with updated overall survival of a multinational phase III trial (TROPIC)
Stephane Oudard, Paris, France

872PD – PSA doubling time is the strongest predictor for metastases, castration resistance, and death in patients with prostate cancer treated with intermittent androgen deprivation for isolated biochemical relapse
Laurence Albiges, Villejuif, France

873PD – A Phase II pharmacodynamic study of pre-operative figitumumab (F) in patients (pts) with localized prostate cancer (PCa)
Kim Chi, Vancouver, BC, Canada

874PD – MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer
Lotta von Boehmer, Zurich, Switzerland

12.30 Invited Discussant, Abstracts 870PD-874PD
Vesa Kataja, Kuopio, Finland

875PD – Survival update of a randomized phase 2 study (IMA901-202) investigating therapeutic vaccination with multiple tumor-associated peptides (TUMAP) in renal cell carcinoma (RCC) patients after failure of previous therapy with cytokines or kinase inhibitors
Wolfram Brugger, Villingen-Schwenningen, Germany

876PD – Combined chemo-radiotherapy with gemcitabine in patients with locally advanced inoperable transitional cell carcinoma (TCC) of the urinary bladder and/or in patients ineligible for surgery: Results of a phase I trial
Maria De Santis, Vienna, Austria
12.30–13.30 **Yellow Hall 2**
**Poster Symposium (Discussion session)**
**Head and neck cancer**
Co-Chairs: Ezra Cohen, Chicago, IL, USA and Amanda Psyri, Athens, Greece

1006PD — Randomized phase II/III trial of a tumor vascular disrupting agent, fosbretabulin tromethamine (CA4P), with carboplatin (C), and paclitaxel (P) in anaplastic thyroid cancer (ATC): Interim safety and efficacy results of the FACT trial
Rossella Elisei, Pisa, Italy

1007PD — Vandetanib in locally advanced or metastatic medullary thyroid cancer (MTC): A randomized, double-blind phase III trial (ZETA)
Eric Baudin, Villejuif, France

1008PD — Vandetanib in locally advanced or metastatic differentiated thyroid cancer (papillary or follicular; DTC): A randomized, double-blind phase II trial
Sophie Leboulleux, Villejuif, France

**12.30 Invited Discussant, Abstracts 1006PD-1008PD**
Ezra Cohen, Chicago, IL, USA

1009PD — Identification and validation of gene expression models that predict outcome in patients with early stage laryngeal cancer
Elena Fountzilas, Boston, MA, USA

1010PD — Updated results of a randomized, open-label phase II study exploring BIBW 2992 versus cetuximab in patients with platinum-refractory metastatic/recurrent head and neck cancer (SCCHN)
Tanguy Seiwert, Chicago, IL, USA

1011PD — Influence of AKT1, AKT2 and FRAP1 polymorphisms on response and survival in head and neck cancer (SCCHN) patients treated with docetaxel and cetuximab
Katharina Pfisterer, Berlin, Germany

**12.45 Invited Discussant, Abstracts 1009PD-1011PD**
Amanda Psyri, Athens, Greece

**13.00 General Discussion**

12.30–13.30 **Yellow Hall 3**
**Poster Symposium (Discussion session)**
**Geriatric oncology**
Co-Chairs: Riccardo Audisio, Liverpool, UK and Pierre Soubeyran, Bordeaux, France

567PD — Comprehensive geriatric assessment-adapted chemotherapy in elderly patients (> 70 years) with diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL): Final results and long term follow-up
Michele Spina, Aviano, Italy

568PD — Evaluation of the Groningen Frailty Index (GFI) as a screening tool in elderly patients (pts): An interim analysis
Dirk Schrijvers, Antwerp, Belgium

569PD — Prediction of chemotherapy toxicity by the Groningen Frailty Index (GFI) and the Comprehensive Geriatric Assessment (CGA) in elderly cancer patients (pts): An interim analysis
Frank van Fraeyenhove, Antwerp, Belgium

570PD — Prognosis of elderly breast cancer patients with intermediate or high risk who received suboptimal adjuvant therapy
Harukaze Yamamoto, Tokyo, Japan

571PD — Identification and validation of gene expression models that predict outcome in patients with early stage laryngeal cancer
Elena Fountzilas, Boston, MA, USA

572PD — Updated results of a randomized, open-label phase II study exploring BIBW 2992 versus cetuximab in patients with platinum-refractory metastatic/recurrent head and neck cancer (SCCHN)
Tanguy Seiwert, Chicago, IL, USA

573PD — Influence of AKT1, AKT2 and FRAP1 polymorphisms on response and survival in head and neck cancer (SCCHN) patients treated with docetaxel and cetuximab
Katharina Pfisterer, Berlin, Germany

574PD — Prognosis of elderly breast cancer patients with intermediate or high risk who received suboptimal adjuvant therapy
Harukaze Yamamoto, Tokyo, Japan

575PD — Screening success and inclusion failure rates in a prospective trial of adjuvant chemotherapy for breast cancer in elderly women by the French Geriatric Oncology Group GERICO
Etienne Brain, Saint Cloud, France

576PD — Evaluation of the Groningen Frailty Index (GFI) as a screening tool in elderly patients (pts): An interim analysis
Dirk Schrijvers, Antwerp, Belgium

577PD — Prediction of chemotherapy toxicity by the Groningen Frailty Index (GFI) and the Comprehensive Geriatric Assessment (CGA) in elderly cancer patients (pts): An interim analysis
Frank van Fraeyenhove, Antwerp, Belgium

578PD — Prognosis of elderly breast cancer patients with intermediate or high risk who received suboptimal adjuvant therapy
Harukaze Yamamoto, Tokyo, Japan

579PD — Identification and validation of gene expression models that predict outcome in patients with early stage laryngeal cancer
Elena Fountzilas, Boston, MA, USA

580PD — Updated results of a randomized, open-label phase II study exploring BIBW 2992 versus cetuximab in patients with platinum-refractory metastatic/recurrent head and neck cancer (SCCHN)
Tanguy Seiwert, Chicago, IL, USA

581PD — Influence of AKT1, AKT2 and FRAP1 polymorphisms on response and survival in head and neck cancer (SCCHN) patients treated with docetaxel and cetuximab
Katharina Pfisterer, Berlin, Germany

13.00 **General Discussion**

13.15–14.30 **Gold Hall**
**Proffered Paper session**
**Chest tumors II**
Chair: Thierry Le Chevalier, Villejuif, France
Co-Chair: Filippo de Marinis, Rome, Italy

13.15 LBA16 — Sorafenib (S) + gemcitabine/cisplatin (GC) vs GC alone in the first-line treatment of advanced non–small cell lung cancer (NSCLC): Phase III NSCLC research Experience Utilizing Sorafenib (NExUS) trial
Ulrich Gatzemeier, Hamburg, Germany
13.30 Invited Discussant, LBA16
Benjamin Besse, Villejuif, France
13.45 LBA17 – Randomized phase 2b study of pralatrexate vs erlotinib in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) after failure of prior platinum-based therapy
Karen Kelly, Kansas City, KS, USA
14.00 LBA18 – Efficacy and safety of PF299804 as first-line treatment (tx) of patients (pts) with advanced (adv) NSCLC selected for activating mutation (mu) of epidermal growth factor receptor (EGFR)
Tony S. K. Mok, Hong Kong, China
14.15 Invited Discussant, LBA17 and LBA18
Giuseppe Giaccone, Bethesda, MD, USA

13.30–15.15 Silver Hall
Awards session
Co-Chairs: David J. Kerr, Oxford, UK and Josep Tabernero, Barcelona, Spain
13.30 Hamilton Fairley Award to Bengt Glimelius presented by David J. Kerr
13.35 Hamilton Fairley Award Lecture “Colorectal Cancer: A multidisciplinary disease revealing significant progress” Bengt Glimelius, Uppsala and Stockholm, Sweden
13.50 ESMO 2009 Best Exam Award to Juergen Wehmeyer, Münster, Germany
13.50 Fellowship Awards 2010, presented by David J. Kerr and Josep Tabernero
14.00 Fellowship Program – new Institutes, presented by Josep Tabernero
• Karolinska Institut, Stockholm, Sweden
• Vall d’Hebron Hospital, Barcelona, Spain
14.05 Palliative Care Designated Centre accreditation presented by Nathan Cherny, Jerusalem, Israel
14.15 ESMO Lifetime Achievement Award supported by an unrestricted grant from GSK to Alan Hilary Calvert, presented by David J. Kerr
14.20 ESMO Lifetime Achievement Award lecture Alan Hilary Calvert
14.35 ESMO Flower of Hope to José Baselga, ESMO Honorary Member, presented by David J. Kerr

13.30–15.15 Red Hall
Special Symposium
Ovarian cancer: New biology, new targets
Chair: Stan Kaye, Sutton, UK
Co-Chair: David Huntsman, Vancouver, BC, Canada

13.15–14.45
Introduction
Stan Kaye, Sutton, UK
13.20 Molecular subtypes of ovarian cancer: Insights into the drivers of high-grade ovarian serous and clear cell tumours
David Bovtett, Melbourne, Australia
13.40 The molecular classification of ovarian carcinoma: implications for treatment
David Huntsman, Vancouver, BC, Canada

13.45–15.15 Violet Hall
Proffered Paper session
Genitourinary tumors
Co-Chairs: Carsten Bokemeyer, Hamburg, Germany and Maria De Santis, Vienna, Austria

13.30 LBA22– Randomized, double-blind phase III study of pazopanib in patients with advanced/metastatic renal cell carcinoma (mRCC): final overall survival (OS) results
Cora N. Sternberg, Rome, Italy
13.45 8670 – Evaluation of different polymorphisms as markers of sunitinib efficacy and toxicity in first line treatment of renal clear cell carcinoma: a prospective study of the Spanish Oncologic GenitoUrinary Group
Jesus Garcia-Donas, Alcorcon, Spain
14.00 8680 – Phase 2 Randomized Discontinuation Trial (RDT) of Tivozanib in Patients With Renal Cell Carcinoma (RCC): Results in Patients Randomized to Tivozanib vs. Placebo
Dmitry Nosov, Moscow, Russian Federation
14.15 Invited Discussant, LBA22 and Abstracts 8670 and 8680
Tim Eisen, Cambridge, UK
14.35  LBA23 – Phase II study of Pazopanib monotherapy for patients with relapsed/refractory urothelial cancer (INT 70/09, NCT 0131875)
Andrea Necchi, Milan, Italy

14.50  8690 – A prospective multicenter GETUG phase II trial of gemcitabine, cisplatin, and ifosfamide (GIP) in patients with relapsed metastatic germ-cell tumors (GCT)
Karim Fizazi, Villejuif, France

15.05  Invited Discussant, LBA23 and Abstract 8690
Jörg Beyer, Berlin, Germany

13.30–14.45  Blue Hall
Proffered Paper session
Head and neck cancer
Chair: Lisa Licitra, Milan, IT
Co-Chair: Francesco Cognetti, Rome, Italy

13.30  LBA26 – Primary efficacy and safety results of SPECTRUM, a phase 3 trial in patients (pts) with recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) receiving chemotherapy with or without panitumumab (pmab)
Jan Vermorken, Edegem, Belgium

13.45  10030 – Phase III study of pemetrexed in combination with cisplatin (PEM/CIS) versus placebo plus cisplatin (CIS) in patients with recurrent or metastatic squamous cell head and neck cancer (HNC)
Susan Urba, Ann Arbor, MI, USA

14.00  Invited Discussant, LBA26 and Abstract 10030
Marshall Posner, New York, NY, USA

14.15  10040 – Five-year survival (OS) and patterns of failure for human papillomavirus (HPV) positive and negative oropharynx cancer (OPC) in the TAX 324 clinical trial: Results of sequential therapy
Marshall Posner, New York, NY, USA

14.30  Invited Discussant, Abstract 10040
Lisa Licitra, Milan, Italy

15.00–17.30  Gold Hall
Presidential Symposium
Chair: David J. Kerr, Oxford, UK
Co-Chair: Rolf A. Stahel, Zurich, Switzerland

15.00  LBA1 – Phase IIb/III double-blind randomized trial of afatinib (BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2) + best supportive care (BSC) versus placebo + BSC in patients with NSCLC failing 1–2 lines of chemotherapy and erlotinib or gefitinib (LUX-Lung 1)
Vincent Miller, New York, NY, USA

15.15  LBA2 – Final overall survival (OS) results from a phase III, randomised, open-label, first-line study of gefitinib (G) v carboplatin/paclitaxel (C/P) in clinically selected patients with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS)
Chi-Hsin Yang, Taipei, Taiwan

15.30  Invited Discussant, LBA1 and LBA2
Jean-Charles Soria, Villejuif, France

15.45  274O – The addition of cetuximab to cisplatin increases overall response rate (ORR) and progression-free survival (PFS) in metastatic triple-negative breast cancer (TNBC): results of a randomized phase II study (BALI-1)
José Baselga, Boston, MA, USA

16.00  LBA3 – Efficacy and safety of trastuzumab-DM1 versus trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: preliminary results of a randomized, multicenter, open-label phase 2 study (TDM4450g)
Edith Perez, Jacksonville, FL, USA

16.15  Invited Discussant, LBA3
Michael Bookman, Tucson, AZ, USA

16.30  LBA4 – ICON7: A phase III randomised Gynaecologic Cancer InterGroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC)
Tim Perren, Leeds, UK

16.45  Invited Discussant, LBA4
Cora Sternberg, Rome, Italy

17.00  LBA5 – Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel-based chemotherapy (chemo): Results of COU-AA-301, a randomized double-blind placebo-controlled phase III study
Johann de Bono, Sutton, UK

17.15  Invited Discussant, LBA5
Cora Sternberg, Rome, Italy
15.30–17.00 **Pink Hall**
Special Symposium
**Tailoring treatment of metastatic colorectal cancer**
Chair: Jean-Yves Douillard, St. Herblain, France
Co-Chair: Eduardo Diaz-Rubio, Madrid, Spain

15.30 **Introduction**
Eduardo Diaz-Rubio, Madrid, Spain

15.35 **Aggressive versus non-aggressive initial treatment**
Tim Maughan, Cardiff, UK

15.55 **Intermittent or continuous therapy**
Cornelis Punt, Nijmegen, Netherlands

16.15 **2IN – Personalizing treatment based on biomarkers**
Sabine Tejpar, Leuven, Belgium

16.35 **22IN – The combination of targeted agents: A look to the future**
Arnaud Roth, Geneva, Switzerland

16.55 **Conclusions**
Jean-Yves Douillard, St-Herblain, France

15.30–17.00 **Blue Hall**
Proffered Paper session
**Hematological malignancies**
Chair: Lena Specht, Copenhagen, Denmark
Co-Chair: TBC

15.30 **1132O – Zoledronic acid (ZOL) significantly reduces skeletal-related events (SREs) versus clodronate (CLO) in patients (pts) with multiple myeloma (MM): Results of the Medical Research Council (MRC) Myeloma IX study**
Gareth Morgan, London, UK

15.45 **1133O – Bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance for initial therapy of multiple myeloma: A prospective randomized trial**
Sara Bringhen, Turin, Italy

16.00 **1134O – Cytokine interleukin-16 is an important growth-promoting factor for multiple myeloma**
Djordje Atanackovic, Hamburg, Germany

16.15 **Invited Discussant, Abstracts 1132O, 1133O and 1134O**
Joan Bladé, Barcelona, Spain

16.35 **1135O – Long-term follow-up of rituximab and infusional cyclophosphamide, doxorubicin, and etoposide (CDE) in combination with HAART in HIV-related non-Hodgkin’s lymphomas (NHL)**
Michele Spina, Aviano, Italy

16.55 **Invited Discussant, Abstract 1135O**
TBC

15.30–17.00 **Red Hall**
Special Symposium
**MicroRNA’s: The new genes involved in cancer**
Chair: Carlo Croce, Columbus, OH, USA
Co-Chair: Ruggero De Maria, Rome, Italy

15.30 **Introduction**
Ruggero De Maria, Rome, Italy

15.35 **MicroRNA identification in plasma and serum: A new tool to diagnose and monitor diseases**
George Calin, Houston, TX, USA

15.55 **Micromanagers of malignancy: The role of microRNAs in regulating metastasis**
Carlo Croce, Columbus, OH, USA

16.15 **miRNA in lymphomas, profile expression/prognosis**
Charles Lawrie, Oxford, UK

16.35 **Cancerous microRNAs and regulatory RNA binding proteins**
Reuven Agami, Amsterdam, Netherlands

16.55 **Conclusions**
Ruggero De Maria, Rome, Italy
**Poster Plan**

**Basic science and translational research**
Chair: Maria Grazia Daidone, Milan, Italy

- **84P** – Novel gold speckled silica nanoparticles as mediators of tumor imaging and photothermal ablation therapy for breast cancer
  Nobutaka Iwakuma, Fukuoka, Japan
- **85P** – Cytotoxicity of curcumin combined with docetaxel in MCF7 breast tumor cells implicates the glutathione cycle and an antioxidant response: A metabolomics investigation
  Mathilde Bayet-Robert, Clermont-Ferrand, France
- **86P** – S-nitrosothiol homeostasis and nitrosative stress modulate proliferation of breast cancer cells
  Amanda Cañas, Cordoba, Spain
- **87P** – Molecular mechanisms involved in the response to combined antiangiogenic-antihormonal therapy in breast cancer
  Miguel Angel Berciano Guerrero, Cordoba, Spain
- **88P** – Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells
  Nicola Normanno, Naples, Italy
- **89P** – Breast cancer stem cells involvement in bone marrow metastasis
  Tsuyoshi Shirakawa, Fukuoka, Japan
- **90P** – Epigenetics silencing of the tumor suppressor protein 14-3-3 sigma by methylation in sporadic breast cancer
  Joaquina Martinez-Galan, Granada, Spain
- **91P** – The significance of DNA methylation of estrogen receptor alpha (ERa) expression in primary breast cancer (BC)
  Klearchos Desiris, Thessaloniki, Greece
- **92P** – Downregulation of Med19 gene expression inhibited the growth of breast cancer cells
  Lihua Li, Wuxi, Jiangsu, China
- **93P** – A novel approach using the telomerase-selective adenoviral marker for detection of circulation tumor cells in breast cancers
  Seung Jin Kim, Suita, Japan
- **94P** – The influence of TYMS and MTHFR gene polymorphisms on toxicity and response in breast cancer patients treated with 5-fluorouracil-based chemotherapy
  Elzbieta Nowara, Gliwice, Poland
- **95P** – Hedgehog signalling is active in biliary tract cancer and amenable to pharmacological inhibition
  Tobias Kiesslich, Salzburg, Austria
96P – Sorafenib mediates apoptosis in hepatocellular carcinoma cells through kinase-independent inhibition of signal transducers and activators of transcription 3
Kuen-Feng Chen, Taipei, Taiwan
97P – Involvement of microRNAs in the invasion of esophageal cancer cells
Kayoko Matsushima, Nagasaki, Japan
98P – HB-EGF-CTF nuclear translocation induces gastric cancer invasion
Takaya Shimura, Nagoya, Japan
99P – Amphiregulin nuclear translocation might reduce chemosensitivity in gastric cancer
Michihiro Yoshida, Nagoya-city, Aichi Prefecture, Japan
100P – Plasma M30 and M65 levels in patients with advanced gastric cancer: Is there an impact on survival of patients?
Ahmet Bilici, Istanbul, Turkey
101P – The development of the novel photodynamic therapy with glycoconjugated chlorine for stomach and colon cancer
Mamoru Tanaka, Nagoya, Japan
102P – Metastasis suppressing/promoting microRNA expression in primary and metastatic colorectal cancer
Michael Vickers, Ottawa, ON, Canada
103P – Detection and functional analysis of miRNAs in peripheral blood exosomes from cancer patients
Masato Komoda, Fukuoka, Japan
104P – Expression of XIAP and miRNA-21 as predictor factors for lymph node invasion in rectum cancer
Fernanda Peria, Ribeirão Preto, Brazil
105P – The p53 status affects the prognosis of patients with colorectal adenocarcinoma depending on the protein expression of NFY-C (Nuclear Factor Y, subunit C)
Anastasia Kottorou, Patras, Greece
106P – Glutathione S-transferase Pi (GSTPi) for prediction of chemotherapy response and survival in stage IV colorectal cancer
Wei Chua, Sydney, Australia
107P – Predictive value of molecular markers expression in locally advanced rectal cancer (LARC) treated with neoadjuvant bevacizumab (BEV) and capecitabine (CAPE) + standard radiotherapy (RT)
Francesco Torino, Rome, Italy
108P – Extensive characterization of EGFR pathways may help in integrating the use of EGFR-targeted therapies in patients with squamous cell anal cancer
Sara De Dosso, Bellinzona, Switzerland
109P – Differential effect of oxaliplatin and irinotecan in KRAS mutant colon carcinoma in vitro
Zsuzsanna Bago-Horvath, Vienna, Austria
110P – TRAP1 and Sorcin cooperate in a survival pathway responsible for inducing drug-resistance in human colorectal carcinoma (CRC)
Matteo Landrisicina, Foggia, Italy
111P – Antitumor activity of Toll-like Receptor 9 agonist IMO overcomes K-Ras mutation and cooperates with cetuximab in colon and pancreatic cancers
Giampaolo Tortora, Naples, Italy
112P – The potential of molecular-targeted therapy with EGFR and VEGFR signaling inhibitors against biliary tract cancer
Daitaro Yoshikawa, Asahikawa, Japan
113P – The influence of SLCO1B3 polymorphisms on docetaxel disposition in Asian nasopharyngeal carcinoma patients
Sin-Chi Chew, Singapore
114P – Combined modalities of resistance in a cisplatin-driven human betel-associated oral squamous cell carcinoma
Yen-Ting Cheng, Tainan, Taiwan
115P – Differential expression patterns of MMPs and the role in invasion in epithelial premalignant tumors and invasive squamous cell carcinoma
Soichi Takiguchi, Fukuoka, Japan
116P – Merkel cell polyomavirus (MCPyV) DNA present in non small cell lung cancer (NSCLC)
Joongho Joh, Louisville, KY, USA
117P – Possible involvement of CXCL14 in anchorage-independent growth and bone metastasis from lung cancer
Joongho Joh, Louisville, KY, USA
118P – Some PPARα ligands sensitize human non-small lung cancer cells to ionizing radiation-induced apoptosis through up-regulation of OS generation
Sung Hee Hong, Seoul, South Korea
119P – Preclinical and clinical activity of BMS-690514 in the treatment of non-small cell lung cancer (NSCLC)
Eric Sbar, Princeton, NJ, USA
120P – Nilotinib enhances the cytotoxic effect of doxorubicin through selectively inhibiting the activity and cellular expression of the multidrug resistance protein P-glycoprotein in soft tissue sarcomas
Regina Alemany, Palma de Mallorca, Spain
121P – PML expression in soft tissue sarcoma: Prognostic value in alkylating agents/anthracyclin based first-line therapy
Bruno Vincenzi, Rome, Italy
122P – The hypermutagenetic role of overexpressed DNA polymerase iota and its variant in bladder cancer
Jin Yang, Chongqing, China
123P – Identification of plasma biomarkers for the multikinase inhibitor regorafenib (BAY 73-4506) in patients (pts) with renal cell cancer (RCC)
Michael Jeffers, Montville, NJ, USA
124P – Pharmacokinetics (PK) of sunitinib and its metabolite in patients with castrated refractory prostate cancer (CRPC) enrolled in the French multicenter PROSUT phase II study
Marie-Christine Etienne-Grimaldi, Nice, France
125P – HPV infection in epithelial ovarian cells of women at high risk of developing ovarian cancer
Olena Bilyk, Kiev, Ukraine
126P – Synergistic cytotoxic and apoptotic effect by AT-101 and cisplatin combination through DNA methyltransferase and histone deacetylase enzymes in human ovarian cancer cell lines
Burcak Karaca, Izmir, Turkey
127P – Diagnostic approach in patients with unknown primary cancer
Blanca Homet, Madrid, Spain
128P – Prognostic significance of gene expression profile in patients with carcinomas of unknown primary (CaUP)
John Souglakos, Heraklion, Greece
129P – Determination of molecular markers for BRCA1/2 heterozygosity using gene expression profiling
Asher Salmon, Jerusalem, Israel
130P – Carboxyl Terminus of Hsc70-Interacting Protein (CHIP) mediates degradation of C-MET receptor
Ji Won Park, Daejeon, South Korea
131P – Quantitative high-dimensional monitoring of proteins in response to anti-cancer agents
Satoshi Nishizuka, Morioka, Japan
132P – Nilotinib and sorafenib are more potent inhibitors for exon 11/17 c-Kit mutants than sunitinib: Results of incorporating cell-based screening platform and virtual molecular modeling study
Yuan-Shuo Hsueh, Tainan, Taiwan
133P – Preclinical and clinical anti-angiogenic activity of BMS-690514
Tai Wong, Princeton, NJ, USA
134P – Preclinical evaluation of trabectedin in patient derived tumor xenografts in vitro and in vivo, and identification of a predictive gene signature
Heinz-Herbert Fiebig, Freiburg, Germany
135P – Radiotherapy may potentiate immunotherapy through presentation of novel tumor antigens
Lotta von Boehmer, Zurich, Switzerland
136P – Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin (PLD) formulations in preclinical models: Is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of PLD products?
Rao N. V. S. Mamidi, Raritan, USA
137P – Assessment of neuropathy-inducing effects of eribulin mesylate versus paclixatel and ixabepilone in mice
Krystyna Wozniak, Baltimore, MD, USA
138P – Immuno-positron emission tomography (PET) of Lewis Y (Ley) expressing xenografts using 89zr-labelled humanised antibody hu3S193
Fook Lee, Heidelberg, Australia
139P – Speckle tracking echocardiography identifies cardiac dysfunction induced by the anticancer Erb-B2 blocker lapatinib
Carlo Tocchetti, Naples, Italy
140P – Analysis of time-to-progression (TTP) and progression-free-survival (PFS): Possible implications for optimizing the development, approval, costs and consequences of cancer therapies
Franz Porzsolt, Ulm, Germany
141P – p53 responsive PIG3 gene polymorphism seems not associated with cerebral, colorectal and lung cancer
Donatella Bianchessi, Milan, Italy

Biomarkers
Chair: Antonella Isacchi, Milan, Italy

178P – Association of epigenetic inactivation of the ESR1 gene by aberrant methylation promoter with prognostic factors in breast cancer patients
Joaquina Martinez-Galan, Granada, Spain
179P – Clinical significance and functional relevance of MAGED-4B in breast cancer
Serena Germano, Dublin, Ireland
180P – Clinical significance of soluble vascular endothelial growth factor receptor-3 as a candidate biomarker for breast cancer patients
Akihiko Takeda, Saitama, Japan
181P – SPARC microenvironment signature (SMS) in patients treated with nab-paclitaxel (nab-P)/carboplatin (C)/bevacizumab(B) for triple negative metastatic breast cancer (TNMBC)
Kimberly Blackwell, Springfield, IL, USA
182P – A novel, simple and cost-effective KRAS mutation detection method, Luminex® assay: Results from a multicenter, prospective clinical trial
EIJI Shinozaki, Tokyo, Japan
183P – A biopsy-driven and biomarker discovery clinical trial in metastatic colorectal cancer led by a new Quebec-wide translational research network, to identify signatures of clinical resistance
Gerald Batist, Montreal, QC, Canada
184P – Clinical validation of a 26-gene signature predicting response to cetuximab in wild type K-ras metastatic colorectal cancer
Vincent Vuaroqueaux, Riehen, Switzerland
185P – Integrative omics based next-generation molecular markers and targets in colorectal cancer
Debmalya Barh, Nonakuri, Purba Medinipur, India
186P – Circulating endothelial cells (CECs) and their apoptotic fraction (APO-CECs): Mutually independent biomarkers during bevacizumab-based treatment for advanced colorectal cancer patients
Mariangela Manzoni, Pavia, Italy
187P – Clinical value of circulating VEGFR2+pAKT+ cells as a functional surrogate biomarker in metastatic colorectal cancer treated with bevacizumab and chemotherapy
Sang Joon Shin, Seoul, South Korea
188P – Evaluation of ERCC1, BRCA1, thymidylate synthase (TS), class III beta tubulin (bTubIII), p53R2, RRM2 in stage I-III non-small cell lung cancer (NSCLC): A tissue microarray (TMA) study
Francesco Grossi, Genoa, Italy
189P – Overexpression of mTOR a novel marker for poor survival in early stage NSCLC: A validation study
Kathy Gately, Dublin, Ireland
190P – Localization, expression and impact on outcome of CXCR4 expression in resected early stage on small cell lung cancer
Dafydd Gwyn Bebb, Calgary, AB, Canada
191P – KRAS mutations differing for aminoacid substitution confer different drug sensitivity and resistance in NSCLC
Mirko Marabese, Milan, Italy
192P – The usefulness of measuring circulating tumor cells in patients with small-cell lung cancer
Tateaki Naito, Shizuoka, Japan
193P – Serum M30 AND M65 values in patients with advanced stage non-small cell lung cancer compared with healthy control group
Basak Oven Ustaalioglu, Istanbul, Turkey
194P – Proteomic analysis of large cell neuroendocrine carcinoma, small cell lung carcinoma and large cell carcinoma from formalin-fixed paraffin embedded samples and validation by immunohistochemical staining
Masaharu Nomura, Tokyo, Japan
195P – Detection of circulating tumor cells in gastric cancer patients using telomerase-specific replication-selective adenoviral agent: Prospective feasibility study
Hiroaki Ito, Yokohama, Japan
196P – Biomarker results from ARQ 197-114: A phase Ib trial evaluating the cMET inhibitor ARQ 197 in cirrhotic patients (pts) with hepatocellular carcinoma (HCC)
Carlos Rodriguez-Lopez, Barcelona, Spain
197P – Loss of immunolabeling of Kruppel like factor 10 is associated with advanced stage and rapid progression of pancreatic cancer
Hui-Ju Ch’Ang, Tainan, Taiwan
198P – Circulating endothelial cells and their clinical manifestation in pancreatic cancer patients treated with gemcitabine based chemotherapy
Shunsuke Kondo, Tokyo, Japan
199P – Enhancing detection of BRAF-mutated circulating melanoma cells by pre-PCR cleavage of wild-type sequences
Alberto Fusi, Berlin, Germany
200P – Promoter hypermethylation of tumor suppressor genes in urine sediment from prostate cancer patients
Raluca Dumache, Timisoara, Romania
201P – Usefulness of noninvasive biomarkers to predict prognosis in bladder cancer
Raluca Dumache, Timisoara, Romania
202P – Determination of a new RECIST threshold using everolimus treatment in metastatic renal cell carcinoma: Evaluation from the RECORD-1 study
Rokhaya Thiam, Paris, France
203P – Co-administration of pazopanib and simvastatin increases the incidence of transaminase elevations in patients with cancer
Chun-Fang Xu, Harlow, UK
204P – Expression of the gastrin-releasing peptide receptor in hepatocellular carcinomas and its role as a prognostic biomarker
Nicolas Lazaretti, Passo Fundo, Brazil
205P – Value of bone resorption marker N-telopeptide crosslinks in predicting skeletal related events and response to zoledronic acid in bone metastases
Nermine Kamal, Cairo, Egypt

Chest tumors
Chair: Rafal Dziadziusko, Gdansk, Poland
376P – Third CECOG consensus on the systemic treatment of non small cell lung cancer
Tudor-Eliaede Ciuleanu, Cluj-Napoca, Romania
377P – Outcomes of phase II clinical trials in advanced/metastatic non-small-cell lung cancer published within the last decade
Filip Janku, Houston, TX, USA

378P – Lung cancer in never-smokers
Yoichi Naito, Minato-ku, Japan

379P – Prospective study of host cell reactivation assay (HCRA) in non-small-cell lung cancer (NSCLC) patients (p)
Pedro Mendez, Badalona, Spain

380P – Alcohol drinking and risk of lung cancer
Arthur Klatsky, Oakland, CA, USA

381P – Mutations and beyond: Identification of predictors of outcome in randomized clinical trials (RCT) of 1st-line gefinitib (G) in advanced non-small cell lung cancer (NSCLC) with sensitizing epidermal growth factor receptor (EGFR-M)
Emilio Bria, Rome, Italy

382P – Validation study of epidermal growth factor receptor (EGFR) mutation tests using DNA from control admixture samples and formalin-fixed paraffin-embedded (FFPE) samples in non-small cell lung cancer (NSCLC) in the diagnostic setting
Koichi Goto, Kashiwa City, Chiba, Japan

383P – AXL mRNA overexpression correlates with lung metastases in erlotinib-treated non-small-cell lung cancer (NSCLC) patients (p) with EGFR mutations
Carlota Costa, Barcelona, Spain

384P – Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer (NSCLC) patients (p) with EGFR mutations
Rafael Rosell, Badalona, Barcelona, Spain

385P – Validation study of epidermal growth factor receptor (EGFR) mutation tests using bronchofiberscopic brushing cytology samples and pleural effusion from non-small-cell lung cancer (NSCLC) patients in the diagnostic setting
Miyako Satouchi, Hyogo, Japan

386P – Does the type of EGFR activating mutation impact outcomes with erlotinib treatment?
David Heigener, Grosshansdorf, Germany

387P – Stem cell marker nestin expression correlates with proliferation and cell cycle in non-small cell lung cancer
Chen Zhenguang, Guangzhou City, China

388P – LACE-Bio: Results of pooled analysis of prognostic and predictive values of histology and lymphocytic infiltration
Elisabeth Brambilla, Grenoble, France

389P – LACE-Bio pooled analysis of the prognostic and predictive value of p53 mutations and expression by immunohistochemistry (IHC) in patients with resected non-small cell lung cancer (NSCLC)
Stephen Graziano, Syracuse, NY, USA

390P – ERCC1, RRM1, TYMS and BRCA1 profiling for predicting response to chemotherapy in patients with non-small cell lung cancer (NSCLC)
Vassiliki Kotoula, Thessaloniki, Greece

391P – Serum tumor markers CEA, CYFRA and Ca125 are associated with worse prognosis in advanced non-small cell lung cancer (NSCLC)
Susana Cedrés, Barcelona, Spain

392P – A systematic review and consensus recommendations on the use of biomarkers in the treatment of non-small cell lung carcinoma (NSCLC)
Peter Ellis, Hamilton, ON, Canada

393P – Sorafenib activity in NSCLC cell lines seems related to a different type of K-RAS mutations
Massimo Broggini, Milan, Italy

394P – 1st-cycle rash as a clinical marker of outcome in patients with advanced non-small cell lung cancer (NSCLC) receiving 1st-line chemotherapy (CT) plus cetuximab: Analysis by histology
Ken O’Byrne, Dublin, Ireland

395P – Are primary tumour standardized uptake value (PT SUVmax), total lesion glycolysis (TLG) and metabolic volume (MV) measured on FDG PET (CT) predictors of survival in non-small cell lung cancer (NSCLC)?
Vanessa Terrones, Brussels, Belgium

396P – Prognostic significance of the maximum standardized uptake value on positron emission tomography according to histological subtypes for non-small cell lung cancer
Yasuhiro Tsutani, Hiroshima, Japan

397P – Biomarkers determination in non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study
Giorgio Cruciani, Ravenna, Italy

398P – The risk of lifelong DNA damage caused by lung cancer among rural male smokers who begin at teenage
Emmanuel Odiase, Abuja, Nigeria

399P – Reaction of plasma hepatocyte growth factor by administration EGFR-TKIs in lung cancer patients
Hidori Tanaka, Osaka, Japan

400P – Mixed histology lung cancer – better or worse than pure histology lung cancer?
Courtney Krug, Huntington, WV, USA

401P – Prognostic factors of lung cancer patients with carcinomatous meningitis
Yukiko Nakamura, Shizuoka, Japan
402P – Treatment of lung cancer patients and concomitant use of drugs interacting with cytochrome P450 isoenzymes
Henrik Finnern, Ingelheim, Germany

403P – MAGE-A3 gene expression frequency and demography data of stage IB-IIIA NSCLC patients from ongoing MAGRIT phase III trial evaluating MAGE-A3 antigen specific cancer immunotherapeutic (ASCI) as adjuvant treatment
Joo Hang Kim, Seoul, South Korea

404P – A randomized phase II trial of adjuvant chemotherapy with docetaxel (DOC) plus cisplatin (CIS) versus paclitaxel (PAC) plus carboplatin (CAR) in patients with completely resected non-small cell lung cancer (NSCLC) (TORG0503)
Takuro Kometani, Fukuoka, Japan

405P – Oral vinorelbine (NVBo) + cisplatin (CDDP) as chemoradiotherapy (CT-RT) treatment (Trt) after induction in locally advanced non small cell lung cancer (NSCLC): Results of a phase II study
Delphine Lerouge, Caen, France

406P – Multicenter phase II study of S-1 (S) plus cisplatin (P) with concurrent thoracic radiotherapy (TRT) for locally advanced non-small cell lung cancer (LA-NSCLC): West Japan Oncology Group (WJOG) 3706 trial
Haruko Daga, Osaka, Japan

407P – A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: Updated results of CALGB 30407
Ramaswamy Govindan, St. Louis, MO, USA

408P – Randomized phase II trial of uracil/tegafur (UFT) and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer: NULCG 0601
Motoko Tachihara, Fukushima, Japan

409P – The result of percutaneous cryoablation for resectable primary lung cancer
Yoshikane Yamauchi, Tokyo, Japan

410P – Study B021247: A phase I feasibility trial of concurrent chemoradiation (CCRT) and bevacizumab (Bv) in patients (pts) with locally advanced non-squamous non-small cell lung cancer (NSCLC)
Robert Macrae, Ottawa, ON, Canada

411P – A randomized clinical trial of paclitaxel loaded polymeric micelle and cisplatin versus paclitaxel and cisplatin in advanced non-small cell lung cancer (NSCLC)
Sung Lee, Seoul, South Korea

412P – A randomized, phase II study of paclitaxel (P) and carboplatin (C) ± conatumumab (CON) for first-line treatment of non-small cell lung cancer (NSCLC)
Luis Paz-Ares, Seville, Spain

413P – A randomized trial of 1st line docetaxel and cisplatin (75/60 vs 60/60 mg/m²) for patients with stage IIIB or IV non-small cell lung cancer
Young-Chul Kim, Hwasungun, Jeonnam, South Korea

414P – Randomized phase II study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer (GOIRC 02/2006): Preliminary results
Marcello Tiseo, Parma, Italy

415P – Activity of BIBW 2992, an irreversible EGFR/HER1 and HER2 TKI, in lung adenocarcinoma patients harboring less common EGFR mutations
Jin-Yuan Shih, Taipei, Taiwan

416P – A phase II trial of linifanib treatment in non-small cell lung cancer (NSCLC) patients
Eng-Huat Tan, Singapore

417P – Randomized phase II study of sunitinib (SU) plus erlotinib (E) vs. placebo (P) plus E for the treatment of metastatic non-small cell lung cancer (NSCLC)
Harry J M Groen, Groningen, Netherlands

418P – Randomized, double-blind, placebo-controlled phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer (NSCLC) following 1st-line platinum-doublet chemotherapy
Myung-Ju Ahn, Seoul, South Korea

419P – Everolimus plus erlotinib versus erlotinib alone in previously treated patients with advanced non-small-cell lung cancer (NSCLC)
Jaafar Bennouna, Saint Herblain, France

420P – A phase II study of erlotinib plus capecitabine (XEL) as first-line treatment for Asian elderly patients (pts) with advanced adenocarcinoma of lung (ML 22206 study)
Hong Yun Zhao, Guangzhou, China

421P – Pharmacokinetic (PK) evaluation of erlotinib with or without sunitinib to treat metastatic non-small cell lung cancer (NSCLC) in a phase II trial
Ana Ruiz-Garcia, San Diego, CA, USA

422P – Gemcitabine or erlotinib in combination with sorafenib in elderly patients with advanced non small cell lung tumor (GEST): A randomized phase II study
Cesare Gridelli, Avellino, Italy

423P – A final results of a phase II study of first-line gefitinib for elderly patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations; NEJ 003 study
Akira Inoue, Sendai, Japan
424P – Treatment of leptomeningeal metastasis from non-small cell lung cancer with epidermal growth factor receptor tyrosine kinase inhibitors
Shigeki Nanjo, Kobe, Japan

425P – Clinical outcomes (COs) by sex in non-small cell lung cancer (NSCLC) patients (pts): Preliminary results from ARIES, a bevacizumab (BV) observational cohort study (OCS)
Neal Fischbach, Fairfield, CT, USA

426P – The impact of tumor histology on effectiveness in bevacizumab (BV) treated patients (pts) with advanced non-small cell lung cancer (NSCLC): Results from ARIES, a BV observational cohort study (OCS)
Julie Brahmer, Baltimore, MD, USA

427P – Final safety outcomes by chemotherapy (CT) regimen for the MO19390 (SAiL) trial: First-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC)
Lucio Crino, Perugia, Italy

428P – Final safety data from patients (pts) who received maintenance (mnt) bevacizumab (Bv) in the MO19390 (SAiL) trial: First-line Bv plus chemotherapy (CT) in advanced or recurrent non-small cell lung cancer (NSCLC)
Janessa Laskin, Vancouver, BC, Canada

429P – Safety of first-line bevacizumab (Bv)-based therapy in the SAIL (MO19390) trial: Central tumour location (CTL) and hypertension (HTN) in patients (pts) with advanced non-small cell lung cancer (NSCLC)
Frank Griesinger, Oldenburg, Germany

430P – Maintenance bevacizumab (Bv) with or without pemetrexed (pem) following first-line Bv-cisplatin (cis)-pem in patients (pts) with advanced non-squamous non-small cell lung cancer (NSCLC): Preliminary safety data from AVAPERL1 (MO22089)
Fabrice Barlesi, Marseille, France

431P – Bevacizumab (BV) treatment (Tx) to progression (BTP): Outcomes from a US community practice network
Arliene Ravelo, San Francisco, CA, USA

432P – A Galician lung cancer group phase II study of bevacizumab (B), cisplatin and vinorelbine in chemo-naive patients (p) with non squamous non small cell lung cancer (NSCLC)
Maria Areses Manrique, Santiago de Compostela, Spain

433P – Clinical management patterns in non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study
Alfredo Carrato, Madrid, Spain

434P – Salvage chemotherapy (CT) with pemetrexed (PEM) for non small cell lung cancer (NSCLC): An implementation study
Thierry Berghmans, Brussels, Belgium

435P – Compliance to vitamin supplementation and toxicity during 2nd line treatment with pemetrexed in patients with stage III/IV non small cell lung cancer (NSCLC) in daily practice
Wolfgang Schuette, Halle, Germany

436P – Chemotherapy (CT) plus cetuximab as 1st-line treatment for advanced non-small cell lung cancer (NSCLC): Meta-analysis of individual patient data
Nick Thatcher, Manchester, UK

437P – Meta-analysis of randomized phase II/III trials adding bevacizumab to platin-based chemotherapy as 1st-line treatment in patients with advanced non-small cell lung cancer (NSCLC)
Jean Pierre-Pignon, Villejuif, France

438P – Assessment of quality of life (QoL) in phase III trials in advanced non-small cell lung cancer (NSCLC)
Krzysztof Adamowicz, Wejherowo, Poland

439P – Maintenance therapy of non-small cell lung cancer with erlotinib preserves quality of life
E Juhász, Piheno, Hungary

440P – Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small-cell lung cancer
Akitoshi Kinoshita, Ohmura, Japan

441P – Refractory vs sensitive relapsed SCLC: Validation of standard definition and assessment of alternative classification
Andrea Ardizzoni, Parma, Italy

442P – Results of a randomized phase III study of single-agent amrubicin (AMR) versus carboplatin and etoposide (CE) in elderly patients with extensive-disease small cell lung cancer (ED-SCLC)
Naoya Hida, Yokohama, Japan

443P – Results of a multicenter phase II trial with the deacetylase inhibitor (DACi) panobinostat in relapsed small cell lung cancer (SCLC)
Filippo de Marinis, Rome, Italy

444P – Safety and pharmacokinetics of first-line AMG 479 (MAb to IGF1R) or AMG 102 (MAb to HGF/SF) with platinum-based chemotherapy in extensive-stage small cell lung cancer (SCLC)
Paul Lorigan, Manchester, UK

445P – Phase II study of belotecan and cisplatin as first-line chemotherapy for extensive disease of small cell lung cancer: Preliminary results
Junshik Hong, Incheon, South Korea

446P – NGR-hTNF in combination with doxorubicin in relapsed small-cell lung cancer (SCLC)
Vanesa Gregorc, Milan, Italy

447P – Clinical outcomes (COs) by sex in non-small cell lung cancer (NSCLC) patients (pts): Preliminary results from ARIES, a bevacizumab (BV) observational cohort study (OCS)
Neal Fischbach, Fairfield, CT, USA

448P – Safety of first-line bevacizumab (Bv)-based therapy in the SAIL (MO19390) trial: Central tumour location (CTL) and hypertension (HTN) in patients (pts) with advanced non-small cell lung cancer (NSCLC)
Frank Griesinger, Oldenburg, Germany

449P – Maintenance bevacizumab (Bv) with or without pemetrexed (pem) following first-line Bv-cisplatin (cis)-pem in patients (pts) with advanced non-squamous non-small cell lung cancer (NSCLC): Preliminary safety data from AVAPERL1 (MO22089)
Fabrice Barlesi, Marseille, France

450P – Bevacizumab (BV) treatment (Tx) to progression (BTP): Outcomes from a US community practice network
Arliene Ravelo, San Francisco, CA, USA

451P – A Galician lung cancer group phase II study of bevacizumab (B), cisplatin and vinorelbine in chemo-naive patients (p) with non squamous non small cell lung cancer (NSCLC)
Maria Areses Manrique, Santiago de Compostela, Spain

452P – Clinical management patterns in non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study
Alfredo Carrato, Madrid, Spain

453P – Salvage chemotherapy (CT) with pemetrexed (PEM) for non small cell lung cancer (NSCLC): An implementation study
Thierry Berghmans, Brussels, Belgium

454P – Compliance to vitamin supplementation and toxicity during 2nd line treatment with pemetrexed in patients with stage III/IV non small cell lung cancer (NSCLC) in daily practice
Wolfgang Schuette, Halle, Germany

455P – Chemotherapy (CT) plus cetuximab as 1st-line treatment for advanced non-small cell lung cancer (NSCLC): Meta-analysis of individual patient data
Nick Thatcher, Manchester, UK

456P – Meta-analysis of randomized phase II/III trials adding bevacizumab to platin-based chemotherapy as 1st-line treatment in patients with advanced non-small cell lung cancer (NSCLC)
Jean Pierre-Pignon, Villejuif, France

457P – Assessment of quality of life (QoL) in phase III trials in advanced non-small cell lung cancer (NSCLC)
Krzysztof Adamowicz, Wejherowo, Poland

458P – Maintenance therapy of non-small cell lung cancer with erlotinib preserves quality of life
E Juhász, Piheno, Hungary

459P – Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small-cell lung cancer
Akitoshi Kinoshita, Ohmura, Japan

460P – Refractory vs sensitive relapsed SCLC: Validation of standard definition and assessment of alternative classification
Andrea Ardizzoni, Parma, Italy

461P – Results of a randomized phase III study of single-agent amrubicin (AMR) versus carboplatin and etoposide (CE) in elderly patients with extensive-disease small cell lung cancer (ED-SCLC)
Naoya Hida, Yokohama, Japan

462P – Results of a multicenter phase II trial with the deacetylase inhibitor (DACi) panobinostat in relapsed small cell lung cancer (SCLC)
Filippo de Marinis, Rome, Italy

463P – Safety and pharmacokinetics of first-line AMG 479 (MAb to IGF1R) or AMG 102 (MAb to HGF/SF) with platinum-based chemotherapy in extensive-stage small cell lung cancer (SCLC)
Paul Lorigan, Manchester, UK

464P – Phase II study of belotecan and cisplatin as first-line chemotherapy for extensive disease of small cell lung cancer: Preliminary results
Junshik Hong, Incheon, South Korea

465P – NGR-hTNF in combination with doxorubicin in relapsed small-cell lung cancer (SCLC)
Vanesa Gregorc, Milan, Italy
<table>
<thead>
<tr>
<th>Paper Number</th>
<th>Title</th>
<th>Author(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>447P</td>
<td>Meta-analysis of published randomized clinical trials (RCTs) comparing platinum/etoposide (PE) versus platinum/topoisomerase 1 inhibitors (PTIs) regimens for extensive-disease small-cell lung cancer (ED-SCLC)</td>
<td>Olga Martelli, Rome, Italy</td>
<td></td>
</tr>
<tr>
<td>504P</td>
<td>Complete results from phase I dose escalation study of metMab, a monovalent antagonistic antibody to the receptor met, dosed as single agent and in combination with bevacizumab in patients with advanced solid malignancies</td>
<td>Rebbecca Moss, New Brunswick, NJ, USA</td>
<td></td>
</tr>
<tr>
<td>505P</td>
<td>Open-label phase Ib study of AMG 386, a selective angiopeptin1/2-neutralizing peptibody, in combination with sorafenib or sunitinib in advanced renal cell carcinoma (RCC): Interim results</td>
<td>Eric Anjevin, Villejuif, France</td>
<td></td>
</tr>
<tr>
<td>506P</td>
<td>Cardiovascular adverse events (CV-AEs) in a pooled analysis of 1090 patients (pt) from phase 3 sunitinib (SU) trials</td>
<td>Michael Ewer, Houston, TX, USA</td>
<td></td>
</tr>
<tr>
<td>507P</td>
<td>A phase I/II study of TKI258 (dovitinib), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell cancer (mRCC): Preliminary phase II results</td>
<td>Michael Ewer, Houston, TX, USA</td>
<td></td>
</tr>
<tr>
<td>508P</td>
<td>Phase I dose escalation trial of selective c-MET inhibitor ARQ 197 in Japanese patients with metastatic solid tumors</td>
<td>Nobuyuki Yamamoto, Osaka, Japan</td>
<td></td>
</tr>
<tr>
<td>509P</td>
<td>A phase I dose escalation trial evaluating ARQ 197 administered in combination with sorafenib in adult patients with advanced solid tumors</td>
<td>Alex Adjei,Buffalo, NY, USA</td>
<td></td>
</tr>
<tr>
<td>510P</td>
<td>Phase 1b dose escalation trial evaluating c-met inhibitor ARQ 197 and gemcitabine in patients (pts) with advanced solid tumors on schedules refined by in vitro mechanistic studies</td>
<td>Shubham Pant, Oklahoma City, OK, USA</td>
<td></td>
</tr>
<tr>
<td>511P</td>
<td>Phase I study for KRN951 (AV-951), a selective VEGFR receptor 1, 2, 3 tyrosine kinase inhibitor in Japanese patients with metastatic solid tumors</td>
<td>Raizoh Yamaguchi, Shizuoka, Japan</td>
<td></td>
</tr>
<tr>
<td>512P</td>
<td>High inconsistencies among lists of cautioned &amp; prohibited drugs in oncology phase I and phase II trials</td>
<td>Benoit You, Pierre Benite, France</td>
<td></td>
</tr>
<tr>
<td>513P</td>
<td>An analysis of the risk of toxicity associated with participation in phase I oncology trials of novel molecularly targeted agents (MTA) at the Drug Development Unit, Royal Marsden Hospital</td>
<td>Salma Alam, Sutton, UK</td>
<td></td>
</tr>
<tr>
<td>514P</td>
<td>Nature and subjectivity of dose-limiting toxicities in contemporary phase I trials: Comparison of cytotoxic versus non-cytotoxic drugs</td>
<td>Stephanie Clisant, Lille, France</td>
<td></td>
</tr>
<tr>
<td>516P</td>
<td>Clinical outcome of patients with metastatic melanoma undergoing phase I clinical trials</td>
<td>Montserrat Blanco Codesido, Sutton, UK</td>
<td></td>
</tr>
<tr>
<td>517P</td>
<td>An international pooled analysis identifying predictive factors of serious side effects and DLTs during cycle 1 in patients included in phase I trials</td>
<td>Carlos Gomez- Roca, Villejuif, France</td>
<td></td>
</tr>
<tr>
<td>518P</td>
<td>Development of a new objective prognostic score for cancer patients treated in phase I trials</td>
<td>Ingrid Desar, Nijmegen, Netherlands</td>
<td></td>
</tr>
<tr>
<td>519P</td>
<td>Do patients on molecular targeted therapy suffer from sexual disorders?</td>
<td>Yohann Loriot, Villejuif, France</td>
<td></td>
</tr>
<tr>
<td>520P</td>
<td>A phase I dose finding study of the class 1 selective histone deacetylase inhibitor (HDACi) CHR-3996 in patients with treatment refractory metastatic cancer</td>
<td>Dionysis Papadatos-Pastos, Sutton, UK</td>
<td></td>
</tr>
<tr>
<td>521P</td>
<td>Updated results of a phase 1b/2 Study using a 30 min infusion of carfilzomib (CFZ) in patients (pts) with relapsed malignancies</td>
<td>Kyriakos Papadopoulos, San Antonio, TX, USA</td>
<td></td>
</tr>
<tr>
<td>522P</td>
<td>A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941</td>
<td>Richard Baird, London, UK</td>
<td></td>
</tr>
<tr>
<td>523P</td>
<td>Results of a phase I, dose escalation study to assess the safety, efficacy and pharmacokinetics of siltuximab, an anti-IL-6 antibody in patients with solid tumors</td>
<td>Razelle Kurzrock, Houston, TX, USA</td>
<td></td>
</tr>
<tr>
<td>524P</td>
<td>Phase I study to assess the safety and tolerability of saracatinib (AZD0530) plus carboplatin (C) and/or paclitaxel (P) in patients with solid tumours</td>
<td>Steinar Aamdal, Oslo, Norway</td>
<td></td>
</tr>
<tr>
<td>525P</td>
<td>Complete phase IB study of TH-302 in combination with gemcitabine (G), docetaxel (D) or pemetrexed (P)</td>
<td>Mitesh Borad, Scottsdale, AZ, USA</td>
<td></td>
</tr>
<tr>
<td>526P</td>
<td>Antitumor immunity, efficacy and safety of CGTG-102 (Ad5/3-D24-GMCSF), an infectivity enhanced oncolytic adenovirus, in treatment of chemotherapy refractory solid tumors</td>
<td>Akseli Hemminki, Helsinki, Finland</td>
<td></td>
</tr>
</tbody>
</table>
527P — Clinical development of namitecan (ST1968), a novel camptothecin derivative: Phase I clinical data D1 Q3WK schedule
Cristiana Sessa, Bellinzona, Switzerland

528P — Phase I and pharmacodynamic study of NGR-hTNF administered at high doses in refractory patients with solid tumors
Paolo Zucali, Rozzano, Italy

529P — Cilengitide in patients with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter: Safety run-in results from a randomized, controlled, phase II study (CORE)
Tom Mikkelsen, Detroit, MI, USA

530P — Phase I study to assess the safety, tolerability, and pharmacokinetics of the specific Eg5 inhibitor AZD4877 in Japanese patients with solid tumours
Taito Esaki, Fukuoka, Japan

531P — A phase I study of ridaforolimus, the oral mTOR inhibitor, as a single agent in Japanese patients with advanced solid tumors
Yoshitaka Seki, Tokyo, Japan

532P — Targeting CD70 in non-Hodgkin lymphoma and renal cell carcinoma: A phase 1 study of the antibody-drug conjugate SGN-75
Stephen Ansell, Rochester, MN, USA

533P — First report of the safety, pharmacokinetics (PK), and preliminary activity of PF299804 in Japanese patients (pts) with advanced solid tumors
Toshiaki Takahashi, Shizuoka, Japan

534P — Preliminary results of a phase I study of intravenous administration of GL-ONC1 Vaccinia virus in patients with advanced solid cancer with real time imaging
Joanna Pedersen, Sutton, UK

535P — A novel immunotherapy platform targeting paired cancer antigens through intra-lymph node immunization: Final results of two phase 1 clinical trials
Mihail Obrocea, Valencia, CA, USA

536P — Phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumours
Penella Woll, Sheffield, UK

537P — Encouraging data from a phase I study of the first oral PARP inhibitor olaparib in Japanese patients with solid tumours
Noboru Yamamoto, Tokyo, Japan

538P — A phase I study of AZD1152, an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia
Shuichi Miyawaki, Tokyo, Japan

539P — Phase I/II trial of zoledronic acid plus interleukin-2 in patients with solid and hematological malignancies
Volker Kunzmann, Wuerzburg, Germany

540P — Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced nonsmall cell lung cancer: Safety run-in results of an open-label, randomized, phase II (CERTO) study
Johan Vansteenkiste, Leuven, Belgium

541P — Natural history and management of everolimus (E) induced oral ulcers (OU)
Charles Ferte, Lille, France

542P — Characterisation of the hepatic safety profile of trabectedin: Pooled analysis of 19 phase II clinical trials (CTs) in 1132 patients with solid tumours
Jean-Yves Blay, Lyon, France

543P — Phase I study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors
Binghe Xu, Beijing, China

544P — Effect of PF299804 on CYP2D6 activity in healthy volunteers (HVs) who are extensive metabolizers (EM)
Carlo Bello, New York, NY, USA

545P — Cytotoxic activity of engineered 5-fluorouracil-loaded poly(butylcyanoacrylate) nanoparticles
Radostina Alexandrova, Sofia, Bulgaria

546P — Pro-senescence therapy for neuroblastoma initiating stem cells
Donatella Amendola, Rome, Italy

547P — A first in class AEMD to combat cancer
Robert Shepard, Raleigh, NC, USA

548P — Accuracy of pulmonary function tests in patients treated in phase I trials
Carlos Gomez-Roca, Villejuif, France

549P — Population pharmacokinetics of temsirolimus in pediatric patients with relapsed/refractory solid tumors
Joe Boni, Collegeville, PA, USA

550P — Desensitization to different chemotherapy agents: A successful collaboration between oncology and immunoallergology
Joana Caiado, Lisbon, Portugal

Hematological malignancies
Chair: TBC

1145P — Long-term outcomes in early favourable Hodgkin’s lymphoma treated with single modality ABVD: A single centre experience
Bella Pajares Hachero, Málaga, Spain

1146P — Late relapses in Hodgkin’s disease
Blanca Cantos, Madrid, Spain

1147P — Vinorelbine, ifosfamide and prednisolone as a salvage regimen in relapsed Hodgkin’s lymphoma
Inas Abdel-Halim, Mansoura, Egypt
**1148P** – VEBEP regimen and highly active antiretroviral therapy (HAART) in patients (pts) with HD and HIV infection (HD-HIV): Final results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study
Michele Spina, Aviano, Italy

**1149P** – Primary bone lymphoma
Cristina Azevedo, Coimbra, Portugal

**1150P** – CNS prophylaxis and rituximab based regimen may improve the outcome and decrease the incidence of CNS relapse in poor risk patients with DLBCL
Mervat Mahrous, El-Minia, Egypt

**1151P** – Investigation of the molecular basis of lenalidomide treatment in lymphoma cell lines
Erica Ballabio, Oxford, UK

**1152P** – Modeling the pharmacokinetic/pharmacodynamic platelet response of inotuzumab ozogamicin, a novel antibody drug conjugate, administered alone or in combination with rituximab in patients with non-Hodgkin’s lymphoma
Joseph Boni, Collegeville, PA, USA

**1153P** – Non-random integration of Epstein-Barr virus (EBV) into chromosomes of Burkitt’s lymphomas cell lines
Eva Murga Penas, Hamburg, Germany

**1154P** – Prognostic significance of apoptosis-related proteins in diffuse large B-cell lymphoma (DLBL) patients (pts) treated with CHOP-based chemotherapy
Jin Hyuk Choi, Suwon, South Korea

**1155P** – Morphological alterations in rats and rabbits after infection with bovine leukemia virus. In vivo laboratory model of a human viral T-lymphocytic leukemogenesis
Petar Dimitrov, Sofia, Bulgaria

**1156P** – In vitro and in vivo synergistic anticancer effect of the HDAC inhibitor panobinostat (LBH589) plus zoledronic acid (ZOL) in human prostate cancer (PC) and multiple myeloma (MM) models
Alfredo Budillon, Naples, Italy

**1157P** – Molecular cytogenetic characterization of chromosome 1 abnormalities in human multiple myeloma cell lines
Snjezana Janjetovic, Hamburg, Germany

**1158P** – The study of pathogenetic mechanisms of thrombosis in patients with polycythemia vera syndrome
Oana Badulescu, Iasi, Romania

**1159P** – BCR-ABL kinase mutations and imatinib resistance in chronic myeloid leukemia
Satheesh Chiradoni Thungappa, Bangalore, India

**1160P** – Detection of BCR ABL fusion protein in CML and ALL by flowcytometric bead assay: An Indian experience
Soma Mukhopadhyay, Kolkata, India

**1161P** – Early complete cytogenetic remissions in acute promyelocytic leukemia patients treated with arsenic trioxide as a first-line therapy
Amol Akhade, Mumbai, India

**1162P** – Oral chemotherapeutic agent followed by aggressive chemotherapy improves overall outcome in adult acute myeloid leukemia (AML): A study from developing country
Ashis Mukhopadhyay, Kolkata, India

**1163P** – Evaluation of hepatocyte growth factor (HGF) as a prognostic indicator in acute myeloid leukemia
Hanan Mohmed, Giza, Egypt

**1164P** – Effect of arsenic trioxide on nucleostemin gene expression in acute promyelocytic leukemia patients
Farzaneh Ashrafi, Isfahan, Iran

**1165P** – Criteria of prognosis for radiation-associated myelofibrosis with myeloid metaplasia following the Chernobyl accident
Iryna Prokopenko, Kiev, Ukraine

**1166P** – Selective cytotoxicity of BIBR 1532 on acute promyelocytic leukemia cells through induction of P21 and suppression of C-Myc-dependent transcription of hTERT
David Bashash, Tehran, Iran

---

**Psycho-oncology**
Chair: TBC

**1201P** – Psychosocial care of Italian adult cancer patients: A large collaborative, hospital-based quality improvement project (HUCARE)
Rodolfo Passalacqua, Cremona, Italy

**1202P** – The impression we give to patients when breaking bad news: A multicenter study in a Turkish cancer population
Emel Yaman, Mersin, Turkey

**1203P** – Breaking bad news in a Greek regional hospital
Apostolos Konstantis, Komotini, Greece

**1204P** – Job stress in health care professionals. A psycho-oncological analysis of the oncology division
Guya Castellano, Treviglio, Italy

**1205P** – Influence of income and education on anticancer drug purchasing decisions in Hong Kong Chinese cancer patients
Richard Epstein, Sydney, Australia

**1206P** – Psychological distress, fatigue, and pain in advanced breast cancer patients: Relationships with quality of life impairment
Svetlana Kalyadina, Saint-Petersburg, Russian Federation

**1207P** – The effect of psychological support on quality of life in breast cancer patients
Marina Maglakelidze, Tbilisi, Georgia
Tuesday, 12 October 2010

08.00–09.00  Yellow Hall 1
Challenge Your Expert session (Repetition)
Nasopharyngeal cancer
Anthony Chan, Hong Kong, China

08.00–09.00  Yellow Hall 2
Challenge Your Expert session (Repetition)
Multiple myeloma
Joan Bladé, Barcelona, Spain

08.00–09.00  Yellow Hall 3
Challenge Your Expert session (Repetition)
Advances of systemic treatment in metastatic melanoma
Alexander M. M. Eggermont, Rotterdam, Netherlands

08.00–09.00  Green Hall 3
Challenge Your Expert session (Repetition)
Advances in the treatment of metastatic or unresectable biliary tract cancer
Juan W. Valle, Manchester, UK

08.00–09.00  Green Halls 1+2
Patient Cases
Approaches to adjuvant treatment of small tumors
Co-Chairs: Raimund Jakesz, Vienna, Austria and Eric Winer, Boston, MA, USA

08.00  The risk of stage and the risk of tumor biology: microscopic nodal tumor
Raimund Jakesz, Vienna, Austria

08.10  Triple negative small tumors
Eric Winer, Boston, MA, USA

08.20  Discussion

08.00–09.00  Orange Halls 2+3
Patient Cases
Diagnosis and management of transformation
Co-Chairs: Gianluca Gaidano, Novara, Italy and Silvia Montoto, London, UK

08.00  Richter's syndrome
Gianluca Gaidano, Novara, Italy

08.10  Transformed follicular lymphoma
Silvia Montoto, London, UK

08.20  Discussion
09.00–10.00  **Gold Hall**  
**Controversy session**  
Anti-angiogenic agents should be used for the first-line treatment of ovarian cancer  
Moderator: Jonathan Ledermann, London, UK

09.00  Introduction and vote  
Jonathan Ledermann, London, UK

09.10  Pro Speaker  
Nicoletta Colombo, Milan, Italy

09.30  Contra Speaker  
Gordon Rustin, Northwood, UK

09.50  Vote and conclusions  
Jonathan Ledermann, London, UK

09.00–10.30  **Red Hall**  
**Educational session (Repetition)**  
Towards an individualized approach of advanced non-small cell lung cancer  
Chair: Enriqueta Felip, Barcelona, Spain  
Co-Chair: Rafal Dziadzio, Gdansk, Poland

09.00  Should we continue to use the term non-small cell lung cancer?  
Adi F Gazdar, Dallas, TX, USA

09.30  How to integrate current knowledge in selecting first-line therapy  
Enriqueta Felip, Barcelona, Spain

10.00  Consequences of targeted treatments for second-line therapy  
Federico Cappuzzo, Livorno, Italy

09.00–10.30  **Blue Hall**  
**Educational session (Repetition)**  
Soft tissue sarcoma: From molecular diagnosis to selection of treatment  
Chair: Ian Judson, Sutton, UK  
Co-Chair: Serge Leyvraz, Lausanne, Switzerland

09.00  Pathologic diagnosis of soft tissue sarcoma amid molecular biology and targeted therapies  
Eva Wardelmann, Bonn, Germany

09.30  Histology-driven chemotherapy of soft tissue sarcoma  
Mikael Eriksson, Lund, Sweden

10.00  Targeted therapies in soft tissue sarcoma  
Ian Judson, Sutton, UK

09.15–10.45  **Silver Hall**  
**Special Symposium**  
Emerging concepts in head and neck cancer diagnostics and therapy  
Chair: Fortunato Ciardiello, Naples, Italy  
Co-Chair: Lisa Licitra, Milan, Italy

09.15  Introduction  
Lisa Licitra, Milan, Italy

09.20  Biomarkers in molecular classification and diagnostics of head and neck squamous cell carcinoma  
Amanda Psyrri, Athens, Greece

09.40  New signalling pathway inhibitors and EGFR resistance  
Fortunato Ciardiello, Naples, Italy

10.00  Therapeutic implications of HPV positive tumors  
Maura Gillison, Columbus, OH, USA

10.20  Molecularly-targeted therapies in thyroid cancer  
Jean-Pierre Droz, Lyon, France

10.40  Conclusions  
Lisa Licitra, Milan, Italy

09.15–10.45  **Pink Hall**  
**Special Symposium**  
The use of biomarkers to guide treatment in hematological malignancies  
Chair: Martin Dreyling, Munich, Germany  
Co-Chair: Andreas Hochhaus, Jena, Germany

09.15  Introduction  
Martin Dreyling, Munich, Germany

09.20  Chronic lymphocytic leukemia The use of biomarkers to guide treatment in hematological malignancies  
Stephan Stilgenbauer, Ulm, Germany

09.40  Multiple myeloma  
Niels van de Donk, Utrecht, Netherlands

10.00  Mantle cell lymphoma  
Martin Dreyling, Munich, Germany

10.20  Chronic myelogeneous leukemia  
Andreas Hochhaus, Jena, Germany

10.40  Conclusions  
Martin Dreyling, Munich, Germany
09.15–10.15 Orange Hall 1
Multidisciplinary Interactive session (MIS)
Locally advanced laryngeal cancer
Co-Chairs: Guy Andry, Brussels, Belgium and Jacques Bernier, Genolier, Switzerland

09.15 Surgery
Guy Andry, Brussels, Belgium
09.30 Radiotherapy
Jacques Bernier, Genolier, Switzerland
09.45 Discussion

10.15–13.00 Gold Hall
Congress Highlights
Chair: Rolf A. Stahel, Zurich, Switzerland

10.15 GLOBOCAN 2008: The worldwide burden of cancer
Eva Stelinarova-Foucher, Lyon, France
10.30 Gastrointestinal tumors
David Cunningham, Sutton, UK
10.40 Colorectal cancer
Jean-Yves Douillard, St. Herblain, France
10.50 Head and neck cancer
Marco Merlano, Cuneo, Italy
11.00 Hematological malignancies
Lena Specht, Copenhagen, Denmark
11.10 Supportive & Palliative
Dorothy M. K. Keefe, Adelaide, Australia
11.20 Breast cancer, early
TBC
11.30 Breast cancer, advanced
Fatima Cardoso, Lisbon, Portugal
11.40 Sarcoma
Paolo G. Casali, Milan, Italy
11.50 Melanoma
TBC
12.00 Basic Science, biomarkers and TR
Giampaolo Tortora, Naples, Italy
12.10 Developmental therapeutics
James Spicer, London, UK
12.20 Gynecological cancer
Isabelle Ray-Coquard, Lyon, France
12.30 Genitourinary tumors
Maria De Santis, Vienna, Austria
12.40 Chest tumors
Lucio Crinò, Perugia, Italy
12.50 Congress closing remarks
Rolf A. Stahel, Zurich, Switzerland

11.00–12.30 Red Hall
Educational session (Repetition)
Diagnostic and management issues in gastroesophageal cancer
Chair: Florian Lordick, Hannover, Germany
Co-Chair: João Oliveira, Lisbon, Portugal

11.00 Is there any role for surgery in the multidisciplinary treatment of esophageal cancer?
Michael Stahl, Essen, Germany
11.30 Multimodality treatment for localized gastroesophageal cancer
David Cunningham, Sutton, UK
12.00 New trends for staging and therapy for localized gastroesophageal cancer: The role of PET scan
Florian Lordick, Hannover, Germany

11.15–12.45 Blue Hall
Educational session (Repetition)
Advances in head and neck cancer
Chair: Jan Vermorken, Edegem, Belgium
Co-Chair: Marshall Posner, New York, NY, USA

11.15 The role of papilloma virus infection
Stina Syrjänen, Turku, Finland
11.45 Integrating systemic agents into multimodality treatment of locally advanced diseases
Marshall Posner, New York, NY, USA
12.15 Optimal treatment for relapsing or metastatic disease
Jan Vermorken, Edegem, Belgium

11.15–12.45 Silver Hall
Special Symposium
ESMO DCTF/UITC/WHO Joint Symposium: Meeting the challenge of managing cervical cancer in the developing world
Co-Chairs: Eduardo Cazap, Buenos Aires, Argentina and Andreas Ullrich, Geneva, Switzerland

11.15 What is the optimum screening method for cervical cancer in developing countries?
Rengaswamy Sankaranarayanan, Lyon, France
11.35 HPV vaccination: What practical experience tells us to date
Vivien Tsu, Seattle, WA, USA
11.55 Cervical cancer control: A global strategy
Eduardo Cazap, Buenos Aires, Argentina
12.15 The Health Minister’s response to managing cervical cancer in low-income countries
Carlos Vallejos Sologuren, Lima, Peru
12.35 Conclusions
Eduardo Cazap, Buenos Aires, Argentina